```
=> fil reg
FILE 'REGISTRY' ENTERED AT 07:55:02 ON 05 JUL 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    4 JUL 2005  HIGHEST RN 853727-85-2
DICTIONARY FILE UPDATES:   4 JUL 2005  HIGHEST RN 853727-85-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

**********************************************************************
*                                                                    *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,    *
* effective March 20, 2005.  A new display format, IDERL, is now     *
* available and contains the CA role and document type information. *
*                                                                    *
**********************************************************************

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=> d sta que l23
L1              STR
```




```
VAR G1=S/N/C/17
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  18

STEREO ATTRIBUTES: NONE
L14             STR
```



VAR G1=S/N/C/17
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 17

STEREO ATTRIBUTES: NONE
L16 1063 SEA FILE=REGISTRY SSS FUL L14
L23 77 SEA FILE=REGISTRY SUB=L16 SSS FUL L1

100.0% PROCESSED 1063 ITERATIONS 77 ANSWERS
SEARCH TIME: 00.00.01

=> d ide can l115

L115 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN 304853-42-7 REGISTRY
ED Entered STN: 29 Nov 2000
CN 1H-Pyrrole-2-carbonitrile, 5-(1,4-dihydro-4,4-dimethyl-2-thioxo-2H-3,1-benzoxazin-6-yl)-1-methyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 5-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1-methyl-1H-pyrrole-2-carbonitrile
CN NSP 989
CN Tanaproget
FS 3D CONCORD
MF **C16 H15 N3 O S**
SR CA
LC STN Files: ADISINSIGHT, CA, CAPLUS, IMSDRUGNEWS, IMSRESEARCH, PHAR, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)

4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 142:266842

REFERENCE 2: 140:71530

REFERENCE 3: 140:53469

REFERENCE 4: 133:350228

=> d his

```
     (FILE 'HOME' ENTERED AT 07:18:36 ON 05 JUL 2005)
                SET COST OFF

     FILE 'REGISTRY' ENTERED AT 07:18:43 ON 05 JUL 2005
L1              STR
L2            5 S L1

     FILE 'HCAPLUS' ENTERED AT 07:20:57 ON 05 JUL 2005
L3            1 S US20040014798/PN OR (US2003-601968# OR WO2003-US19860 OR US20
                E FONSOME A/AU
                E FENSOME A/AU
L4           37 S E3,E6,E7
                E HARRISON D/AU
L5          123 S E3,E8,E114-E116,E118
                E WINNEKER R/AU
L6           59 S E4-E7
                E ZHANG P/AU
L7          307 S E3,E17
                E ZHANG PU/AU
L8          136 S E3,E24,E25
                E ZHANG P/AU
L9          694 S E3-E20
                E KERN J/AU
L10         203 S E3,E5,E29-E31,E34
                E TEREFENKO E/AU
L11          24 S E4-E7
                E WYETH/PA,CS
                E WYET/PA,CS
L12        4429 S E4-E7 OR WYETH?/PA,CS
                SEL RN L3

     FILE 'REGISTRY' ENTERED AT 07:24:43 ON 05 JUL 2005
L13          84 S E1-E84
L14             STR L1
L15          50 S L14
L16        1063 S L14 FUL
                SAV L16 KWON601/A
L17          60 S L13 AND L16
L18          24 S L13 NOT L17
L19          10 S L18 AND NR>=3 NOT C5-C6-C6-C6/ES
L20          14 S L18 NOT L19
L21           4 S L20 AND NCOC3-C6/ES
L22          14 S L19,L21
L23          77 S L1 FUL SUB=L16
                SAV L23 KWON601A/A
L24          17 S L23 NOT L17
```

```
     FILE 'HCAOLD' ENTERED AT 07:28:34 ON 05 JUL 2005
L25           0 S L23
L26           0 S L22

     FILE 'HCAPLUS' ENTERED AT 07:28:44 ON 05 JUL 2005
L27          10 S L23
L28           6 S L22
L29          13 S L27,L28
L30           6 S L29 AND L3-L12
                E HIRSUTISM/CT
                E E3+ALL
L31         968 S E4
L32        1517 S E4,E5/BI
                E HYPERTRICH
L33         134 S E4-E7
                E HIRSUT
L34           1 S L29 AND L31-L33
L35           1 S L29 AND HIRSUT?
                E ACNE/CT
L36        3716 S E3-E8
                E E3+ALL
L37        3741 S E6+NT
L38        6082 S E6,E7/BI
L39         243 S PIMPL?
L40        6272 S ACNE?
                E ACNE/CT
                E E6+ALL
L41         301 S E2
L42           1 S L29 AND L36-L41
                E ECZEMA/CT
L43        2222 S E3,E4
                E E3+ALL
L44        2222 S E9
L45        3655 S E9,E10/BI
L46           1 S L29 AND ECZEM?
L47           1 S L3,L34,L35,L42,L46
                E SKIN/CT
                E E3+ALL
L48      105580 S E6+OLD,NT
L49      124391 S E6+PFT,RT
                E E37+ALL
L50      139455 S E5+OLD,NT,PFT,RT
                E E181+ALL
L51      155162 S E3+OLD,NT,PFT,RT
L52      142584 S E13+OLD,NT,PFT,RT
L53       16036 S E16+OLD,NT,PFT,RT
L54           2 S L29 AND L48-L53
                E HAIR/CT
L55       52596 S E3+OLD,NT,PFT,RT
L56       52664 S E43+OLD,NT,PFT,RT
L57       20289 S E86+OLD,NT,PFT,RT
                E SKIN CONDITION/CT
                E E4+ALL
L58        1145 S E2
L59           1 S L29 AND L55-L58
L60           2 S L47,L54,L59
L61           4 S L29 AND PROGESTERONE(L)RECEPTOR(L)?MODULAT?
                E PROGESTERONE RECEPTOR/CT
L62        3809 S E8-E14
                E E8+ALL
```

```
L63        4894 S E11+OLD,NT
L64        9236 S E11+PFT,RT
L65           7 S L29 AND L62-L64
                E ENDOMETRIOSIS/CT
                E E3+ALL
L66        1849 S E2
L67        2470 S E1/BI
                E BENIGN PROSTATIC HYPERTROPHY/CT
                E E3+ALL
L68        1469 S E3
L69         655 S E1/BI
                E BENIGN PROSTATIC HYPERTROPHY/CT
L70        2319 S E2/BI
                E ENDOMETRIUM/CT
                E E3+ALL
L71        9801 S E2
L72         647 S E6,E7
L73        1424 S E9,E10
L74         854 S E12,E13
L75         370 S E15,E16
L76         386 S E18,E19
L77         243 S E21,E22
L78        3398 S E24
                E OVARY/CT
L79       57237 S E3+OLD,NT
L80       18487 S E54+OLD,NT
L81       14597 S E67+OLD,NT
                E BREAST/CT
                E E3+ALL
                E E2+ALL
L82       63582 S E3+OLD,NT
L83       50658 S E9+OLD,NT
                E MAMMARY GLAND/CT
L84       65709 S E3+OLD,NT OR E47+OLD,NT
L85       47677 S E53+OLD,NT
                E COLON/CT
                E E3+ALL
L86       31294 S E1,E2
                E COLON, DISEASE/CT
                E E2+ALL
L87       18615 S E2
                E PROSTATE/CT
L88          26 S E3+OLD,NT
L89       32483 S E18+OLD,NT
L90       32840 S E53+OLD,NT,PFT,RT OR E57+OLD,NT,PFT,RT
                E PITUITARY/CT
                E E3+ALL
                E E2+ALL
L91       41881 S E3+OLD,NT OR E15+OLD,NT
                E MENINGIOMA/CT
                E E3+ALL
L92         668 S E2,E3
                E UTERIN MYOMETRIAL FIBROID/CT
                E UTERINE MYOMETRIAL FIBROID/CT
                E MYOMETRIAL FIBROID/CT
                E E5+ALL
L93        3124 S E2
                E UTERINE FIBROID/CT
                E FIBROID/CT
                E E4+ALL
```

```
L94          722 S E2
L95            3 S L29 AND L66-L94
L96            9 S L60,L65,L95
                 E UTERUS, NEOPLASM/CT
L97        12762 S E3+OLD,NT
                 E PROSTATE, NEOPLASM/CT
                 E PROSTATIC NEOPLASM/CT
                 E E4+ALL
L98        19786 S E2+OLD,NT
                 E PITUITARY NEOPLASM/CT
                 E E3+ALL
L99         3354 S E2+OLD,NT
                 E BREAST, NEOPLASM/CT
                 E BREAST NEOPLASM/CT
                 E E3+ALL
L100       47677 S E2+OLD,NT
                 E OVARY, NEOPLASM/CT
L101       14597 S E3+OLD,NT
                 E COLON, NEOPLASM/CT
                 E COLON NEOPLASM/CT
                 E E4+ALL
L102       18615 S E2
L103           2 S L29 AND L97-L102
L104           9 S L96,L103
                 E CARCINOMA/CT
L105      108005 S E3+OLD,NT
L106           1 S L29 AND L105
                 E ANTIPROGEST/CT
                 E E4+ALL
L107         344 S E1,E2
L108           5 S L29 AND L107
L109           9 S L104,L106,L108
L110           9 S L30,L109
L111          11 S L29 AND (PD<=20020625 OR PRD<=20020625 OR AD<=20020625)
L112           7 S L110 AND L111
L113           4 S L111 NOT L112

     FILE 'REGISTRY' ENTERED AT 07:51:16 ON 05 JUL 2005
L114          11 S L23 AND NC4/ES
L115           1 S L114 AND C16H15N3OS

     FILE 'HCAPLUS' ENTERED AT 07:53:31 ON 05 JUL 2005
L116           5 S L115 OR TANAPROGET OR NSP989 OR NSP 989
L117           3 S L116 AND (PD<=20020625 OR PRD<=20020625 OR AD<=20020625)
L118           9 S L116,L117,L112
L119           9 S L118 AND L3-L12,L27-L113

     FILE 'REGISTRY' ENTERED AT 07:55:02 ON 05 JUL 2005

=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 07:55:28 ON 05 JUL 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)
```

FILE COVERS 1907 - 5 Jul 2005 VOL 143 ISS 2
FILE LAST UPDATED: 4 Jul 2005 (20050704/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d l119 all fhitstr tot

L119 ANSWER 1 OF 9 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2005:219714 HCAPLUS
DN 142:266842
ED Entered STN: 11 Mar 2005
TI Partially absorbable fiber-reinforced composites for controlled drug delivery
IN Shalaby, Shalaby W.
PA USA
SO U.S. Pat. Appl. Publ., 9 pp., Cont.-in-part of U.S. Ser. No. 860,677.
CODEN: USXXCO
DT Patent
LA English
IC ICM A61F002-00
INCL 424426000
CC 63-6 (Pharmaceuticals)
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005053639	A1	20050310	US 2004-935808	20040908
	US 2004265355	A1	20041230	US 2004-860677	20040603
PRAI	US 2003-482898P	P	20030626		
	US 2004-860677	A2	20040603		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2005053639	ICM	A61F002-00
	INCL	424426000
US 2005053639	NCL	424/426.000
	ECLA	A61L031/12D10; A61L031/16
US 2004265355	NCL	424/426.000
	ECLA	A61L031/12D10; A61L031/16

AB This invention describes a partially absorbable, fiber-reinforced composite in the form of a ring, or a suture-like thread, with modified terminals for use as a controlled delivery system of at least one bioactive agent, wherein said composite comprising an absorbable fiber construct capable of providing time-dependent mech. properties of a biostable elastomeric matrix containing an absorbable microparticulate ion-exchanger to modulate the release of the bioactive agent(s) for a desired period(s) of time at a specific biol. site, such as a vaginal canal, peritoneal cavity, scrotum, prostate gland, an ear loop, or s.c. tissue. Such drug delivery systems can be used for the local administration of at least one bioactive agent, including those used as contraceptive, antimicrobial, anti-inflammatory and/or antiviral agents as well as for cancer treatment. For example, an antimicrobial intravaginal

ring was prepared containing a two-component Silastic matrix comprising Component A 2.3 g and Component B 2.3 g, fiber-reinforcing construct, i.e., suture made of segmented L-lactide-trimethylene carbonate copolymer 300 mg, polyglycolide cation-exchanging microparticulate 7 mg, metronidazole 137 mg, and D&C Violet #2 3.8 mg.

ST polymer fiber composite controlled delivery system; elastomer matrix ion exchanger microparticle fiber controlled release

IT Silicone rubber, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Silastic, matrix; partially absorbable fiber-reinforced composites for controlled drug delivery)

IT Infection
(bacterial, treatment of; partially absorbable fiber-reinforced composites for controlled drug delivery)

IT Coating materials
(bioadhesive; partially absorbable fiber-reinforced composites for controlled drug delivery)

IT Polyesters, biological studies
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(caprolactone-based; partially absorbable fiber-reinforced composites for controlled drug delivery)

IT **Uterus, neoplasm**
(cervix, treatment of; partially absorbable fiber-reinforced composites for controlled drug delivery)

IT Drug delivery systems
(controlled-release; partially absorbable fiber-reinforced composites for controlled drug delivery)

IT Silicone rubber, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(di-Me, matrix; partially absorbable fiber-reinforced composites for controlled drug delivery)

IT Polyesters, biological studies
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(glycolide-based, microparticulate; partially absorbable fiber-reinforced composites for controlled drug delivery)

IT Parturition
(inducers; partially absorbable fiber-reinforced composites for controlled drug delivery)

IT Polyester fibers, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(lactone-based; partially absorbable fiber-reinforced composites for controlled drug delivery)

IT Ear
(loop; partially absorbable fiber-reinforced composites for controlled drug delivery to specific biol. site)

IT Cation exchangers
Ion exchangers
(microparticles; partially absorbable fiber-reinforced composites for controlled drug delivery)

IT Antibodies and Immunoglobulins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(monoclonal; partially absorbable fiber-reinforced composites for controlled drug delivery)

IT Infection
(parasitism, treatment of; partially absorbable fiber-reinforced composites for controlled drug delivery)

IT Analgesics
Anesthetics

Anti-inflammatory agents
Antimicrobial agents
Antipsychotics
Antitumor agents
Antiviral agents
Composites
Contraceptives
(partially absorbable fiber-reinforced composites for controlled drug delivery)

IT **Antiprogestins**
Hormones, animal, biological studies
Synthetic polymeric fibers, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(partially absorbable fiber-reinforced composites for controlled drug delivery)

IT Muscle
Peritoneum
Prostate gland
Skin
Vagina
(partially absorbable fiber-reinforced composites for controlled drug delivery to specific biol. site)

IT Urethane rubber, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(polyether-, matrix; partially absorbable fiber-reinforced composites for controlled drug delivery)

IT Vaccines
(recombinant; partially absorbable fiber-reinforced composites for controlled drug delivery)

IT Connective tissue
(s.c.; partially absorbable fiber-reinforced composites for controlled drug delivery to specific biol. site)

IT Reproductive organ
(scrotum; partially absorbable fiber-reinforced composites for controlled drug delivery to specific biol. site)

IT Contraceptives
(spermicidal; partially absorbable fiber-reinforced composites for controlled drug delivery)

IT Medical goods
(sutures; partially absorbable fiber-reinforced composites for controlled drug delivery)

IT Mycosis
Ovary, neoplasm
(treatment of; partially absorbable fiber-reinforced composites for controlled drug delivery)

IT Immunomodulators
(vaccines; partially absorbable fiber-reinforced composites for controlled drug delivery)

IT Drug delivery systems
(vaginal, ring; partially absorbable fiber-reinforced composites for controlled drug delivery)

IT Infection
(viral, treatment of; partially absorbable fiber-reinforced composites for controlled drug delivery)

IT 41706-81-4P, ε-Caprolactone-glycolide copolymer
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(coating; partially absorbable fiber-reinforced composites for controlled drug delivery)

IT 140397-67-7, L-Lactide-trimethylene carbonate block copolymer

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(fiber; partially absorbable fiber-reinforced composites for controlled drug delivery)

IT 26009-03-0P, Polyglycolide 26202-08-4P, Polyglycolide
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(microparticulate; partially absorbable fiber-reinforced composites for controlled drug delivery)

IT 7631-86-9, Silica, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(microparticulate; partially absorbable fiber-reinforced composites for controlled drug delivery)

IT 50-81-7, Ascorbic acid, biological studies 58-22-0, Testosterone 299-29-6, Iron gluconate 443-48-1, Metronidazole 13598-36-2D, Phosphonic acid, alkylidenebis- derivs. **304853-42-7, Tanaproget**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(partially absorbable fiber-reinforced composites for controlled drug delivery)

IT 9016-00-6, Polydimethylsiloxane 31900-57-9, Polydimethylsiloxane
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(rubber, matrix; partially absorbable fiber-reinforced composites for controlled drug delivery)

IT **304853-42-7, Tanaproget**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(partially absorbable fiber-reinforced composites for controlled drug delivery)

RN 304853-42-7 HCAPLUS

CN 1H-Pyrrole-2-carbonitrile, 5-(1,4-dihydro-4,4-dimethyl-2-thioxo-2H-3,1-benzoxazin-6-yl)-1-methyl- (9CI) (CA INDEX NAME)



L119 ANSWER 2 OF 9 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:658042 HCAPLUS

ED Entered STN: 15 Aug 2004

TI Synthesis and SAR of novel, 6-aryl-1,4-dihydrobenzo[d][1,3]oxazine-2-thiones as progesterone receptor modulators leading to the potent and selective non-steroidal PR agonist **Tanaproget**

AU **Fensome, Andrew**; Chopra, Rajiv; Cohen, Jeff; Collins, Mark A.; Hudak, Valerie; Malakian, Karl; Olland, Andrea; Svenson, Kristine; **Terefenko, Eugene A.**; Unwalla, Ray J.; Wilhelm, James, M.; Wolfrom, Scott; Zhu, Yuan; Zhang, Zhiming; **Zhang, Puwen**; **Winneker, Richard C.**; Wrobel, Jay

CS Chemical and Screening Sciences, **Wyeth** Research, Collegeville, PA, 19426, USA

SO Abstracts of Papers, 228th ACS National Meeting, Philadelphia, PA, United States, August 22-26, 2004 (2004), MEDI-178 Publisher: American Chemical Society, Washington, D. C.
CODEN: 69FTZ8

DT Conference; Meeting Abstract

LA English
AB Previously, we described the synthesis and SAR of a novel series of progesterone receptor (PR) antagonists based upon the 6-aryl-1,4-dihydro-benzo[d][1,3]oxazin-2-one ring system (e.g. 1, IC50 = 30 nM). More recently, we described the conversion of this class into potent PR agonists by the incorporation of sulfur to give 6-aryl-1,4-dihydro-benzo[d][1,3]oxazine-2-thiones (e.g. 2, EC50 = 0.4 nM). We also found in the antagonist series that we could make functional agonists by changing the 6-aryl group to a 2-cyanopyrrole (e.g. 3, EC50 = 1.1 nM). It was then apparent that combining these features would increase potency. Incorporation of the 5'-cyano-2'-pyrrole moiety onto the 1,4-dihydrobenzo[d][1,3]oxazine-2-thione core produced the highly potent and selective non-steroidal PR receptor agonist 4, **tanaproget** (EC50 = 0.12 nM). In this presentation, we will demonstrate that **tanaproget** represents a potential first-in-class nonsteroidal PR agonist for contraception. Addnl. SAR, biol. activity and structural information from a **tanaproget**/hPR-LBD co-crystal structure will be presented.

L119 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:2847 HCAPLUS
DN 140:71530
ED Entered STN: 02 Jan 2004
TI Use of cyclothiocarbamate derivatives as selective androgen antagonists in contraception, hormone replacement therapy and in treatment of other hormone-related conditions
IN **Fensome, Andrew**; Grubb, Gary; **Harrison, Diane Deborah**; **Winneker, Richard Craig**; **Zhang, Puwen**; **Kern, Jeffrey Curtis**; **Terefenko, Eugene Anthony**
PA **Wyeth, John, and Brother Ltd., USA**
SO PCT Int. Appl., 79 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C07D
CC 2-4 (Mammalian Hormones)
Section cross-reference(s): 1, 28, 63
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004000801	A2	20031231	WO 2003-US19751	20030623 <--
	WO 2004000801	A3	20040325		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2489847	AA	20031231	CA 2003-2489847	20030623 <--
	US 2004006060	A1	20040108	US 2003-601481	20030623 <--
	BR 2003012024	A	20050322	BR 2003-12024	20030623 <--
	EP 1515725	A2	20050323	EP 2003-761263	20030623 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRAI	US 2002-391871P	P	20020625 <--		
	WO 2003-US19751	W	20030623		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2004000801	ICM	C07D
WO 2004000801	ECLA	A61K031/426+M; A61K031/536; A61K031/536+M; A61K031/54; A61K031/54+M; A61K031/554; A61K031/554+M <--
US 2004006060	NCL	514/211.030; 514/227.200; 514/369.000
	ECLA	A61K031/426; A61K031/426+M; A61K031/536+M; A61K031/54; A61K031/54+M; A61K031/554; A61K031/554+M <--

OS MARPAT 140:71530

GI



I



II



III

AB The present invention provides methods of inducing contraception which includes delivering to a female a composition containing cyclothiocarbamates (shown as I and II; variables defined below; e.g. III) or tautomers thereof, in a regimen which involves delivering ≥1 of a selective estrogen receptor modulator. Methods of providing hormone replacement therapy and for treating carcinomas, dysfunctional bleeding, uterine leiomyomata, **endometriosis**, and polycystic ovary syndrome is provided which includes delivering I or II and a selective estrogen receptor modulator are also described. III (5-(4,4-dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1-methyl-1H-pyrrole-2-carbonitrile) showed significant antagonistic activity towards androgens in L929 cells over a nine point dose response (IC50 = 109 nM) and only marginal agonistic activity at the maximum concentration tested (i.e., 10 nM). Although neither I nor II nor the methods of preparation are claimed, 6 example prepns. are included. For example, 1-methyl-5-[2-thioxo-1,2-dihydrospiro[3,1-benzoxazine-4,1'-cyclobutan]-6-yl]-1H-pyrrole-2-carbonitrile was prepared in 5 steps (32, 58, 52, 79, and 49 % yields, resp.) starting from phenylcarbamic acid tert-Bu ester, cyclobutanone and tBuLi in Et2O and involving intermediates tert-Bu [2-(1-hydroxycyclobutyl)phenyl]carbamate, spiro[3,1-benzoxazine-4,1'-cyclobutan]-2(1H)-one, 6-bromospiro[3,1-benzoxazine-4,1'-cyclobutan]-2(1H)-one, and 1-methyl-5-[2-oxo-1,2-dihydrospiro[3,1-benzoxazine-4,1'-cyclobutan]-6-yl]-1H-pyrrole-2-carbonitrile. For I: R1 and R2 = H, (un)substituted C1 to C6 alkyl, (un)substituted C2-C6 alkenyl, (un)substituted C2-C6 alkynyl, (un)substituted C3-C8 cycloalkyl, (un)substituted aryl, (un)substituted C-based heterocyclic ring having in its backbone 1-3 heteroatoms, CORA, and NRBCORA; or R1 and R2 are fused to form a ring (a), (b) and (c), wherein said ring is (un)substituted by 1-3 substituents H and C1 to C3 alkyl ((a) a C-based 3 to 8 membered saturated spirocyclic ring; (b) a C-based 3 to 8 membered spirocyclic ring having

≥1 C-C double bonds; and (c) a 3 to 8 membered spirocyclic ring having in its backbone 1-3 heteroatoms O, S and N). R3 = H, OH, NH2, (un)substituted C1 to C6 alkyl, (un)substituted C3-C6 alkenyl, (un)substituted alkynyl, and CORC; R4 = H, halogen, CN, NO2, (un)substituted C1 to C6 alkyl, C1 to C6 alkoxy, C1 to C6 aminoalkyl; R5 = an X/Y/Z-substituted Ph or a five or six membered C-based heterocyclic ring having in its backbone 1-3 heteroatoms O, S, SO, SO2, and NR6 and having one or two independent substituents H, halogen, CN, NO2, (un)substituted C1 to C4 alkyl, (un)substituted C1 to C3 alkoxy, (un)substituted C1 to C3 aminoalkyl, (un)substituted C1 to C3 perfluoroalkyl, (un)substituted 5 or 6 membered C-based heterocyclic ring having in its backbone 1-3 heteroatoms, (un)substituted C1 to C3 thioalkyl, CORF, and NRGCORF; Q1 = S, NR7, and CR8R9; addnl. details are given in the claims. For II: R1' = Me, Et, trifluoromethyl; R2' = Me, Et, trifluoromethyl; or R1' and R2' are joined to form a spirocyclic ring containing 3 to 7 C atoms; and R3 =C1 to C4 alkyl; other variables are as for I.

ST cyclothiocarbamate prepn androgen antagonist contraceptive hormone replacement therapy compn; antitumor agent carcinoma cyclothiocarbamate prepn; dysfunctional bleeding cyclothiocarbamate therapy; uterine leiomyomata cyclothiocarbamate therapy; **endometriosis** cyclothiocarbamate therapy; polycystic ovary syndrome cyclothiocarbamate therapy; benzoxazinone prepn androgen antagonist contraceptive hormone replacement therapy compn

IT **Mammary gland, neoplasm**
Ovary, neoplasm
Prostate gland, neoplasm
Uterus, neoplasm
(**carcinoma**; use of cyclothiocarbamate derivs. as selective androgen antagonists in contraception, hormone replacement therapy and in treatment of other hormone-related conditions)

IT Selective estrogen receptor modulators
(codrugs; use of cyclothiocarbamate derivs. as selective androgen antagonists in contraception, hormone replacement therapy and in treatment of other hormone-related conditions)

IT **Intestine, neoplasm**
(**colon**, **carcinoma**; use of cyclothiocarbamate derivs. as selective androgen antagonists in contraception, hormone replacement therapy and in treatment of other hormone-related conditions)

IT **Carcinoma**
(colon; use of cyclothiocarbamate derivs. as selective androgen antagonists in contraception, hormone replacement therapy and in treatment of other hormone-related conditions)

IT Hemorrhage
(dysfunctional; use of cyclothiocarbamate derivs. as selective androgen antagonists in contraception, hormone replacement therapy and in treatment of other hormone-related conditions)

IT **Carcinoma**
(**endometrial**; use of cyclothiocarbamate derivs. as selective androgen antagonists in contraception, hormone replacement therapy and in treatment of other hormone-related conditions)

IT **Uterus, disease**
(**endometriosis**; use of cyclothiocarbamate derivs. as selective androgen antagonists in contraception, hormone replacement therapy and in treatment of other hormone-related conditions)

IT **Uterus, neoplasm**
(**endometrium**, **carcinoma**; use of cyclothiocarbamate derivs. as selective androgen antagonists in contraception, hormone replacement therapy and in treatment of other hormone-related

conditions)
IT Contraceptives
(female; use of cyclothiocarbamate derivs. as selective androgen antagonists in contraception, hormone replacement therapy and in treatment of other hormone-related conditions)
IT **Uterus, neoplasm**
(**leiomyomata**; use of cyclothiocarbamate derivs. as selective androgen antagonists in contraception, hormone replacement therapy and in treatment of other hormone-related conditions)
IT **Carcinoma**
(mammary; use of cyclothiocarbamate derivs. as selective androgen antagonists in contraception, hormone replacement therapy and in treatment of other hormone-related conditions)
IT **Carcinoma**
(ovarian; use of cyclothiocarbamate derivs. as selective androgen antagonists in contraception, hormone replacement therapy and in treatment of other hormone-related conditions)
IT **Ovary, disease**
(**polycystic**; use of cyclothiocarbamate derivs. as selective androgen antagonists in contraception, hormone replacement therapy and in treatment of other hormone-related conditions)
IT **Carcinoma**
(prostatic; use of cyclothiocarbamate derivs. as selective androgen antagonists in contraception, hormone replacement therapy and in treatment of other hormone-related conditions)
IT Antitumor agents
Carcinoma
Drug delivery systems
Hemostatics
Hormone replacement therapy
Human
(use of cyclothiocarbamate derivs. as selective androgen antagonists in contraception, hormone replacement therapy and in treatment of other hormone-related conditions)
IT Antiandrogens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(use of cyclothiocarbamate derivs. as selective androgen antagonists in contraception, hormone replacement therapy and in treatment of other hormone-related conditions)
IT **Carcinoma**
(uterine; use of cyclothiocarbamate derivs. as selective androgen antagonists in contraception, hormone replacement therapy and in treatment of other hormone-related conditions)
IT **304853-32-5P**, 6-(3-Chlorophenyl)-4,4-dimethyl-1,4-dihydrobenzo[d][1,3]oxazin-2-thione **304853-33-6P**, 4-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-benzo[d][1,3]oxazin-6-yl)thiophene-2-carbonitrile **304853-35-8P**, 3-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-benzo[d][1,3]oxazin-6-yl)-5-fluorobenzonitrile **304853-37-0P**, 3-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-benzo[d][1,3]oxazin-6-yl)benzonitrile **304853-38-1P**, 6-(3-Fluorophenyl)-4-methyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione **304853-39-2P**, 5-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-4-methylthiophene-2-carbonitrile **304853-40-5P**, 5-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1H-pyrrole-2-carbonitrile **304853-41-6P**, [6-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)pyridin-2-yl]acetonitrile **304853-42-7P**, 5-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1-methyl-1H-pyrrole-2-carbonitrile **304853-43-8P**, 5-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1H-pyrrole-2-carbothioamide **304853-44-9P**, 5-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-

benzo[d][1,3]oxazin-6-yl)thiophene-3-carbonitrile **304853-45-0P**, 5-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1-ethyl-1H-pyrrole-2-carbonitrile **304853-46-1P**, 4-[1,2-Dihydro-2-thioxospiro[4H-3,1-benzoxazin-4,1-cyclohexan]-6-yl]-2-thiophenecarbonitrile **304853-47-2P**, 5-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-2-fluorobenzonitrile **304853-48-3P**, 6-(5-Bromopyridin-3-yl)-4,4-dimethyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione **304853-49-4P**, 6-(3-Chloro-5-fluorophenyl)-4,4-dimethyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione **304853-50-7P**, 6-(3-Bromo-5-methylphenyl)-4,4-dimethyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione **304853-51-8P**, 6-(3-Bromo-5-trifluoromethoxyphenyl)-4,4-dimethyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione **304853-52-9P**, 3-[1,2-Dihydro-2-thioxospiro[4H-3,1-benzoxazine-4,1-cyclohexan]-6-yl]-5-fluorobenzonitrile **304853-53-0P**, 3-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-5-methylbenzonitrile **304853-54-1P**, 6-(3,5-Dichlorophenyl)-4,4-dimethyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione **304853-56-3P**, 5-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-2-furonitrile **304853-57-4P**, 4,4-Diethyl-6-(3-nitrophenyl)-1,4-dihydro-2H-3,1-benzoxazine-2-thione **304853-58-5P**, 6-(3-Chlorophenyl)-4-methyl-4-phenyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione **304853-59-6P**, 4-Allyl-6-(3-chlorophenyl)-4-methyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione **304853-60-9P**, 3-Chloro-5-(4,4-dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)benzonitrile **304853-61-0P**, 6-(3,5-Difluorophenyl)-4,4-dimethyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione **304853-62-1P**, 6-(3-Fluoro-5-methoxyphenyl)-4,4-dimethyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione **304853-63-2P**, 3-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-5-methoxybenzonitrile **304853-64-3P**, 6-(3-Fluorophenyl)-4,4-dimethyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione **304853-65-4P**, 6-[3-Fluoro-5-(trifluoromethyl)phenyl]-4,4-dimethyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione **304853-66-5P**, 6-(2-Fluorophenyl)-4,4-dimethyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione **304853-67-6P**, 6-(3,4-Difluorophenyl)-4,4-dimethyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione **304853-68-7P**, 6-(4-Fluorophenyl)-4,4-dimethyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione **304853-69-8P**, 3-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-4-fluorobenzonitrile **304853-70-1P**, 6-(2,3-Difluorophenyl)-4,4-dimethyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione **304853-71-2P**, 3-(8-Bromo-4,4-dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-5-fluorobenzonitrile **304853-72-3P**, 4,4-Dimethyl-6-(3-nitrophenyl)-1,4-dihydro-2H-3,1-benzoxazine-2-thione **304853-73-4P**, 6-(3-Chlorophenyl)-4,4-diethyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione **304853-74-5P**, 6-(3-Methoxyphenyl)-4,4-dimethyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione **304853-75-6P**, 6-(2-Chlorophenyl)-4,4-dimethyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione **304853-76-7P**, 4-Benzyl-6-(3-chlorophenyl)-4-methyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione **304853-77-8P**, 6-(3-Bromo-5-fluorophenyl)-4,4-dimethyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione **304853-78-9P**, 5-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)thiophene-2-carbonitrile **304853-79-0P**, 3-Fluoro-5-(8-fluoro-4,4-dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)benzonitrile **304853-80-3P**, 3-[1,2-Dihydro-2-thioxospiro[4H-3,1-benzoxazine-4,1'-cyclohexan]-6-yl]benzonitrile **304853-81-4P**, 5-[1,2-Dihydro-2-thioxospiro[4H-3,1-benzoxazine-4,1'-cyclohexan]-6-yl]-4-methyl-2-thiophenecarbonitrile **304853-82-5P**, 5-[1,2-Dihydro-2-thioxospiro[4H-3,1-benzoxazine-4,1'-cyclohexan]-6-yl]-2-thiophenecarbonitrile **304853-83-6P**, 6-(3-Chloro-4-fluorophenyl)-4,4-dimethyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione **304853-84-7P**, 5-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-4-propylthiophene-2-carbonitrile **304853-85-8P**,

4-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-2-furonitrile **304853-86-9P**, 4-Butyl-5-(4,4-dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)thiophene-2-carbonitrile **304853-87-0P**, 6-(3-Bromophenyl)-4,4-dimethyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione **304853-88-1P**, 2-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)thiophene-3-carbonitrile **304853-95-0P**, 2-Cyano-5-(4,4-dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1H-pyrrole-1-carboxylic acid tert-Butyl ester **638989-33-0P**, 1-Methyl-5-[2-thioxo-1,2-dihydrospiro[3,1-benzoxazine-4,1'-cyclobutan]-6-yl]-1H-pyrrole-2-carbonitrile **638989-38-5P**, 5-(4,4-Diethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1-methyl-1H-pyrrole-2-carbonitrile **638989-41-0P**, 5-(4-Ethyl-4-methyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1-methyl-1H-pyrrole-2-carbonitrile **638989-44-3P**, 1-Methyl-5-[2-thioxo-1,2-dihydrospiro[3,1-benzoxazine-4,1'-cyclohexan]-6-yl]-1H-pyrrole-2-carbonitrile **638989-46-5P**, 1-Methyl-5-[2-thioxo-1,2-dihydrospiro[3,1-benzoxazine-4,1'-cyclopentan]-6-yl]-1H-pyrrole-2-carbonitrile **638989-48-7P**, 1-Methyl-5-[2-thioxo-4,4-bis(trifluoromethyl)-1,4-dihydro-2H-3,1-benzoxazin-6-yl]-1H-pyrrole-2-carbonitrile **639085-00-0P**, 5-(4,4-Dimethyl-1,2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)isophthalonitrile
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; use of cyclothiocarbamate derivs. as selective androgen antagonists in contraception, hormone replacement therapy and in treatment of other hormone-related conditions)

IT 50-41-9, Clomiphene citrate 1845-11-0, Nafoxidene 31477-60-8, Centchroman 54965-24-1, Tamoxifen citrate 78994-23-7, Levormeloxifene 82413-20-5, Droloxifene 82640-04-8, Raloxifene hydrochloride 89778-27-8, Toremifene citrate 116057-75-1, Idoxifene 180916-16-9, Lasofoxifene 182133-25-1, Arzoxifene 182167-02-8, EM-652 182167-03-9, EM-800 198480-55-6, Pipendoxifene 198481-32-2, Bazedoxifene 638186-49-9
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(selective estrogen receptor modulator as codrug; use of cyclothiocarbamate derivs. as selective androgen antagonists in contraception, hormone replacement therapy and in treatment of other hormone-related conditions)

IT 684-16-2, Hexafluoroacetone 1191-95-3, Cyclobutanone 3422-01-3 29124-56-9, 1-(2-Amino-5-bromophenyl)ethanone 34884-10-1, 1-Methyl-1H-pyrrole-2-carbonitrile **304854-04-4**, 6-Bromospiro[4H-3,1-benzoxazine-4,1'-cyclohexan]-2(1H)-one **305799-84-2**, 6-Bromospiro[4H-3,1-benzoxazine-4,1'-cyclopentan]-2-(1H)-one **638989-40-9**, 6-Bromo-4,4-diethyl-1,4-dihydrobenzo[d][1,3]oxazin-2-one
RL: RCT (Reactant); RACT (Reactant or reagent)
(use of cyclothiocarbamate derivs. as selective androgen antagonists in contraception, hormone replacement therapy and in treatment of other hormone-related conditions)

IT 2713-62-4P, 2-(2-Aminophenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol 638989-34-1P, tert-Butyl [2-(1-hydroxycyclobutyl)phenyl]carbamate **638989-35-2P**, Spiro[3,1-benzoxazine-4,1'-cyclobutan]-2(1H)-one **638989-36-3P**, 6-Bromospiro[3,1-benzoxazine-4,1'-cyclobutan]-2(1H)-one **638989-37-4P**, 1-Methyl-5-[2-oxo-1,2-dihydrospiro[3,1-benzoxazine-4,1'-cyclobutan]-6-yl]-1H-pyrrole-2-carbonitrile **638989-39-6P**, 5-(4,4-Diethyl-2-oxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1-methyl-1H-pyrrole-2-carbonitrile **638989-42-1P**, 6-Bromo-4-ethyl-4-methyl-1,4-dihydro-2H-3,1-benzoxazin-2-one **638989-43-2P**, 5-(4-Ethyl-4-methyl-2-oxo-1,4-dihydro-2H-3,1-

benzoxazin-6-yl)-1-methyl-1H-pyrrole-2-carbonitrile **638989-45-4P**, 1-Methyl-5-[2-oxo-1,2-dihydrospiro[3,1-benzoxazine-4,1'-cyclohexan]-6-yl]-1H-pyrrole-2-carbonitrile **638989-47-6P**, 1-Methyl-5-[2-oxo-1,2-dihydrospiro[3,1-benzoxazine-4,1'-cyclopentan]-6-yl]-1H-pyrrole-2-carbonitrile **638989-49-8P**, 4,4-Bis(trifluoromethyl)-1,4-dihydro-2H-3,1-benzoxazin-2-one **638989-50-1P**, 6-Bromo-4,4-bis(trifluoromethyl)-1,4-dihydro-2H-3,1-benzoxazin-2-one **638989-51-2P**, 1-Methyl-5-[2-oxo-4,4-bis(trifluoromethyl)-1,4-dihydro-2H-3,1-benzoxazin-6-yl]-1H-pyrrole-2-carbonitrile
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(use of cyclothiocarbamate derivs. as selective androgen antagonists in contraception, hormone replacement therapy and in treatment of other hormone-related conditions)

IT **304853-32-5P**, 6-(3-Chlorophenyl)-4,4-dimethyl-1,4-dihydrobenzo[d][1,3]oxazin-2-thione
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; use of cyclothiocarbamate derivs. as selective androgen antagonists in contraception, hormone replacement therapy and in treatment of other hormone-related conditions)

RN 304853-32-5 HCAPLUS
CN 2H-3,1-Benzoxazine-2-thione, 6-(3-chlorophenyl)-1,4-dihydro-4,4-dimethyl- (9CI) (CA INDEX NAME)



L119 ANSWER 4 OF 9 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:2636 HCAPLUS
DN 140:53469
ED Entered STN: 02 Jan 2004
TI Cyclothiocarbamate derivatives as **progesterone receptor modulators** and use thereof for treatment of skin disorders
IN **Fensome, Andrew; Harrison, Diane Deborah; Winneker, Richard Craig; Zhang, Puwen; Kern, Jeffrey Curtis; Terefenko, Eugene Anthony**
PA **Wyeth, John, and Brother Ltd., USA**
SO PCT Int. Appl., 83 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K
CC 1-12 (Pharmacology)
Section cross-reference(s): 27

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004000230	A2	20031231	WO 2003-US19860	20030623 <--
WO 2004000230	A3	20040429		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2489815 AA 20031231 CA 2003-2489815 20030623 <--
US 2004014798 A1 20040122 US 2003-601968 20030623 <--
EP 1531824 A2 20050525 EP 2003-739286 20030623 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
PRAI US 2002-391885P P 20020625 <--
WO 2003-US19860 W 20030623 <--

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2004000230	ICM	A61K
WO 2004000230	ECLA	A61K008/49; A61K031/536; A61K031/536+M; A61K031/565+M; A61Q007/00; A61Q019/00 <--
US 2004014798	NCL	514/369.000 <--

OS MARPAT 140:53469

AB The present invention provides for the use of a compds. that **modulate progesterone receptors** and thereby treat skin disorders. Specifically, methods for treating **acne**, **hirsutism**, and conditioning the skin are described.

ST **progesterone receptor modulator**
cyclothiocarbamate deriv skin disease

IT **Eczema**
Hirsutism
Skin, disease
(cyclothiocarbamate derivs. as **progesterone receptor modulators** and use thereof for treatment of skin disorders)

IT Antiandrogens
Antiprogestins
Progesterone receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(cyclothiocarbamate derivs. as **progesterone receptor modulators** and use thereof for treatment of skin disorders)

IT Drug delivery systems
(injections; cyclothiocarbamate derivs. as **progesterone receptor modulators** and use thereof for treatment of skin disorders)

IT Drug delivery systems
(tablets; cyclothiocarbamate derivs. as **progesterone receptor modulators** and use thereof for treatment of skin disorders)

IT **Acne**
(**vulgaris**; cyclothiocarbamate derivs. as **progesterone receptor modulators** and use thereof for treatment of skin disorders)

IT **638989-33-0P 638989-38-5P 638989-41-0P**
638989-44-3P 638989-46-5P 638989-48-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(cyclothiocarbamate derivs. as **progesterone receptor modulators** and use thereof for treatment of skin disorders)

IT **304853-32-5 304853-35-8 304853-37-0**

304853-38-1 304853-39-2 304853-40-5
304853-41-6 304853-42-7 304853-43-8
304853-44-9 304853-45-0 304853-46-1
304853-47-2 304853-48-3 304853-49-4
304853-50-7 304853-51-8 304853-52-9
304853-53-0 304853-54-1 304853-55-2
304853-56-3 304853-57-4 304853-58-5
304853-59-6 304853-60-9 304853-61-0
304853-62-1 304853-63-2 304853-64-3
304853-66-5 304853-67-6 304853-68-7
304853-69-8 304853-70-1 304853-71-2
304853-72-3 304853-73-4 304853-74-5
304853-75-6 304853-76-7 304853-77-8
304853-78-9 304853-79-0 304853-80-3
304853-81-4 304853-82-5 304853-83-6
304853-84-7 304853-85-8 304853-86-9
304853-87-0 304853-88-1 304853-95-0
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cyclothiocarbamate derivs. as **progesterone receptor modulators** and use thereof for treatment of skin disorders)

IT 684-16-2, Hexafluoroacetone 1191-95-3, Cyclobutanone 3422-01-3 29124-56-9 34884-10-1, 1-Methyl-1H-pyrrole-2-carbonitrile **304854-04-4 305799-84-2 638989-40-9**
RL: RCT (Reactant); RACT (Reactant or reagent)
(cyclothiocarbamate derivs. as **progesterone receptor modulators** and use thereof for treatment of skin disorders)

IT 2713-62-4P 638989-34-1P **638989-35-2P 638989-36-3P 638989-37-4P 638989-39-6P 638989-42-1P 638989-43-2P 638989-45-4P 638989-47-6P 638989-49-8P 638989-50-1P 638989-51-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(cyclothiocarbamate derivs. as **progesterone receptor modulators** and use thereof for treatment of skin disorders)

IT 57-83-0, **Progesterone**, biological studies 797-63-7, Levonorgestrel 54048-10-1, 3-Ketodesogestrel
RL: PAC (Pharmacological activity); BIOL (Biological study)
(reference compound; cyclothiocarbamate derivs. as **progesterone receptor modulators** and use thereof for treatment of skin disorders)

IT **638989-33-0P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(cyclothiocarbamate derivs. as **progesterone receptor modulators** and use thereof for treatment of skin disorders)

RN 638989-33-0 HCAPLUS
CN 1H-Pyrrole-2-carbonitrile, 5-(1,2-dihydro-2-thioxospiro[4H-3,1-benzoxazine-4,1'-cyclobutan]-6-yl)-1-methyl- (9CI) (CA INDEX NAME)



L119 ANSWER 5 OF 9 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:669675 HCAPLUS
DN 137:201317
ED Entered STN: 05 Sep 2002
TI Preparation of benzoxazinone cyclic carbamate antiprogestins for use in combination therapies and regimens with progestational agents.
IN Grubb, Gary S.; **Zhang, Puwen**; **Terefenko, Eugene A.**; **Fensome, Andrew**; Wrobel, Jay E.; Fletcher, Iii Horace; Edwards, James P.; Jones, Todd K.; Tegley, Christopher M.; Zhi, Lin
PA **Wyeth, John and Brother Ltd., USA**; Ligand Pharmaceuticals Incorporated
SO U.S., 44 pp.
CODEN: USXXAM
DT Patent
LA English
IC ICM A61K031-535
ICS A61K031-56
INCL 514230500
CC 28-13 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 2
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	US 6444668	B1	20020903	US 2000-552350	20000419	<--
	CA 2372773	AA	20001109	CA 2000-2372773	20000501	<--
	JP 2002543155	T2	20021217	JP 2000-615048	20000501	<--
	AT 275973	E	20041015	AT 2000-928611	20000501	<--
	ES 2226833	T3	20050401	ES 2000-928611	20000501	<--
	US 2003045511	A1	20030306	US 2002-141792	20020509	<--
	US 6759408	B2	20040706			
	HK 1043736	A1	20050401	HK 2002-104868	20020628	<--
PRAI	US 1999-229346P	P	19990504	<--		
	US 1999-304712	A	19990504	<--		
	US 2000-552350	A	20000419	<--		
	WO 2000-US11643	W	20000501	<--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES	
US 6444668	ICM	A61K031-535	
	ICS	A61K031-56	
	INCL	514230500	
US 6444668	NCL	514/230.500; 514/178.000; 514/843.000	
	ECLA	A61K031/535+M; A61K031/56+M	<--
US 2003045511	NCL	514/230.500; 514/170.000; 514/171.000; 514/178.000; 514/182.000; 514/228.800; 514/230.800; 514/247.000; 514/359.000; 514/843.000	
	ECLA	A61K031/535+M; A61K031/56+M	<--

OS MARPAT 137:201317
GI



I

AB A method of contraception comprises administration to a female of a progestational agent in a first phase and in a second phase administration of [I; R1, R2 = H, (un)substituted C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, aryl, heterocyclyl, amino derivative; R1R2 = atoms to form spirocyclic or heterospirocyclic rings; R3 = H, OH, NH2, (un)substituted C1-6 alkyl, C3-6 alkenyl, alkynyl, COR6; R6 = H, (un)substituted C1-3 alkyl, aryl, C1-3 alkoxy, C1-3 aminoalkyl; R4 = H, halo, CN, NO2, (un)substituted C1-6 alkyl, alkynyl, C1-6 alkoxy, amino, C1-6 aminoalkyl; R5 = trisubstituted benzene ring, 5-6 membered ring with 1, 2, or 3 O, S, SO, SO2, NR7 and containing 1-2 H, halo, CN, NO2, amino, C1-3 alkyl, C1-3 alkoxy, C1-3 aminoalkyl, COR8, NR9COR8; R7 = H, C1-3 alkyl; R8 = H, (un)substituted C1-3 alkyl, aryl, C1-3 alkoxy, C1-3 aminoalkyl; R9 = H, (un)substituted C1-3 alkyl]. Thus, 6-(3-chlorophenyl)-4,4-dimethyl-1,4-dihydrobenzo[d][1,3]-oxazin-2-one was prepared from 2-(2-amino-5-bromophenyl)propan-2-ol via cyclocondensation with 1,1-carbonyldiimidazole followed by palladium-catalyzed coupling with 3-chlorophenylboronic acid. I demonstrated IC50's of 2.7-68 nM in a hPR decidualization assay.

ST cyclocarbamate aryl prepn antiprogestin combination therapy regimen progestational agent; benzoxazinone prepn progesterone receptor antagonist; oxazinone benzo prepn progesterone receptor antagonist; contraceptive benzoxazinone antiprogestin progestin

IT Contraceptives
Human
(preparation of benzoxazinone cyclic carbamate antiprogestins for use in combination therapies and regimens with progestational agents)

IT **Progesterone receptors**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of benzoxazinone cyclic carbamate antiprogestins for use in combination therapies and regimens with progestational agents)

IT **Antiprogestins**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzoxazinone cyclic carbamate antiprogestins for use in combination therapies and regimens with progestational agents)

IT Estrus
(regulation of; preparation of benzoxazinone cyclic carbamate antiprogestins for use in combination therapies and regimens with progestational agents)

IT 51-98-9, Norethindrone acetate 68-22-4, Norethindrone 427-51-0, Cyproterone acetate 797-63-7, Levonorgestrel 6533-00-2, Norgestrel 35189-28-7, Norgestimate 53016-31-2, 17-Deacetylnorgestimate 54024-22-5, Desogestrel 54048-10-1, 3-KetoDesogestrel 58691-88-6, Nomegestrol 60282-87-3, Gestodene 65928-58-7, Dienogest 67392-87-4, Drospirenone 74513-62-5, Trimegestone 105149-04-0, Osaterone
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination therapy; preparation of benzoxazinone cyclic carbamate antiprogestins for use in combination therapies and regimens with progestational agents)

IT 304853-93-8P, 2H-3,1-Benzoxazin-2-one, 6-(3-fluorophenyl)-1,4-dihydro-4-methyl- 304853-94-9P, 2-Thiophenecarbonitrile, 5-(1,4-dihydro-4,4-dimethyl-2-oxo-2H-3,1-benzoxazin-6-yl)-4-methyl- 304853-98-3P, 2-Pyridineacetonitrile, 6-(1,4-dihydro-4,4-dimethyl-2-oxo-2H-3,1-benzoxazin-6-yl)- 304854-01-1P, 3-Thiophenecarbonitrile, 5-(1,4-dihydro-4,4-dimethyl-2-oxo-2H-3,1-benzoxazin-6-yl)-
RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzoxazinone cyclic carbamate antiprogestins for use in combination therapies and regimens with progestational agents)

IT 304853-28-9P, 2H-3,1-Benzoxazin-2-one, 6-(3-chlorophenyl)-1,4-dihydro-4,4-dimethyl- 304853-29-0P, 2H-3,1-Benzoxazin-2-one, 6-(3-bromo-5-fluorophenyl)-1,4-dihydro-4,4-dimethyl- 304853-30-3P, Benzonitrile, 3-(1,4-dihydro-4,4-dimethyl-2-oxo-2H-3,1-benzoxazin-6-yl)-5-fluoro- 304853-31-4P, 2-Thiophenecarbonitrile, 4-(1,4-dihydro-4,4-dimethyl-2-oxo-2H-3,1-benzoxazin-6-yl)- 304853-36-9P, Benzonitrile, 3-(1,4-dihydro-4,4-dimethyl-2-oxo-2H-3,1-benzoxazin-6-yl)- 304853-96-1P, 1H-Pyrrole-1-carboxylic acid, 2-(1,4-dihydro-4,4-dimethyl-2-oxo-2H-3,1-benzoxazin-6-yl)-, 1,1-dimethylethyl ester 304854-06-6P, 2-Thiophenecarbonitrile, 4-(1,2-dihydro-2-oxospiro[4H-3,1-benzoxazine-4,1'-cyclohexan]-6-yl)- 304854-07-7P, Benzonitrile, 5-(1,4-dihydro-4,4-dimethyl-2-oxo-2H-3,1-benzoxazin-6-yl)-2-fluoro- 304854-08-8P, 2H-3,1-Benzoxazin-2-one, 6-(5-bromo-3-pyridinyl)-1,4-dihydro-4,4-dimethyl- 304854-09-9P, 2H-3,1-Benzoxazin-2-one, 6-(3-chloro-5-fluorophenyl)-1,4-dihydro-4,4-dimethyl- 304854-10-2P, 2H-3,1-Benzoxazin-2-one, 6-(3-bromo-5-methylphenyl)-1,4-dihydro-4,4-dimethyl- 304854-11-3P, 2H-3,1-Benzoxazin-2-one, 6-[3-bromo-5-(trifluoromethoxy)phenyl]-1,4-dihydro-4,4-dimethyl- 304854-12-4P, Benzonitrile, 3-(1,2-dihydro-2-oxospiro[4H-3,1-benzoxazine-4,1'-cyclohexan]-6-yl)-5-fluoro- 304854-13-5P, Benzonitrile, 3-(1,4-dihydro-4,4-dimethyl-2-oxo-2H-3,1-benzoxazin-6-yl)-5-methyl- 304854-14-6P, 2H-3,1-Benzoxazin-2-one, 6-(3,5-dichlorophenyl)-1,4-dihydro-4,4-dimethyl- 304854-15-7P, 1,3-Benzenedicarbonitrile, 5-(1,4-dihydro-4,4-dimethyl-2-oxo-2H-3,1-benzoxazin-6-yl)- 304854-16-8P, 2-Furancarbonitrile, 5-(1,4-dihydro-4,4-dimethyl-2-oxo-2H-3,1-benzoxazin-6-yl)- 304854-17-9P, 2H-3,1-Benzoxazin-2-one, 4,4-diethyl-1,4-dihydro-6-(3-nitrophenyl)- 304854-20-4P, 2H-3,1-Benzoxazin-2-one, 6-(3-chlorophenyl)-1,4-dihydro-4-methyl-4-phenyl- 304854-21-5P, 2H-3,1-Benzoxazin-2-one, 6-(3-chlorophenyl)-1,4-dihydro-4-methyl-4-(2-propenyl)- 304854-22-6P, Benzonitrile, 3-chloro-5-(1,4-dihydro-4,4-dimethyl-2-oxo-2H-3,1-benzoxazin-6-yl)- 304854-23-7P, 2H-3,1-Benzoxazin-2-one, 6-(3,5-difluorophenyl)-1,4-dihydro-4,4-dimethyl- 304854-24-8P, 2H-3,1-Benzoxazin-2-one, 6-(3-fluoro-5-methoxyphenyl)-1,4-dihydro-4,4-dimethyl- 304854-25-9P, Benzonitrile, 3-(1,4-dihydro-4,4-dimethyl-2-oxo-2H-3,1-benzoxazin-6-yl)-5-methoxy- 304854-26-0P, 2H-3,1-Benzoxazin-2-one, 6-(3-fluorophenyl)-1,4-dihydro-4,4-dimethyl- 304854-27-1P, 2H-3,1-Benzoxazin-2-one, 6-[3-fluoro-5-(trifluoromethyl)phenyl]-1,4-dihydro-4,4-dimethyl- 304854-28-2P, 2H-3,1-Benzoxazin-2-one, 6-(2-fluorophenyl)-1,4-dihydro-4,4-dimethyl- 304854-29-3P, 2H-3,1-Benzoxazin-2-one, 6-(3,4-difluorophenyl)-1,4-dihydro-4,4-dimethyl- 304854-30-6P, 2H-3,1-Benzoxazin-2-one, 6-(4-fluorophenyl)-1,4-dihydro-4,4-dimethyl- 304854-31-7P, Benzonitrile, 3-(1,4-dihydro-4,4-dimethyl-2-oxo-2H-3,1-benzoxazin-6-yl)-4-fluoro- 304854-32-8P, 2H-3,1-Benzoxazin-2-one, 6-(2,3-difluorophenyl)-1,4-dihydro-4,4-dimethyl- 304854-33-9P, Benzonitrile, 3-(8-bromo-1,4-dihydro-4,4-dimethyl-2-oxo-2H-3,1-benzoxazin-6-yl)-5-fluoro- 304854-34-0P, 2H-3,1-Benzoxazin-2-one, 1,4-dihydro-4,4-dimethyl-6-(3-nitrophenyl)- 304854-35-1P, 2H-3,1-Benzoxazin-2-one, 6-(3-chlorophenyl)-4,4-diethyl-1,4-dihydro- 304854-36-2P, 2H-3,1-Benzoxazin-2-one, 1,4-dihydro-6-(3-methoxyphenyl)-4,4-dimethyl- 304854-37-3P, 2H-3,1-Benzoxazin-2-one,

6-(2-chlorophenyl)-1,4-dihydro-4,4-dimethyl- 304854-38-4P, 2H-3,1-Benzoxazin-2-one, 6-(3-chlorophenyl)-1,4-dihydro-4-methyl-4-(phenylmethyl)- 304854-39-5P, 2-Thiophenecarbonitrile, 5-(1,4-dihydro-4,4-dimethyl-2-oxo-2H-3,1-benzoxazin-6-yl)- 304854-41-9P, Benzonitrile, 3-fluoro-5-(8-fluoro-1,4-dihydro-4,4-dimethyl-2-oxo-2H-3,1-benzoxazin-6-yl)- 304854-42-0P, Benzonitrile, 3-(1,2-dihydro-2-oxospiro[4H-3,1-benzoxazine-4,1'-cyclohexan]-6-yl)- 304854-43-1P, 2-Thiophenecarbonitrile, 5-(1,2-dihydro-2-oxospiro[4H-3,1-benzoxazine-4,1'-cyclohexan]-6-yl)-4-methyl- 304854-44-2P, 2-Thiophenecarbonitrile, 5-(1,2-dihydro-2-oxospiro[4H-3,1-benzoxazine-4,1'-cyclohexan]-6-yl)- 304854-45-3P, 2H-3,1-Benzoxazin-2-one, 6-(3-chloro-4-fluorophenyl)-1,4-dihydro-4,4-dimethyl- 304854-46-4P, 2-Thiophenecarbonitrile, 5-(1,4-dihydro-4,4-dimethyl-2-oxo-2H-3,1-benzoxazin-6-yl)-4-propyl- 304854-47-5P, 2-Furancarbonitrile, 4-(1,4-dihydro-4,4-dimethyl-2-oxo-2H-3,1-benzoxazin-6-yl)- 304854-48-6P, 2-Thiophenecarbonitrile, 4-butyl-5-(1,4-dihydro-4,4-dimethyl-2-oxo-2H-3,1-benzoxazin-6-yl)- 304854-49-7P, 2H-3,1-Benzoxazin-2-one, 6-(3-bromophenyl)-1,4-dihydro-4,4-dimethyl- 304854-50-0P, 3-Thiophenecarbonitrile, 2-(1,4-dihydro-4,4-dimethyl-2-oxo-2H-3,1-benzoxazin-6-yl)- 305799-74-0P, 2H-3,1-Benzoxazin-2-one, 6-(4-chlorophenyl)-1,4-dihydro-4,4-dimethyl- 305799-76-2P, 2H-3,1-Benzoxazin-2-one, 6-(3-chlorophenyl)-1,4-dihydro-4-methyl- 305799-78-4P, 2H-3,1-Benzoxazin-2-one, 6-(3-chlorophenyl)-4-ethyl-1,4-dihydro- 305799-80-8P, 2H-3,1-Benzoxazin-2-one, 6-(3-chlorophenyl)-1,4-dihydro-4-phenyl- 305799-81-9P, 3-Pyridinecarbonitrile, 5-(1,4-dihydro-4,4-dimethyl-2-oxo-2H-3,1-benzoxazin-6-yl)- 305799-83-1P, Spiro[4H-3,1-benzoxazine-4,1'-cyclohexan]-2-one, 6-(3-chlorophenyl)-1,2-dihydro- 305799-85-3P, Spiro[4H-3,1-benzoxazine-4,1'-cyclopentan]-2(1H)-one, 6-(3-chlorophenyl)- 305799-86-4P, Spiro[4H-3,1-benzoxazine-4,1'-cyclohexan]-2-one, 1,2-dihydro-6-(3-nitrophenyl)- 305799-87-5P, 2H-3,1-Benzoxazin-2-one, 6-(3-chlorophenyl)-1,4-dihydro-4-methyl-4-(1-propynyl)- 305799-88-6P, 2H-3,1-Benzoxazin-2-one, 6-(3-chlorophenyl)-4-ethynyl-1,4-dihydro-4-methyl- 305799-89-7P, 2H-3,1-Benzoxazin-2-one, 6-(3-chlorophenyl)-4-cyclopropyl-1,4-dihydro-4-methyl- 305799-93-3P, 2H-3,1-Benzoxazin-2-one, 6-(3-chlorophenyl)-4-cyclopropyl-1,4-dihydro-4-(1-propynyl)- 305799-95-5P, 2H-3,1-Benzoxazin-2-one, 6-(3-chlorophenyl)-4,4-dicyclopropyl-1,4-dihydro- 305799-97-7P, 2H-3,1-Benzoxazin-2-one, 6-(3-chlorophenyl)-1,4-dihydro-4,4-di-1-propynyl- 305799-98-8P, 2H-3,1-Benzoxazin-2-one, 6-(3-bromo-5-fluorophenyl)-1,4-dihydro-1,4,4-trimethyl- 305799-99-9P, 2H-3,1-Benzoxazin-2-one, 6-chloro-1,4-dihydro-4-methyl-4-(trifluoromethyl)- 305800-00-4P, 2H-3,1-Benzoxazin-2-one, 1,4-dihydro-6-(3-methoxyphenyl)-4-methyl-4-(trifluoromethyl)- 305800-02-6P, 2H-3,1-Benzoxazin-2-one, 1,4-dihydro-7-(3-methoxyphenyl)-4,4-dimethyl- 305800-03-7P, 2H-3,1-Benzoxazin-2-one, 6-(3-acetylphenyl)-1,4-dihydro-4,4-dimethyl- 305800-04-8P, 2H-3,1-Benzoxazin-2-one, 6-(3-benzoylphenyl)-1,4-dihydro-4,4-dimethyl- 305800-05-9P, 2H-3,1-Benzoxazin-2-one, 1,4-dihydro-4,4-dimethyl-6-[3-(1H-tetrazol-5-yl)phenyl]- 305800-08-2P, 2-Thiophenecarbonitrile, 4-(4,4-dicyclopropyl-1,4-dihydro-2-oxo-2H-3,1-benzoxazin-6-yl)- 305800-09-3P, 2H-3,1-Benzoxazin-2-one, 6-(3-bromo-5-fluorophenyl)-4,4-dicyclopropyl-1,4-dihydro- 305800-10-6P, Benzonitrile, 3-(4,4-dicyclopropyl-1,4-dihydro-2-oxo-2H-3,1-benzoxazin-6-yl)-5-fluoro- 305800-11-7P, Benzonitrile, 3-(1,4-dihydro-4,4-dimethyl-2-oxo-2H-3,1-benzoxazin-6-yl)-5-(trifluoromethoxy)- 305800-12-8P, 2H-3,1-Benzoxazin-2-one, 6-[3,5-bis(trifluoromethyl)phenyl]-1,4-dihydro-4,4-dimethyl- 305800-14-0P, Benzonitrile, 3-[1-(diethoxymethyl)-1,4-dihydro-4,4-dimethyl-2-oxo-2H-3,1-benzoxazin-6-yl]-5-fluoro- 305800-15-1P, Benzonitrile, 3-[1,4-dihydro-1-(methoxymethyl)-4,4-dimethyl-2-oxo-2H-3,1-benzoxazin-6-yl]-5-fluoro- 305800-16-2P, Phosphoric acid, 6-(3-cyano-5-fluorophenyl)-4,4-dimethyl-4H-3,1-benzoxazin-2-yl diethyl ester 305800-18-4P,

2H-3,1-Benzoxazin-2-one, 6-(3-chloro-4-fluorophenyl)-8-fluoro-1,4-dihydro-4,4-dimethyl- 305800-19-5P, 2H-3,1-Benzoxazin-2-one, 1,4-dihydro-4,4-dimethyl-6-[3-[(trimethylsilyl)ethynyl]phenyl]- 305800-20-8P, 2H-3,1-Benzoxazin-2-one, 6-(3-ethynylphenyl)-1,4-dihydro-4,4-dimethyl- 305800-21-9P, 2-Propynenitrile, 3-[3-(1,4-dihydro-4,4-dimethyl-2-oxo-2H-3,1-benzoxazin-6-yl)phenyl]- 305800-22-0P, 2H-3,1-Benzoxazin-2-one, 6-(3-fluoro-5-nitrophenyl)-1,4-dihydro-4,4-dimethyl- 305800-23-1P, 2H-3,1-Benzoxazin-2-one, 6-(3,5-dinitrophenyl)-1,4-dihydro-4,4-dimethyl- 305800-24-2P, 2H-3,1-Benzoxazin-2-one, 1,4-dihydro-4,4-dimethyl-6-[3-(2-thiazolyl)phenyl]- 305800-25-3P, 2H-3,1-Benzoxazin-2-one, 6-(5-bromo-1-oxido-3-pyridinyl)-1,4-dihydro-4,4-dimethyl- 305800-26-4P, 2H-3,1-Benzoxazine-1(4H)-carboxylic acid, 6-(3-cyano-5-fluorophenyl)-4,4-dimethyl-2-oxo-, 1,1-dimethylethyl ester 305800-27-5P, 2-Thiophenecarbonitrile, 4-(8-fluoro-1,4-dihydro-4,4-dimethyl-2-oxo-2H-3,1-benzoxazin-6-yl)- 305800-34-4P, 2H-3,1-Benzoxazin-2-one, 1,4-dihydro-4,4-dimethyl-6-[3-(1,2,4-thiadiazol-3-yl)phenyl]- 305800-36-6P, 1H-Pyrrole-1-carboxylic acid, 2-(1,4-dihydro-4,4-dimethyl-2-oxo-2H-3,1-benzoxazin-6-yl)-5-nitro-,1,1-dimethylethylester 305800-37-7P, 2H-3,1-Benzoxazin-2-one, 1,4-dihydro-4,4-dimethyl-6-(5-nitro-1H-pyrrol-2-yl)- 305800-38-8P, 2H-3,1-Benzoxazin-2-one, 1,4-dihydro-4,4-dimethyl-6-(1H-pyrrol-2-yl)- 305800-39-9P, 2H-3,1-Benzoxazin-2-one, 1,4-dihydro-4,4-dimethyl-6-(1-methyl-1H-pyrrol-2-yl)- 305800-40-2P, 2H-3,1-Benzoxazin-2-one, 1,4-dihydro-4,4-dimethyl-6-(1-methyl-5-nitro-1H-pyrrol-2-yl)- 305800-45-7P, 2-Thiophenecarbonitrile, 5-(1,4-dihydro-4,4-dimethyl-2-oxo-2H-3,1-benzoxazin-6-yl)-4-ethyl- 305800-46-8P, Benzonitrile, 4-(1,4-dihydro-4,4-dimethyl-2-oxo-2H-3,1-benzoxazin-6-yl)-2-fluoro- 305800-47-9P, Benzeneacetonitrile, 3-(1,4-dihydro-4,4-dimethyl-2-oxo-2H-3,1-benzoxazin-6-yl)- 305800-48-0P, Benzonitrile, 3-(1,4-dihydro-4,4-dimethyl-2-oxo-2H-3,1-benzoxazin-6-yl)-2-fluoro- 305800-50-4P, Spiro[4H-3,1-benzoxazine-4,1'-cyclobutan]-2(1H)-one, 6-(3-methoxyphenyl)- 305800-51-5P, 2H-3,1-Benzoxazin-2-one, 8-bromo-6-(3-chloro-4-fluorophenyl)-1,4-dihydro-4,4-dimethyl- 305800-52-6P, Benzonitrile, 5-(8-bromo-1,4-dihydro-4,4-dimethyl-2-oxo-2H-3,1-benzoxazin-6-yl)-2-fluoro- 305800-53-7P, 2H-3,1-Benzoxazin-2-one, 6-(3-bromophenyl)-1,4-dihydro-1,4,4-trimethyl- 305800-55-9P, Benzonitrile, 3-(1,4-dihydro-8-methoxy-4,4-dimethyl-2-oxo-2H-3,1-benzoxazin-6-yl)-5-fluoro- 305800-56-0P, Benzonitrile, 3-(1,4-dihydro-8-hydroxy-4,4-dimethyl-2-oxo-2H-3,1-benzoxazin-6-yl)-5-fluoro- 305800-57-1P, Benzonitrile, 3-(1-ethyl-1,4-dihydro-4,4-dimethyl-2-oxo-2H-3,1-benzoxazin-6-yl)-5-fluoro- 305800-59-3P, Benzeneacetonitrile, 3-(1,4-dihydro-4,4-dimethyl-2-oxo-2H-3,1-benzoxazin-6-yl)-5-fluoro- 305800-62-8P, Benzeneacetonitrile, 4-(1,4-dihydro-4,4-dimethyl-2-oxo-2H-3,1-benzoxazin-6-yl)-2-fluoro- 305800-63-9P, Benzeneacetonitrile, 2-(1,4-dihydro-4,4-dimethyl-2-oxo-2H-3,1-benzoxazin-6-yl)- 305800-64-0P, Acetamide, N-[4-(1,4-dihydro-4,4-dimethyl-2-oxo-2H-3,1-benzoxazin-6-yl)-2-fluorophenyl]- 305800-65-1P, 2H-3,1-Benzoxazin-2-one, 6-(3-fluoro-4-methoxyphenyl)-1,4-dihydro-4,4-dimethyl- 305800-66-2P, Benzenesulfonamide, 3-(1,4-dihydro-4,4-dimethyl-2-oxo-2H-3,1-benzoxazin-6-yl)- 305800-67-3P, 2-Thiophenesulfonamide, 5-(1,4-dihydro-4,4-dimethyl-2-oxo-2H-3,1-benzoxazin-6-yl)- 305800-68-4P, 2H-3,1-Benzoxazin-2-one, 6-(6-amino-3-pyridinyl)-1,4-dihydro-4,4-dimethyl- 305800-71-9P, 2-Furancarboxaldehyde, 4-(1,4-dihydro-4,4-dimethyl-2-oxo-2H-3,1-benzoxazin-6-yl)- 305800-72-0P, 2-Furancarboxaldehyde, 4-(1,4-dihydro-4,4-dimethyl-2-oxo-2H-3,1-benzoxazin-6-yl)-, 2-oxime 305839-71-8P, 2H-3,1-Benzoxazin-2-one, 6-[3-fluoro-5-(2-thienyl)phenyl]-1,4-dihydro-4,4-dimethyl- 305839-75-2P, Benzeneacetonitrile, 3-(1,4-dihydro-4,4-dimethyl-2-oxo-2H-3,1-benzoxazin-6-yl)-4-fluoro- 305839-76-3P, 2H-3,1-Benzoxazin-2-one, 6-[5-(diethoxymethyl)-2-furanyl]-1,4-dihydro-4,4-dimethyl-
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzoxazinone cyclic carbamate antiprogestins for use in combination therapies and regimens with progestational agents)

IT 100-58-3, Phenylmagnesium bromide 108-36-1, 1,3-Dibromobenzene 110-52-1, 1,4-Dibromobutane 111-24-0, 1,5-Dibromopentane 122-51-0, Triethylorthoformate 326-66-9, 4'-Bromo-2'-fluoroacetanilide 348-61-8, 1-Bromo-3,4-difluorobenzene 460-00-4, 1-Bromo-4-fluorobenzene 461-96-1, 1-Bromo-3,5-difluorobenzene 623-49-4, Ethylcyano formate 625-92-3, 3,5-Dibromopyridine 814-49-3, Diethyl chlorophosphate 1066-54-2, Trimethylsilylacetylene 1072-85-1, 1-Bromo-2-fluorobenzene 1072-97-5, 2-Amino-5-bromopyridine 1073-06-9, 1-Bromo-3-fluorobenzene 1191-95-3, Cyclobutanone 1435-51-4, 1,3-Dibromo-5-fluorobenzene 1546-79-8, 1-(Trifluoroacetyl)imidazole 1611-92-3, 3,5-Dibromotoluene 1679-18-1, 4-Chlorophenyl boronic acid 1730-25-2, Allylmagnesium bromide 2357-52-0, 4-Bromo-2-fluoroanisole 3177-80-8, 2-Amino-3-methoxybenzoic acid 3900-89-8, 2-Chlorophenyl boronic acid 4333-56-6, Cyclopropyl bromide 4648-54-8, Trimethylsilyl azide 4692-98-2, 5-Bromoisatoic anhydride 4701-17-1, 5-Bromo-2-thiophenecarboxaldehyde 4915-06-4, 2-Bromo-5-cyanofuran 5326-47-6, 2-Amino-5-iodobenzoic acid 5794-88-7, 2-Amino-5-bromobenzoic acid 6165-69-1, 3-Thiophene boronic acid 6638-79-5, N,O-Dimethylhydroxylamine hydrochloride 6952-59-6, 3-Bromobenzonitrile 7087-65-2, Benzene, 1-bromo-3-fluoro-5-nitro- 10365-98-7, 3-Methoxyphenyl boronic acid 13331-27-6, 3-Nitrophenyl boronic acid 14282-76-9, 2-Bromo-3-methylthiophene 18242-39-2, 1-Bromo-3,5-dinitrobenzene 18791-99-6, 2-Thiophenecarbonitrile, 4-bromo- 18792-00-2, 3-Thiophenecarbonitrile, 5-bromo- 19472-74-3, 2-Bromophenylacetonitrile 27065-51-6, Furan, 4-bromo-2-(diethoxymethyl)- 29578-39-0, Anisole, 3-Bromo-5-fluoro- 31938-07-5, 3-Bromophenylacetonitrile 32423-84-0, Propynylmagnesium bromide 33743-87-2, 1,3,4-Oxathiazol-2-one, 5-(3-bromophenyl)- 33863-76-2, 1-Bromo-3-chloro-5-fluorobenzene 35590-37-5, 3-Bromo-5-cyanopyridine 39263-32-6, 2-Amino-5-bromobenzonitrile 51437-00-4, 5-Bromo-2-fluorotoluene 53119-61-2, 2-Bromo-3-ethylthiophene 53595-65-6, 2-Thiophenesulfonamide, 5-bromo- 56182-43-5, 2-Bromo-3-thiophenecarbonitrile 60811-21-4, Benzene, 4-bromo-2-chloro-1-fluoro- 63503-60-6, 3-Chlorophenyl boronic acid 65854-91-3, N-(4-Chlorophenyl)-2,2-dimethylpropanamide 67492-50-6, 3,5-Dichlorophenyl boronic acid 69249-60-1, Thiophene, 2-bromo-3-propyl- 73852-19-4, Boronic acid, [3,5-bis(trifluoromethyl)phenyl]- 89599-01-9, 3-Bromobenzenesulfonamide 105942-08-3, Benzonitrile, 4-bromo-2-fluoro- 112575-11-8, 2-Pyridineacetonitrile, 6-bromo- 114897-91-5, Benzeneacetonitrile, 4-bromo-2-fluoro- 121359-48-6, Thiazole, 2-(tributylstannyl)- 130723-13-6, Benzene, 1-bromo-3-fluoro-5-(trifluoromethyl)- 135884-31-0, 1H-Pyrrole-1-carboxylic acid, 2-borono-, 1-(1,1-dimethylethyl) ester 145543-82-4, 2-Bromo-3-n-butylthiophene 160892-07-9, 5-Bromoisophthalonitrile 161957-56-8, Benzoic acid, 3-bromo-2-fluoro- 179897-89-3, Benzonitrile, 5-bromo-2-fluoro- 179898-34-1, 3-Bromo-5-fluorobenzonitrile 188813-02-7, Benzaldehyde, 3-bromo-5-fluoro- 207226-31-1, Benzene, 1,3-dibromo-5-(trifluoromethoxy)- 216755-57-6, Benzene, 1-bromo-3-(bromomethyl)-5-fluoro- 304854-51-1, [1,1'-Biphenyl]-3-carbonitrile, 4-amino-3'-fluoro- 304854-53-3, 2H-3,1-Benzoxazin-2-one, 4,4-diethyl-1,4-dihydro-6-iodo- 304854-55-5, Benzonitrile, 3-bromo-5-chloro- 304854-57-7, Methanesulfonic acid, trifluoro-, (2,3-difluorophenyl)methyl ester 304854-59-9, [1,1'-Biphenyl]-3-methanol, 4-amino-3'-chloro-α-methyl-α-(phenylmethyl)- 304854-61-3, Boronic acid, (8-fluoro-1,4-dihydro-4,4-dimethyl-2-oxo-2H-3,1-benzoxazin-6-yl)- 304854-63-5, 2-Furancarbonitrile, 4-bromo- 305799-77-3, [1,1'-Biphenyl]-3-methanol, 4-amino-3'-chloro-α-ethyl- 305799-79-5, [1,1'-Biphenyl]-3-

methanol, 4-amino-3'-chloro-α-phenyl- 305799-92-2, [1,1'-Biphenyl]-3-methanol, 4-amino-3'-chloro-α-cyclopropyl-α-1-propynyl- 305800-01-5, 2H-3,1-Benzoxazin-2-one, 7-chloro-1,4-dihydro-4,4-dimethyl- 305800-13-9, Methanesulfonic acid, trifluoro-, 3-cyano-5-methoxyphenyl ester
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of benzoxazinone cyclic carbamate antiprogestins for use in combination therapies and regimens with progestational agents)

IT 2160-62-5P, 2-Thiophenecarbonitrile, 5-bromo- 21440-97-1P, 2H-3,1-Benzoxazin-2-one, 6-bromo-1,4-dihydro-4,4-dimethyl- 21440-99-3P, 2H-3,1-Benzoxazin-2-one, 1,4-dihydro-8-methoxy-4,4-dimethyl- 141940-30-9P, Benzoic acid, 2-[[(1,1-dimethylethoxy)carbonyl]amino]-3-fluoro- 149947-15-9P, Benzaldehyde, 3-bromo-2-fluoro- 154598-53-5P, Ethanone, 1-(2-amino-5-chlorophenyl)-2,2,2-trifluoro- 189331-47-3P, 2-Thiophenecarboxaldehyde, 5-bromo-4-methyl- 206551-41-9P, Benzoic acid, 3-bromo-2-fluoro-, methyl ester 216755-56-5P, Benzenemethanol, 3-bromo-5-fluoro- 304853-89-2P, Benzenemethanol, 2-amino-5-bromo-α,α-dimethyl- 304853-90-5P, Boronic acid, (1,4-dihydro-4,4-dimethyl-2-oxo-2H-3,1-benzoxazin-6-yl)- 304853-91-6P, Ethanone, 1-(4-amino-3'-fluoro[1,1'-biphenyl]-3-yl)- 304853-92-7P, [1,1'-Biphenyl]-3-methanol, 4-amino-3'-fluoro-α-methyl- 304854-03-3P, Cyclohexanol, 1-(2-amino-5-bromophenyl)- **304854-04-4P**, Spiro[4H-3,1-benzoxazine-4,1'-cyclohexan]-2-one, 6-bromo-1,2-dihydro- 304854-05-5P, Boronic acid, (1,2-dihydro-2-oxospiro[4H-3,1-benzoxazine-4,1'-cyclohexan]-6-yl)- 304854-19-1P, Ethanone, 1-(4-amino-3'-chloro[1,1'-biphenyl]-3-yl)- 304854-40-8P, 2H-3,1-Benzoxazin-2-one, 8-fluoro-1,4-dihydro-4,4-dimethyl- 304854-52-2P, 2-Thiophenecarbonitrile, 5-bromo-4-methyl- 304854-54-4P, Benzamide, 2-amino-5-bromo-N-methoxy-N-methyl- 304854-58-8P, 2H-3,1-Benzoxazin-2-one, 1,4-dihydro-6-iodo-4,4-dimethyl- 304854-62-4P, 2-Thiophenecarbonitrile, 5-bromo-4-propyl- 304857-58-7P, [1,1'-Biphenyl]-3-carbonitrile, 4-amino-3'-chloro- 304874-29-1P, 2-Thiophenecarbonitrile, 5-bromo-4-butyl- 305799-75-1P, [1,1'-Biphenyl]-3-methanol, 4-amino-3'-chloro-α-methyl- **305799-84-2P**, Spiro[4H-3,1-benzoxazine-4,1'-cyclopentan]-2(1H)-one, 6-bromo- 305799-94-4P, [1,1'-Biphenyl]-3-methanol, 4-amino-3'-chloro-α,α-dicyclopropyl- 305799-96-6P, 2-Butyn-1-one, 1-(4-amino-3'-chloro[1,1'-biphenyl]-3-yl)- 305800-06-0P, Boronic acid, (4,4-dicyclopropyl-1,4-dihydro-2-oxo-2H-3,1-benzoxazin-6-yl)- 305800-17-3P, 2H-3,1-Benzoxazin-2-one, 6-bromo-8-fluoro-1,4-dihydro-4,4-dimethyl- 305800-29-7P, 1,2,4-Thiadiazole-5-carboxylic acid, 3-(3-bromophenyl)-, ethyl ester 305800-32-2P, 1,2,4-Thiadiazole, 3-(3-bromophenyl)- 305800-41-3P, 2-Thiophenecarboxaldehyde, 5-bromo-4-ethyl- 305800-42-4P, 2-Thiophenecarbonitrile, 5-bromo-4-ethyl- 305800-43-5P, 2-Thiophenecarboxaldehyde, 5-bromo-4-propyl- 305800-44-6P, 2-Thiophenecarboxaldehyde, 5-bromo-4-butyl- 305800-49-1P, Spiro[4H-3,1-benzoxazine-4,1'-cyclobutan]-2(1H)-one, 6-chloro- 305800-54-8P, 2H-3,1-Benzoxazin-2-one, 6-bromo-1,4-dihydro-8-methoxy-4,4-dimethyl- 305839-72-9P, [1,1'-Biphenyl]-3-carboxamide, 3'-chloro-N-methoxy-N-methyl- 305839-73-0P, Methanone, (4-amino-3'-chloro[1,1'-biphenyl]-3-yl)cyclopropyl-, hydrochloride 305839-74-1P, [1,1'-Biphenyl]-3-methanol, 4-amino-3'-chloro-α-cyclopropyl-
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of benzoxazinone cyclic carbamate antiprogestins for use in combination therapies and regimens with progestational agents)

RE.CNT 75 THERE ARE 75 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Andreani, A; Acta Pharm Nord 1990, V2(6), P407 HCAPLUS

(2) Anon; JP 63112584 HCAPLUS
(3) Anon; EP 022317 1981 HCAPLUS
(4) Anon; WO 8603749 1986 HCAPLUS
(5) Anon; DE 3633861 1988 HCAPLUS
(6) Anon; JP 63112584 1988 HCAPLUS
(7) Anon; EP 311135 1989 HCAPLUS
(8) Anon; EP 385850 1990 HCAPLUS
(9) Anon; EP 454330 1991 HCAPLUS
(10) Anon; WO 9104974 1991 HCAPLUS
(11) Anon; WO 9106545 1991 HCAPLUS
(12) Anon; EP 510235 1992 HCAPLUS
(13) Anon; WO 9312085 1993 HCAPLUS
(14) Anon; WO 9414434 1994 HCAPLUS
(15) Anon; WO 9520389 1995 HCAPLUS
(16) Anon; WO 9520972 1995
(17) Anon; WO 9533746 1995 HCAPLUS
(18) Anon; WO 9619458 1996 HCAPLUS
(19) Anon; WO 9619997 1996 HCAPLUS
(20) Anon; WO 9713767 1997 HCAPLUS
(21) Anon; WO 9814436 1998 HCAPLUS
(22) Arndt, F; EP 311135 HCAPLUS
(23) Barengolts, E; Bone 1995, V17(1), P21 HCAPLUS
(24) Brumagniez, N; EP 385850 HCAPLUS
(25) Canonne, P; J Heterocyclic Chem 1989, V26, P113 HCAPLUS
(26) Chen, R; POI-37, 16th Int Cong Het Chem 1997
(27) Chiarino, D; J Heterocycl Chem 1986, V23(6), P1645 HCAPLUS
(28) Chwalisz; US 5719136 A 1998 HCAPLUS
(29) Combs, D; J Med Chem 1992, V35, P172 HCAPLUS
(30) Combs, D; J Med Chem 1995, V38, P4880 HCAPLUS
(31) Edwards, J; J Med Chem 1998, V41, P303 HCAPLUS
(32) Evans, R; Science 1988, V240, P889 HCAPLUS
(33) Fischer; US 4853473 A 1989 HCAPLUS
(34) Fischer; US 5453516 A 1995 HCAPLUS
(35) Forest, M; J Med Chem 1992, V35, P163 HCAPLUS
(36) Gromachevskaya, E; Chem Heterocycl Cmpds 1997, V33(10), P1209 HCAPLUS
(37) Grubb; US 5521166 A 1996 HCAPLUS
(38) Hamann, L; Ann N Y Acad Sci 1995, V761, P383 HCAPLUS
(39) Hartmann, R; Proc West Pharmacol Soc 1978, V21, P51 HCAPLUS
(40) Hodgen; US 5681817 A 1997 HCAPLUS
(41) Horwitz, K; Horm Cancer 1996, P283 HCAPLUS
(42) Horwitz, K; Hormore and Cancer 1996, P283 HCAPLUS
(43) Johnson; US 5475020 A 1995 HCAPLUS
(44) Jones; US 5688808 A 1997 HCAPLUS
(45) Jones; US 5688810 A 1997 HCAPLUS
(46) Jones; US 5693646 A 1997 HCAPLUS
(47) Jones; US 5693647 A 1997 HCAPLUS
(48) Jones; US 5696127 A 1997 HCAPLUS
(49) Jones; US 5696130 A 1997 HCAPLUS
(50) Kekkonen, R; Fertility and Sterility 1993, V60(4), P610 MEDLINE
(51) Kende, A; Synth Commun 1982, V12(1), P1 HCAPLUS
(52) Kettel, L; Fertility and Sterility 1991, V56(3), P402 MEDLINE
(53) Kim; US 5171851 A 1992 HCAPLUS
(54) Kobzina; US 3917592 A 1975 HCAPLUS
(55) Kubla; US 4666913 A 1987 HCAPLUS
(56) Kumar, V; J Org Chem 1992, V57(25), P6995 HCAPLUS
(57) Kume; US 5007952 A 1991 HCAPLUS
(58) Kurihari; J Antibiotics 1997, V50(4), P360
(59) Michna, H; Ann N Y Acad Sci 1995, V761, P224 HCAPLUS
(60) Murphy, A; J Clin Endo Metab 1993, V76(2), P513 MEDLINE
(61) Narr; US 4831027 A 1989 HCAPLUS

(62) Narr, B; 1988 HCAPLUS
(63) Perlman, K; Tet Letters 1994, V35(15), P2295 HCAPLUS
(64) Pflegel, P; Pharmazie 1982, V37(10), P714 HCAPLUS
(65) Pooley; US 5696133 A 1997 HCAPLUS
(66) Sakata; 1993 HCAPLUS
(67) Singh, B; J Med Chem 1994, V37, P248 HCAPLUS
(68) Skorcz; US 3635964 A 1972 HCAPLUS
(69) Tucker, T; J Med Chem 1994, V37, P2347
(70) Turck, A; Tetrahedron 1993, V49(3), P599 HCAPLUS
(71) Ulmann, A; Ann N Y Acad Sci 1995, V261, P248
(72) Von der Saal; US 5414088 A 1995 HCAPLUS
(73) Walsh; US 4440785 A 1984 HCAPLUS
(74) Walsh; US 4670566 A 1987 HCAPLUS
(75) Zhi, L; J Med Chem 1998, V41(3), P291 HCAPLUS

IT **304854-04-4P**, Spiro[4H-3,1-benzoxazine-4,1'-cyclohexan]-2-one, 6-bromo-1,2-dihydro-
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of benzoxazinone cyclic carbamate antiprogestins for use in combination therapies and regimens with progestational agents)

RN 304854-04-4 HCAPLUS

CN Spiro[4H-3,1-benzoxazine-4,1'-cyclohexan]-2(1H)-one, 6-bromo- (9CI) (CA INDEX NAME)



L119 ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2001:167971 HCAPLUS

DN 134:207727

ED Entered STN: 09 Mar 2001

TI Preparation of quinolinones and related bicyclic compounds as androgen and **progesterone receptor modulators.**

IN Zhi, Lin; Tegley, Christopher; Pio, Barbara; Arjan van Oeveren, Cornelis; Motamedi, Mehrnouch; Martinborough, Esther; West, Sarah; Higuchi, Robert; Hamann, Lawrence; Farmer, Luc

PA Ligand Pharmaceuticals Incorporated, USA

SO PCT Int. Appl., 356 pp.
CODEN: PIXXD2

DT Patent

LA English

IC ICM C07D215-00

CC 27-17 (Heterocyclic Compounds (One Hetero Atom))
Section cross-reference(s): 1, 63

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001016108	A2	20010308	WO 2000-US23585	20000825 <--
WO 2001016108	A3	20011220		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,

```
            HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
            LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
            SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
            YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
            DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
            CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
    US 6566372          B1    20030520    US 2000-649466          20000824 <--
    CA 2384435          AA    20010308    CA 2000-2384435         20000825 <--
    BR 2000013653       A     20020514    BR 2000-13653           20000825 <--
    EP 1212303          A2    20020612    EP 2000-959507          20000825 <--
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL
    TR 200200508        T2    20020923    TR 2002-200200508       20000825 <--
    JP 2003508387       T2    20030304    JP 2001-519677          20000825 <--
    ZA 2002001053       A     20030528    ZA 2002-1053            20020206 <--
    NO 2002000912       A     20020429    NO 2002-912             20020225 <--
    BG 106539           A     20021031    BG 2002-106539          20020321 <--
    US 2003130505       A1    20030710    US 2002-299909          20021118 <--
PRAI US 1999-150987P    P     19990827  <--
    US 2000-649466      A3    20000824  <--
    WO 2000-US23585     W     20000825  <--
CLASS
 PATENT NO.       CLASS  PATENT FAMILY CLASSIFICATION CODES
 --------------   -----  ----------------------------------------------
 WO 2001016108    ICM    C07D215-00
 WO 2001016108    ECLA   C07D209/34; C07D209/96; C07D215/22B; C07D215/36;
                         C07D215/38; C07D239/80; C07D265/18B; C07D265/36;
                         C07D277/68B; C07D311/14; C07D311/20;
                         C07D401/04+217+215; C07D401/12+215+209;
                         C07D401/12+215+211; C07D401/12+215+207;
                         C07D401/12+215+209C; C07D401/12+215+213;
                         C07D405/12+307B+215; C07D409/12+333B+215;
                         C07D413/04+263B+215                              <--
 US 6566372       NCL    514/312.000; 514/217.070; 514/253.070; 514/311.000;
                         514/313.000; 514/314.000; 540/599.000; 544/363.000;
                         546/144.000; 546/152.000; 546/157.000; 546/159.000;
                         546/167.000; 546/171.000; 546/173.000; 546/180.000;
                         546/181.000                                      <--
 US 2003130505    NCL    540/575.000; 544/284.000; 546/157.000; 544/105.000;
                         549/283.000; 514/312.000; 514/218.000; 514/230.500;
                         514/456.000                                      <--
OS   MARPAT 134:207727
GI
```



I

AB Title compds., e.g. [I; R1, R2 = COR3, CSR3, SO2R3, NO, NR3R4, alkyl, alkenyl, haloalkyl, haloalkenyl, haloalkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, etc.; R1R2 = atoms to form (substituted) heterocyclyl; R3,

R4 = H, (substituted) alkyl, alkenyl, alkynyl, haloalkyl, heteroalkyl, heteroaryl, aryl; R5 = H, F, Cl, Br, iodo, OR3, SR3, NR3R4, alkyl, haloalkyl, heteroalkyl; R6 = F, Cl, Br, iodo, Me, CF3, CHF2, cyano, CF2Cl, CF2OR3, OR3, SOR3, CO2R3, NR3R4, (substituted) alkyl, alkenyl, alkynyl, haloalkyl, heteroalkyl, etc.; R7, R8 = H, F, Cl, Br, iodo, cyano, OR3, NR3R4, SR3, SOR3, NR3COR4, alkyl, haloalkyl, heteroalkyl, etc.; R9 = H, F, Cl, iodo, OR3, NR3R4, SR3, SOR3, SO2R3, alkyl, haloalkyl, heteroalkyl; R10 = NR1R2, (substituted) heterocyclyl; Y = O, S, NR3, NOR3, CR3R4], were prepared Thus, 6-amino-4-trifluoromethyl-2(1H)-quinolinone (preparation given) was stirred with propionaldehyde and NaBH3CN in MeOH to give 70-95% 6-propylamino-4-trifluoromethyl-2(1H)-quinolinone. The latter showed androgen receptor agonist activity with a potency of 27 nM. A drug composition is given.

ST quinolinone prepn androgen **progesterone receptor modulator**

IT Androgen **receptors**
Progesterone receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study); PROC (Process)
(**modulators**; preparation of quinolinones and related bicyclic compds. as androgen and **progesterone receptor modulators**)

IT 328947-93-9P 328951-07-1P 328955-28-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of quinolinones and related bicyclic compds. as androgen and **progesterone receptor modulators**)

IT 5045-89-6P 21440-97-1P 22246-13-5P 26215-14-5P 57980-15-1P
58721-76-9P 73496-31-8P 79207-68-4P 89446-19-5P 90914-95-7P
124954-76-3P 135631-90-2P 156232-57-4P 304468-42-6P 304853-34-7P
328947-55-3P 328947-57-5P 328947-59-7P 328947-61-1P 328947-63-3P
328947-65-5P 328947-67-7P 328947-69-9P 328947-71-3P 328947-73-5P
328947-75-7P 328947-77-9P 328947-79-1P 328947-81-5P 328947-83-7P
328947-85-9P 328947-87-1P 328947-89-3P 328947-91-7P 328947-95-1P
328947-97-3P 328947-99-5P 328948-01-2P 328948-03-4P 328948-05-6P
328948-07-8P 328948-09-0P 328948-11-4P 328948-13-6P 328948-14-7P
328948-15-8P 328948-17-0P 328948-19-2P 328948-21-6P 328948-23-8P
328948-27-2P 328948-30-7P 328948-33-0P 328948-36-3P 328948-39-6P
328948-42-1P 328948-44-3P 328948-46-5P 328948-48-7P 328948-50-1P
328948-52-3P 328948-54-5P 328948-56-7P 328948-58-9P 328948-60-3P
328948-62-5P 328948-64-7P 328948-66-9P 328948-68-1P 328948-70-5P
328948-72-7P 328948-74-9P 328948-76-1P 328948-78-3P 328948-80-7P
328948-81-8P 328948-83-0P 328948-85-2P 328948-87-4P 328948-89-6P
328948-91-0P 328948-93-2P 328948-95-4P 328948-97-6P 328948-98-7P
328949-00-4P 328949-02-6P 328949-04-8P 328949-06-0P 328949-08-2P
328949-10-6P 328949-12-8P 328949-14-0P 328949-16-2P 328949-18-4P
328949-19-5P 328949-21-9P 328949-22-0P 328949-24-2P 328949-26-4P
328949-28-6P 328949-30-0P 328949-32-2P 328949-34-4P 328949-35-5P
328949-37-7P 328949-39-9P 328949-41-3P 328949-43-5P 328949-45-7P
328949-47-9P 328949-49-1P 328949-50-4P 328949-52-6P 328949-54-8P
328949-56-0P 328949-58-2P 328949-59-3P 328949-61-7P 328949-63-9P
328949-65-1P 328949-67-3P 328949-69-5P 328949-71-9P 328949-73-1P
328949-75-3P 328949-77-5P 328949-79-7P 328949-81-1P 328949-83-3P
328949-85-5P 328949-87-7P 328949-88-8P 328949-90-2P 328949-92-4P
328949-94-6P 328949-96-8P 328949-98-0P 328950-00-1P 328950-02-3P
328950-04-5P 328950-06-7P 328950-07-8P 328950-09-0P 328950-10-3P
328950-12-5P 328950-14-7P 328950-16-9P 328950-18-1P 328950-20-5P
328950-21-6P 328950-23-8P 328950-25-0P 328950-27-2P 328950-29-4P

328950-31-8P 328950-33-0P 328950-34-1P 328950-36-3P 328950-38-5P
328950-40-9P 328950-42-1P 328950-44-3P 328950-46-5P 328950-48-7P
328950-50-1P 328950-52-3P 328950-54-5P 328950-56-7P 328950-58-9P
328950-59-0P 328950-61-4P 328950-63-6P 328950-65-8P 328950-67-0P
328950-69-2P 328950-71-6P 328950-75-0P 328950-77-2P 328950-79-4P
328950-81-8P 328950-83-0P 328950-85-2P 328950-87-4P 328950-89-6P
328950-91-0P 328950-93-2P 328950-95-4P 328950-97-6P 328950-99-8P
328951-01-5P 328951-03-7P 328951-05-9P 328951-09-3P 328951-11-7P
328951-13-9P 328951-15-1P 328951-17-3P 328951-19-5P 328951-21-9P
328951-23-1P 328951-25-3P 328951-27-5P 328951-29-7P 328951-31-1P
328951-33-3P 328951-35-5P 328951-37-7P 328951-39-9P 328951-41-3P
328951-43-5P 328951-45-7P 328951-47-9P 328951-49-1P 328951-51-5P
328951-53-7P 328951-55-9P 328951-57-1P 328951-59-3P 328951-61-7P
328951-62-8P 328951-64-0P 328951-66-2P 328951-68-4P 328951-70-8P
328951-72-0P 328951-74-2P 328951-76-4P 328951-78-6P 328951-80-0P
328951-82-2P 328951-84-4P 328951-86-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of quinolinones and related bicyclic compds. as androgen and **progesterone receptor modulators**)

IT 328951-88-8P 328951-91-3P 328951-93-5P 328951-94-6P 328951-96-8P
328951-98-0P 328952-00-7P 328952-02-9P 328952-04-1P 328952-06-3P
328952-08-5P 328952-10-9P 328952-12-1P 328952-14-3P 328952-16-5P
328952-18-7P 328952-20-1P 328952-22-3P 328952-24-5P 328952-26-7P
328952-28-9P 328952-30-3P 328952-32-5P 328952-34-7P 328952-36-9P
328952-38-1P 328952-40-5P 328952-42-7P 328952-44-9P 328952-46-1P
328952-48-3P 328952-50-7P 328952-52-9P 328952-54-1P 328952-56-3P
328952-58-5P 328952-60-9P 328952-62-1P 328952-64-3P 328952-66-5P
328952-68-7P 328952-71-2P 328952-75-6P 328952-79-0P 328952-84-7P
328952-89-2P 328952-93-8P 328952-96-1P 328952-99-4P 328953-03-3P
328953-07-7P 328953-09-9P 328953-13-5P 328953-17-9P 328953-21-5P
328953-25-9P 328953-29-3P 328953-32-8P 328953-34-0P 328953-36-2P
328953-38-4P 328953-40-8P 328953-42-0P 328953-44-2P 328953-46-4P
328953-48-6P 328953-50-0P 328953-52-2P 328953-54-4P 328953-56-6P
328953-58-8P 328953-60-2P 328953-62-4P 328953-64-6P 328953-66-8P
328953-68-0P 328953-70-4P 328953-72-6P 328953-74-8P 328953-76-0P
328953-78-2P 328953-80-6P 328953-82-8P 328953-84-0P 328953-86-2P
328953-88-4P 328953-90-8P 328953-92-0P 328953-94-2P 328953-96-4P
328953-98-6P 328954-00-3P 328954-02-5P 328954-04-7P 328954-06-9P
328954-07-0P 328954-08-1P 328954-09-2P 328954-10-5P 328954-11-6P
328954-12-7P 328954-14-9P 328954-15-0P 328954-16-1P 328954-17-2P
328954-18-3P 328954-19-4P 328954-20-7P 328954-21-8P 328954-22-9P
328954-23-0P 328954-24-1P 328954-25-2P 328954-26-3P 328954-27-4P
328954-28-5P 328954-29-6P 328954-30-9P 328954-31-0P 328954-32-1P
328954-33-2P 328954-34-3P 328954-35-4P 328954-36-5P 328954-37-6P
328954-38-7P 328954-39-8P 328954-40-1P 328954-41-2P 328954-42-3P
328954-43-4P 328954-44-5P 328954-45-6P 328954-46-7P 328954-47-8P
328954-48-9P 328954-49-0P 328954-50-3P 328954-51-4P 328954-52-5P
328954-53-6P 328954-54-7P 328954-55-8P 328954-56-9P 328954-57-0P
328954-58-1P 328954-59-2P 328954-60-5P 328954-61-6P 328954-62-7P
328954-63-8P 328954-64-9P 328954-65-0P 328954-66-1P 328954-67-2P
328954-68-3P 328954-69-4P 328954-70-7P 328954-71-8P 328954-72-9P
328954-73-0P 328954-74-1P **328954-75-2P** 328954-76-3P
328954-77-4P 328954-78-5P 328954-79-6P 328954-80-9P
328954-81-0P **328954-82-1P** 328954-83-2P 328954-84-3P
328954-85-4P 328954-86-5P 328954-87-6P 328954-88-7P 328954-89-8P
328954-90-1P 328954-91-2P 328954-92-3P 328954-93-4P 328954-94-5P
328954-95-6P 328954-96-7P 328954-97-8P 328954-98-9P 328954-99-0P
328955-00-6P 328955-01-7P 328955-02-8P 328955-03-9P 328955-04-0P

328955-05-1P 328955-06-2P 328955-07-3P 328955-08-4P 328955-09-5P
328955-10-8P 328955-11-9P 328955-12-0P 328955-13-1P 328955-14-2P
328955-15-3P 328955-16-4P 328955-17-5P 328955-18-6P 328955-19-7P
328955-20-0P 328955-21-1P 328955-22-2P 328955-23-3P 328955-24-4P
328955-25-5P 328955-26-6P 328955-27-7P 328955-29-9P 328955-31-3P
328955-33-5P 328955-35-7P 328955-37-9P 328955-39-1P 328955-40-4P
328955-41-5P 328955-43-7P 328955-45-9P 328955-47-1P 328955-49-3P
328955-51-7P 328955-53-9P 328955-55-1P 328955-57-3P 328955-59-5P
328955-61-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of quinolinones and related bicyclic compds. as androgen and **progesterone receptor modulators**)

IT 328955-63-1P 328955-65-3P 328955-66-4P 328955-68-6P 328955-70-0P
328955-73-3P 328955-75-5P 328955-77-7P 328955-80-2P 328955-81-3P
328955-82-4P 328955-83-5P 328955-84-6P 328955-85-7P 328955-86-8P
328955-87-9P 328955-88-0P 328955-89-1P 328955-90-4P 328955-91-5P
328955-92-6P 328955-93-7P 328955-94-8P 328955-95-9P 328955-96-0P
328955-97-1P 328955-98-2P 328955-99-3P 328956-00-9P 328956-01-0P
328956-02-1P 328956-03-2P 328956-04-3P 328956-05-4P 328956-06-5P
328956-07-6P 328956-08-7P 328956-09-8P 328956-10-1P 328956-11-2P
328956-12-3P 328956-13-4P 328956-14-5P 328956-15-6P 328956-16-7P
328956-17-8P 328956-18-9P 328956-19-0P 328956-20-3P 328956-21-4P
328956-22-5P 328956-23-6P 328956-24-7P 328956-25-8P 328956-26-9P
328956-27-0P 328956-28-1P 328956-29-2P 328956-30-5P 328956-31-6P
328956-32-7P 328956-33-8P 328956-34-9P 328956-35-0P 328956-36-1P
328956-38-3P 328956-64-5P 328956-65-6P 328956-66-7P 328956-67-8P
328956-68-9P 328956-69-0P 328956-74-7P 328956-75-8P 328956-76-9P
328956-77-0P 328956-78-1P 328956-79-2P 328956-80-5P 328956-81-6P
328956-82-7P 328956-83-8P 328956-84-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of quinolinones and related bicyclic compds. as androgen and **progesterone receptor modulators**)

IT 59-48-3, 2-Indolone 62-53-3, Aniline, reactions 64-19-7, Acetic acid, reactions 67-64-1, Acetone, reactions 70-34-8, 2,4-Dinitrofluorobenzene 75-07-0, Acetaldehyde, reactions 75-30-9, 2-Iodopropane 75-89-8, 2,2,2-Trifluoroethanol 75-90-1, Trifluoroacetaldehyde 75-98-9, Trimethylacetic acid 76-03-9, Trichloroacetic acid, reactions 76-04-0, Chlorodifluoroacetic acid 76-05-1, Trifluoroacetic acid, reactions 78-84-2, Isobutyraldehyde 78-93-3, 2-Butanone, reactions 78-95-5, Chloroacetone 79-08-3, Bromoacetic acid 79-31-2, Isobutyric acid 79-43-6, Dichloroacetic acid, reactions 79-44-7, Dimethylcarbamoyl chloride 91-21-4, 1,2,3,4-Tetrahydroisoquinoline 92-53-5 92-67-1, 4-Phenylaniline 97-52-9, 2-Amino-5-nitroanisole 97-72-3, Isobutyric anhydride 98-01-1, 2-Furaldehyde, reactions 98-03-3, 2-Thiophenecarboxaldehyde 98-88-4, Benzoyl chloride 99-88-7, 4-Isopropylaniline 100-39-0, Benzyl bromide 100-52-7, Benzaldehyde, reactions 104-94-9, 4-Methoxyaniline 106-40-1, 4-Bromoaniline 106-47-8, 4-Chloroaniline, reactions 106-95-6, Allyl bromide, reactions 107-22-2, Glyoxal 107-87-9, 2-Pentanone 108-01-0, 2-Dimethylaminoethanol 108-24-7, Acetic anhydride 108-27-0, 5-Methyl-2-pyrrolidinone 108-45-2, 1,3-Phenylenediamine, reactions 108-83-8, 2,6-Dimethyl-4-heptanone 108-94-1, Cyclohexanone, reactions 109-05-7, 2-Methylpiperidine 110-12-3, 5-Methyl-2-hexanone 110-13-4, Acetonylacetone 110-89-4, Piperidine, reactions 110-91-8, Morpholine, reactions 111-49-9 115-19-5 116-09-6, Acetol 120-92-3, Cyclopentanone 122-80-5 123-38-6, Propionaldehyde, reactions

123-72-8, Butyraldehyde 123-75-1, Pyrrolidine, reactions 141-97-9, Ethyl acetoacetate 147-85-3, L-Proline, reactions 344-25-2, D-Proline 348-54-9, 2-Fluoroaniline 367-11-3, 1,2-Difluorobenzene 371-40-4, 4-Fluoroaniline 372-19-0, 3-Fluoroaniline 372-31-6, Ethyl 4,4,4-trifluoroacetoacetate 372-39-4, 3,5-Difluoroaniline 381-73-7, Difluoroacetic acid 407-25-0, Trifluoroacetic anhydride 421-50-1 421-53-4, Trifluoroacetaldehyde hydrate 422-06-0, Pentafluoropropionaldehyde 422-64-0, Pentafluoropropionic acid 431-03-8, 2,3-Butanedione 452-77-7, 3-Fluoro-4-methylaniline 459-57-4, 4-Fluorobenzaldehyde 460-37-7, 3,3,3-Trifluoro-1-iodopropane 496-15-1, Indoline 497-38-1, 2-Norbornanone 498-60-2, 3-Furaldehyde 498-62-4, 3-Thiophenecarboxaldehyde 502-42-1, Cycloheptanone 504-03-0, 2,6-Dimethylpiperidine 536-90-3 553-03-7 563-80-4, 3-Methyl-2-butanone 565-80-0, 2,4-Dimethyl-3-pentanone 578-54-1, 2-Ethylaniline 589-38-8, 3-Hexanone 591-24-2, 3-Methylcyclohexanone 603-83-8 607-66-9, 4-Methyl-2(1H)-quinolinone 626-56-2, 3-Methylpiperidine 626-58-4, 4-Methylpiperidine 630-19-3, Trimethylacetaldehyde 685-69-8 765-38-8, 2-Methylpyrrolidine 768-35-4, 3-Fluorobenzeneboronic acid 873-94-9, 3,3,5-Trimethylcyclohexanone 925-90-6, Ethylmagnesium bromide 1068-55-9, Isopropylmagnesium chloride 1121-60-4, 2-Pyridinecarboxaldehyde 1191-95-3, Cyclobutanone 1193-47-1, 2,2-Dimethylcyclohexanone 1423-26-3, 3-Trifluoromethylbenzeneboronic acid 1484-80-6, 2-Ethylpiperidine 1489-69-6, Cyclopropanecarboxaldehyde 1604-29-1, 2-Acetoxy-2-methyl-3-butyne 1765-93-1, 4-Fluorobenzeneboronic acid 1809-10-5, 3-Bromopentane 1810-66-8 1821-39-2, 2-Propylaniline 1993-03-9, 2-Fluorobenzeneboronic acid 2082-59-9, Valeric anhydride 2373-51-5, Chloromethyl methyl sulfide 2408-37-9, 2,2,6-Trimethylcyclohexanone 2497-21-4, 2-Hexen-4-one 2816-57-1, 2,6-Dimethylcyclohexanone 2955-64-8, 3,7-Nonanedione 2987-16-8, 3,3-Dimethylbutyraldehyde 3238-60-6, 2-Propylpiperidine 3378-71-0, 2,5-Dimethylpyrrolidine 4389-50-8, 2-Amino-6-methylbenzoic acid 4541-32-6, 2,2-Dimethylcyclopentanone 4933-14-6 5077-67-8, 1-Hydroxy-2-butanone 5323-87-5, 3-Ethoxy-2-cyclohexenone 5452-35-7, Cycloheptylamine 5720-05-8, 4-Methylbenzeneboronic acid 5720-06-9, 2-Methoxybenzeneboronic acid 5720-07-0, 4-Methoxybenzeneboronic acid 6264-67-1, 4-Fluoro-1,3-phenylenediamine 6342-56-9 6373-50-8, 4-Cyclohexylaniline 7228-52-6, 2,2-Dimethylcycloheptanone 10272-07-8, 3,5-Dimethoxyaniline 10365-98-7, 3-Methoxybenzeneboronic acid 10403-47-1, 2-Bromo-5-nitroaniline 13331-27-6, 3-Nitrobenzeneboronic acid 14446-75-4, cis-3,5-Dimethylpiperidine 15862-72-3 15982-65-7, 5,8-Dodecanedione 16419-60-6, 2-Methylbenzeneboronic acid 17933-03-8, 3-Methylbenzeneboronic acid 20191-74-6, 2-Ethyl-5-nitroaniline 21486-48-6 21655-48-1 22627-70-9, 3-Ethoxy-2-cyclopentenone 22633-21-2, 4,7-Decanedione 24365-65-9 28023-45-2, trans-3,4-Dimethylcyclohexanone 33786-89-9 33863-76-2, 1-Bromo-3-chloro-5-fluorobenzene 35840-91-6, 2-Benzylpyrrolidine 39713-71-8 40635-66-3 43041-12-9, D-Proline methyl ester 51503-10-7, 2-Isopropylpyrrolidine 52562-19-3 53460-46-1, 1,3,3-Trimethyl-6-azabicyclo[3.2.1]octane 55751-54-7, 2-sec-Butylaniline 59016-93-2, 4-Hydroxymethylbenzeneboronic acid 61304-66-3, 4-Ethyl-2(1H)-quinolinone 62266-82-4 63139-21-9, 4-Ethylbenzeneboronic acid 63503-60-6, 3-Chlorobenzeneboronic acid 68716-47-2, 2,4-Dichlorobenzeneboronic acid 73852-19-4, 3,5-Bistrifluoromethylbenzeneboronic acid 76693-04-4 78839-75-5 87199-17-5, 4-Formylbenzeneboronic acid 104678-13-9, 2-Methoxymethylpiperidine 123324-71-0, 4-tert-Butylbenzeneboronic acid 135938-63-5 139301-27-2, 4-Trifluoromethoxybenzeneboronic acid 149104-90-5, 4-Acetylbenzeneboronic acid 151169-74-3, 2,3-Dichlorobenzeneboronic acid 153108-62-4 159330-31-1 159724-40-0 179898-27-2 193806-49-4 204841-19-0, 3-Acetylbenzeneboronic acid

313545-20-9, 3-Chloro-2-methylbenzeneboronic acid 328956-39-4
328956-40-7, 4-Isopropyl-2(1H)-quinolinone 328956-46-3 328956-54-3
328956-55-4 328956-56-5 328956-60-1, 3-Fluoro-5-formylbenzeneboronic
acid 328956-62-3 328956-63-4 328956-70-3 328956-71-4 328956-73-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of quinolinones and related bicyclic compds. as androgen and **progesterone receptor modulators**)

IT 94-73-5P 95-80-7P, 2,4-Diaminotoluene 107-86-8P, 3-Methyl-2-butenal
1185-96-2P, 3-Acetoxy-3-methyl-1-pentyne 1195-06-8P,
4-Ethyl-1,3-phenylenediamine 1575-37-7P, 4-Bromo-1,3-phenylenediamine
10242-21-4P 19155-24-9P, 3,3-Dimethyl-2-indolone 21440-96-0P
57738-18-8P 90267-82-6P 91557-34-5P, 4-Cyclohexyl-3-nitroaniline
93138-52-4P 116922-22-6P 120902-45-6P, 5-Bromo-3,3-dimethyl-2-indolone
121219-16-7P, 2,3-Difluorobenzeneboronic acid 328956-37-2P
328956-41-8P 328956-42-9P 328956-43-0P 328956-44-1P 328956-45-2P
328956-47-4P 328956-48-5P 328956-49-6P 328956-50-9P,
2-sec-Butyl-5-nitroaniline 328956-51-0P 328956-52-1P 328956-53-2P
328956-57-6P 328956-58-7P 328956-59-8P 328956-61-2P,
3-Chloro-5-fluorobenzeneboronic acid 328956-72-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of quinolinones and related bicyclic compds. as androgen and **progesterone receptor modulators**)

IT **328954-75-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of quinolinones and related bicyclic compds. as androgen and **progesterone receptor modulators**)

RN 328954-75-2 HCAPLUS
CN 2H-3,1-Benzoxazine-2-thione, 6-(1-cyclohexen-1-yl)-1,4-dihydro-4,4-dimethyl- (9CI) (CA INDEX NAME)



L119 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2000:790489 HCAPLUS
DN 133:350229
ED Entered STN: 10 Nov 2000
TI Novel cyclocarbamate derivatives as **progesterone receptor modulators**
IN **Zhang, Puwen**; **Terefenko, Eugene A.**; Fletcher, Horace, III; **Fensome, Andrew**; Wrobel, Jay E.; Zhi, Lin; Jones, Todd K.; Marschke, Keith B.; Tegley, Christopher M.
PA American Home Products Corporation, USA; Ligand Pharmaceuticals, Inc.
SO PCT Int. Appl., 135 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C07D265-18
ICS C07D413-04; C07D417-04; C07D413-10; A61K031-536; A61P015-00; A61P035-00

CC 28-13 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 2

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000066571	A1	20001109	WO 2000-US11822	20000501 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6509334	B1	20030121	US 2000-552633	20000419 <--
	CA 2371726	AA	20001109	CA 2000-2371726	20000501 <--
	EP 1173426	A1	20020123	EP 2000-928689	20000501 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 2000010213	A	20020219	BR 2000-10213	20000501 <--
	TR 200103286	T2	20020722	TR 2001-200103286	20000501 <--
	JP 2002543193	T2	20021217	JP 2000-615601	20000501 <--
	AU 766428	B2	20031016	AU 2000-46886	20000501 <--
	NZ 515355	A	20040227	NZ 2000-515355	20000501 <--
	US 2002049204	A1	20020425	US 2001-948309	20010906 <--
	US 6566358	B2	20030520		
	ZA 2001007630	A	20020514	ZA 2001-7630	20010917 <--
	NO 2001005378	A	20020103	NO 2001-5378	20011102 <--
	BG 106079	A	20020531	BG 2001-106079	20011102 <--
	US 2003216388	A1	20031120	US 2003-386799	20030312 <--
	US 6713478	B2	20040330		
	US 2004186101	A1	20040923	US 2004-767813	20040129 <--
PRAI	US 1999-183012P	P	19990504 <--		
	US 2000-552633	A1	20000419 <--		
	WO 2000-US11822	W	20000501 <--		
	US 2001-948309	A3	20010906 <--		
	US 2003-386799	A1	20030312		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2000066571	ICM	C07D265-18
	ICS	C07D413-04; C07D417-04; C07D413-10; A61K031-536; A61P015-00; A61P035-00
WO 2000066571	ECLA	C07D265/18B; C07D413/04+265+213; C07D413/04+265+207; C07D413/04+307B+265; C07D413/04+333B+265; C07D413/10+265+257; C07D417/04+285B+265 <--
US 6509334	NCL	514/230.500; 514/080.000; 514/183.000; 514/211.150; 514/212.020; 514/217.050; 514/228.200; 540/466.000; 540/467.000; 540/481.000; 540/543.000; 540/544.000; 540/545.000; 540/599.000; 544/058.600; 544/069.000; 544/070.000; 544/092.000
	ECLA	C07D265/18B; C07D413/04+265+207; C07D413/04+265+213; C07D413/04+307B+265; C07D413/04+333B+265; C07D413/10+265+257; C07D417/04+285B+265 <--
CA 2371726	ECLA	C07D265/18B; C07D413/04+265+207; C07D413/04+265+213; C07D413/04+307B+265; C07D413/04+333B+265; C07D413/10+265+257; C07D417/04+285B+265 <--
US 2002049204	NCL	514/230.500; 514/212.020; 514/212.080; 514/228.200
	ECLA	C07D265/18B; C07D413/04+265+207; C07D413/04+265+213;

C07D413/04+307B+265; C07D413/04+333B+265;
C07D413/10+265+257; C07D417/04+285B+265 <--
US 2003216388 NCL 514/230.500; 514/211.080; 514/211.150; 514/212.020;
514/217.050; 514/217.060; 514/228.200
ECLA C07D265/18B; C07D413/04+265+207; C07D413/04+265+213;
C07D413/04+307B+265; C07D413/04+333B+265;
C07D413/10+265+257; C07D417/04+285B+265 <--
US 2004186101 NCL 514/230.500
ECLA C07D265/18B; C07D413/04+265+207; C07D413/04+265+213;
C07D413/04+307B+265; C07D413/04+333B+265;
C07D413/10+265+257; C07D417/04+285B+265 <--
OS MARPAT 133:350229
GI



AB This invention discloses novel aryl fused cyclocarbamate derivs. I (R1 or R2 = H, (un)substituted C1-6 alkyl, (un)substituted C2-6 alkenyl, (un)substituted C2-6 alkynyl, (un)substituted C3-8 cycloalkyl, (un)substituted aryl, (un)substituted heterocyclyl, amino derivative or R1 and R2 may be fused to form spirocyclic or heterospirocyclic rings; R3 = H, OH, NH2, (un)substituted C1-6 alkyl, (un)substituted C3-6 alkenyl, (un)substituted alkynyl, or COR6 {R6 = H, (un)substituted C1-3 alkyl, (un)substituted aryl, (un)substituted C1-3 alkoxy, or (un)substituted C1-3 aminoalkyl}; R4 = H, halo, CN, NO2, (un)substituted C1-6 alkyl, (un)substituted alkynyl, (un)substituted C1-6 alkoxy, amino, or (un)substituted C1-6 aminoalkyl; R5 = trisubstituted benzene ring or a five- or six-membered ring with 1, 2, or 3 heteroatoms selected from O, S, SO, SO2 or NR7 and containing one or two independent substituents from the group including H, halo, CN, NO2, amino, C1-3 alkyl, C1-3 alkoxy, C1-3 aminoalkyl, COR8, or NR9COR8 {R7 = H or C1-3 alkyl; R8 = H, (un)substituted C1-3 alkyl, (un)substituted aryl, (un)substituted C1-3 alkoxy or (un)substituted C1-3 aminoalkyl; R9 = H, (un)substituted C1-3 alkyl}) or pharmaceutically acceptable salts thereof, as well as pharmaceutical compns. and methods using the compds. as antagonists of the progesterone receptor. Thus, cyclocarbamate II was prepared from 2-(2-amino-5-bromophenyl)propan-2-ol via cyclocondensation with 1,1-carbonyldiimidazole followed by palladium-catalyzed coupling with 3-chlorophenylboronic acid. Compds. of the invention demonstrated potency in the range of 0.01 nM to 5 μM in the in vitro assays, and 0.001 to 300 mg/kg in the in vivo assays.

ST cyclocarbamate aryl prepn **progesterone receptor modulator**; benzooxazinone prepn **progesterone receptor** antagonist; oxazinone benzo prepn **progesterone receptor** antagonist

IT **Progestogens**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(**antiprogestins**; preparation of benzooxazinone derivs. as **progesterone receptor modulators**)

IT Antitumor agents
Contraceptives
(preparation of benzooxazinone derivs. as **progesterone receptor modulators**)

IT **Progestogens**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of benzooxazinone derivs. as **progesterone receptor modulators**)

IT **Progesterone receptors**
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(preparation of benzooxazinone derivs. as **progesterone receptor modulators**)

IT Estrus
(regulation of; preparation of benzooxazinone derivs. as **progesterone receptor modulators**)

IT 304853-28-9P 304853-29-0P 304853-30-3P 304853-96-1P 304854-08-8P
304854-10-2P 304854-11-3P 304854-31-7P 304854-49-7P 305799-81-9P
305799-99-9P 305800-09-3P 305800-19-5P 305800-20-8P 305800-36-6P
305800-38-8P 305800-39-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of benzooxazinone derivs. as **progesterone receptor modulators**)

IT 304853-31-4P 304853-36-9P 304853-93-8P 304853-94-9P 304853-98-3P
304854-01-1P 304854-06-6P 304854-07-7P 304854-09-9P 304854-12-4P
304854-13-5P 304854-14-6P 304854-15-7P 304854-16-8P 304854-17-9P
304854-20-4P 304854-21-5P 304854-22-6P 304854-23-7P 304854-24-8P
304854-25-9P 304854-26-0P 304854-27-1P 304854-28-2P 304854-29-3P
304854-30-6P 304854-32-8P 304854-33-9P 304854-34-0P 304854-35-1P
304854-36-2P 304854-37-3P 304854-38-4P 304854-39-5P 304854-41-9P
304854-42-0P 304854-43-1P 304854-44-2P 304854-45-3P 304854-46-4P
304854-47-5P 304854-48-6P 304854-50-0P 305799-74-0P 305799-76-2P
305799-78-4P 305799-80-8P 305799-83-1P 305799-85-3P 305799-86-4P
305799-87-5P 305799-88-6P 305799-89-7P 305799-93-3P 305799-95-5P
305799-97-7P 305799-98-8P 305800-00-4P 305800-02-6P 305800-03-7P
305800-04-8P 305800-05-9P 305800-08-2P 305800-10-6P 305800-11-7P
305800-12-8P 305800-14-0P 305800-15-1P 305800-16-2P 305800-18-4P
305800-21-9P 305800-22-0P 305800-23-1P 305800-24-2P 305800-25-3P
305800-26-4P 305800-27-5P 305800-34-4P 305800-37-7P 305800-40-2P
305800-45-7P 305800-46-8P 305800-47-9P 305800-48-0P 305800-50-4P
305800-51-5P 305800-52-6P 305800-53-7P 305800-55-9P 305800-56-0P
305800-57-1P 305800-59-3P 305800-62-8P 305800-63-9P 305800-64-0P
305800-65-1P 305800-66-2P 305800-67-3P 305800-68-4P 305800-71-9P
305800-72-0P 305839-71-8P 305839-75-2P 305839-76-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzooxazinone derivs. as **progesterone receptor modulators**)

IT 100-58-3, Phenylmagnesium bromide 108-36-1, 1,3-Dibromobenzene

110-52-1, 1,4-Dibromobutane 111-24-0, 1,5-Dibromopentane 122-51-0, Triethylorthoformate 326-66-9, 4'-Bromo-2'-fluoroacetanilide 348-61-8, 1-Bromo-3,4-difluorobenzene 460-00-4, 1-Bromo-4-fluorobenzene 461-96-1, 1-Bromo-3,5-difluorobenzene 623-49-4, Ethylcyano formate 625-92-3, 3,5-Dibromopyridine 814-49-3, Diethyl chlorophosphate 1066-54-2, Trimethylsilylacetylene 1072-85-1, 1-Bromo-2-fluorobenzene 1072-97-5, 2-Amino-5-bromopyridine 1073-06-9, 1-Bromo-3-fluorobenzene 1191-95-3, Cyclobutanone 1435-51-4, 1,3-Dibromo-5-fluorobenzene 1546-79-8, 1-(Trifluoroacetyl)imidazole 1611-92-3, 3,5-Dibromotoluene 1679-18-1, 4-Chlorophenyl boronic acid 1730-25-2, Allylmagnesium bromide 2357-52-0, 4-Bromo-2-fluoroanisole 3177-80-8, 2-Amino-3-methoxybenzoic acid 3900-89-8, 2-Chlorophenyl boronic acid 4333-56-6, Cyclopropyl bromide 4648-54-8, Trimethylsilyl azide 4692-98-2, 5-Bromoisatoic anhydride 4701-17-1, 5-Bromo-2-thiophenecarboxaldehyde 4915-06-4, 2-Bromo-5-cyanofuran 5326-47-6, 2-Amino-5-iodobenzoic acid 5794-88-7, 2-Amino-5-bromobenzoic acid 6165-69-1, 3-Thiophene boronic acid 6638-79-5, N,O-Dimethylhydroxylamine hydrochloride 6952-59-6, 3-Bromobenzonitrile 7087-65-2 10365-98-7, 3-Methoxyphenyl boronic acid 13331-27-6, 3-Nitrophenyl boronic acid 14282-76-9, 2-Bromo-3-methylthiophene 18242-39-2, 1-Bromo-3,5-dinitrobenzene 18791-99-6 18792-00-2 19472-74-3, 2-Bromophenylacetonitrile 27065-51-6 29578-39-0, Anisole, 3-Bromo-5-fluoro- 31938-07-5, 3-Bromophenylacetonitrile 32423-84-0, Propynylmagnesium bromide 33743-87-2 33863-76-2, 1-Bromo-3-chloro-5-fluorobenzene 35590-37-5, 3-Bromo-5-cyanopyridine 39263-32-6, 2-Amino-5-bromobenzonitrile 51437-00-4, 5-Bromo-2-fluorotoluene 53119-61-2, 2-Bromo-3-ethylthiophene 53595-65-6 56182-43-5, 2-Bromo-3-thiophenecarbonitrile 60811-21-4 63503-60-6, 3-Chlorophenyl boronic acid 65854-91-3, N-(4-Chlorophenyl)-2,2-dimethylpropanamide 67492-50-6, 3,5-Dichlorophenyl boronic acid 69249-60-1 73852-19-4 89599-01-9, 3-Bromobenzenesulfonamide 105942-08-3 112575-11-8 114897-91-5 121359-48-6 130723-13-6 135884-31-0 145543-82-4, 2-Bromo-3-n-butylthiophene 160892-07-9, 5-Bromoisophthalonitrile 161957-56-8 179897-89-3 179898-34-1, 3-Bromo-5-fluorobenzonitrile 188813-02-7 207226-31-1 216755-57-6 304854-51-1 304854-53-3 304854-55-5 304854-57-7 304854-59-9 304854-61-3 304854-63-5 305799-77-3 305799-79-5 305799-92-2 305800-01-5 305800-13-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of benzooxazinone derivs. as **progesterone receptor modulators**)

IT 2160-62-5P 21440-97-1P 21440-99-3P 141940-30-9P 149947-15-9P 154598-53-5P 189331-47-3P 206551-41-9P 216755-56-5P 304853-89-2P 304853-90-5P 304853-91-6P 304853-92-7P 304854-03-3P **304854-04-4P** 304854-05-5P 304854-19-1P 304854-40-8P 304854-52-2P 304854-54-4P 304854-58-8P 304854-62-4P 304857-58-7P 304874-29-1P 305799-75-1P **305799-84-2P** 305799-94-4P 305799-96-6P 305800-06-0P 305800-17-3P 305800-29-7P 305800-32-2P 305800-41-3P 305800-42-4P 305800-43-5P 305800-44-6P 305800-49-1P 305800-54-8P 305839-72-9P 305839-73-0P 305839-74-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of benzooxazinone derivs. as **progesterone receptor modulators**)

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Dong A Pharm Co Ltd; EP 0510235 A 1992 HCAPLUS
(2) Du Pont Merck Pharma; WO 9814436 A 1998 HCAPLUS
(3) Ligand Pharm Inc; WO 9619458 A 1996 HCAPLUS
(4) Ligand Pharm Inc; US 5688810 A 1997 HCAPLUS
(5) Merck & Co Inc; WO 9520389 A 1995 HCAPLUS

IT **304854-04-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of benzooxazinone derivs. as **progesterone receptor modulators**)
RN 304854-04-4 HCAPLUS
CN Spiro[4H-3,1-benzoxazine-4,1'-cyclohexan]-2(1H)-one, 6-bromo- (9CI) (CA INDEX NAME)



L119 ANSWER 8 OF 9 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2000:790488 HCAPLUS
DN 133:350228
ED Entered STN: 10 Nov 2000
TI Preparation of cyclothiocarbamate derivatives as **progesterone receptor modulators**
IN **Zhang, Puwen**; **Fensome, Andrew**; **Terefenko, Eugene A.**; Zhi, Lin; Jones, Todd K.; Marschke, Keith B.; Tegley, Christopher M.
PA American Home Products Corporation, USA; Ligand Pharmaceuticals, Inc.
SO PCT Int. Appl., 101 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C07D265-18
ICS C07D413-04; A61K031-536; A61P015-00; A61P035-00
CC 28-13 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 2
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000066570	A1	20001109	WO 2000-US11749	20000501 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6436929	B1	20020820	US 2000-552354	20000419 <--
	CA 2371712	AA	20001109	CA 2000-2371712	20000501 <--
	EP 1175411	A1	20020130	EP 2000-930266	20000501 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 2000010214	A	20020213	BR 2000-10214	20000501 <--
	TR 200103285	T2	20020221	TR 2001-200103285	20000501 <--
	JP 2002543192	T2	20021217	JP 2000-615600	20000501 <--

	AU 766801	B2	20031023	AU 2000-48119	20000501 <--
	CN 1131856	B	20031224	CN 2000-807099	20000501 <--
	NZ 515353	A	20040326	NZ 2000-515353	20000501 <--
	ZA 2001007633	A	20020514	ZA 2001-7633	20010917 <--
	NO 2001005381	A	20020103	NO 2001-5381	20011102 <--
	BG 106080	A	20020531	BG 2001-106080	20011102 <--
	US 2003092711	A1	20030515	US 2002-140034	20020506 <--
PRAI	US 1999-183013P	P	19990504 <--		
	US 2000-552354	A1	20000419 <--		
	WO 2000-US11749	W	20000501 <--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2000066570	ICM	C07D265-18
	ICS	C07D413-04; A61K031-536; A61P015-00; A61P035-00
WO 2000066570	ECLA	C07D265/18B; C07D413/04+265+213; C07D413/04+265+207; C07D413/04+307B+265; C07D413/04+333B+265 <--
US 6436929	NCL	514/230.500; 544/070.000; 544/092.000
	ECLA	C07D265/18B; C07D413/04+265+207; C07D413/04+265+213; C07D413/04+307B+265; C07D413/04+333B+265 <--
CN 1131856	ECLA	C07D265/18B; C07D413/04+265+207; C07D413/04+265+213; C07D413/04+307B+265; C07D413/04+333B+265 <--
US 2003092711	NCL	514/230.200; 514/171.000
	ECLA	C07D265/18B; C07D413/04+265+207; C07D413/04+265+213; C07D413/04+307B+265; C07D413/04+333B+265 <--

OS MARPAT 133:350228

GI



I



II

AB The title compds. [I or II; R1, R2 = H, alkyl, alkenyl, etc.; or R1 and R2 are fused to form (un)substituted 3-8 membered spiro cyclic alkyl or alkenyl ring or a spiro cyclic ring containing 1-3 heteroatoms selected from O, S and N; R3 = H, OH, NH2, etc.; R4 = H, halo, CN, etc.; R5 = (un)substituted Ph, 5-6 membered heterocyclic ring with 1-3 ring heteroatoms, 3-pyridyl, 5-pyrimidinyl; Q1 = S, NR7, CR8R9; R7 = CN, alkyl, cycloalkyl, etc.; R8, R9 = H, alkyl, cycloalkyl, etc.; Q2 = NR11OR12, NR11NR12R13, ONR11R13; R11-R13 = H, alkyl, aryl, etc.] which are agonists of the progesterone receptor, and are useful for contraception and the treatment of progesterone-related maladies, were prepared E.g., a multi-step synthesis of I [R1, R2 = Me; R3, R4 = H; R5 = 3-ClC6H4; Q1 = S] which showed EC50 of 0.65 nM against hPR in CV-1 cells, was given.

ST cyclothiocarbamate prepn **progesterone receptor modulator**; benzoxazinthione prepn **progesterone receptor modulator**

IT Contraceptives
(inducing contraception; preparation of cyclothiocarbamate derivs. as **progesterone receptor modulators**)

IT **Progesterone receptors**
RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study)

(preparation of cyclothiocarbamate derivs. as **progesterone receptor modulators**)

IT 304853-28-9P 304853-29-0P 304853-30-3P 304853-31-4P 304853-36-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of cyclothiocarbamate derivs. as **progesterone receptor modulators**)

IT **304853-32-5P 304853-33-6P** 304853-34-7P
304853-35-8P 304853-37-0P 304853-38-1P
304853-39-2P 304853-40-5P 304853-41-6P
304853-42-7P 304853-43-8P 304853-44-9P
304853-45-0P 304853-46-1P 304853-47-2P
304853-48-3P 304853-49-4P 304853-50-7P
304853-51-8P 304853-52-9P 304853-53-0P
304853-54-1P 304853-55-2P 304853-56-3P
304853-57-4P 304853-58-5P 304853-59-6P
304853-60-9P 304853-61-0P 304853-62-1P
304853-63-2P 304853-64-3P 304853-65-4P
304853-66-5P 304853-67-6P 304853-68-7P
304853-69-8P 304853-70-1P 304853-71-2P
304853-72-3P 304853-73-4P 304853-74-5P
304853-75-6P 304853-76-7P 304853-77-8P
304853-78-9P 304853-79-0P 304853-80-3P
304853-81-4P 304853-82-5P 304853-83-6P
304853-84-7P 304853-85-8P 304853-86-9P
304853-87-0P 304853-88-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of cyclothiocarbamate derivs. as **progesterone receptor modulators**)

IT 100-58-3, Phenylmagnesium bromide 108-36-1, 1,3-Dibromobenzene 111-24-0, 1,5-Dibromopentane 348-61-8, 1-Bromo-3,4-difluorobenzene 460-00-4, 1-Bromo-4-fluorobenzene 461-96-1, 1-Bromo-3,5-difluorobenzene 625-92-3, 3,5-Dibromopyridine 1072-85-1, 1-Bromo-2-fluorobenzene 1073-06-9, 1-Bromo-3-fluorobenzene 1435-51-4, 1,3-Dibromo-5-fluorobenzene 1611-92-3, 3,5-Dibromotoluene 1730-25-2, Allylmagnesium bromide 2160-62-5, 5-Bromo-2-thiophenecarbonitrile 3900-89-8, 2-Chlorophenylboronic acid 4915-06-4, 2-Bromo-5-cyanofuran 5794-88-7, 2-Amino-5-bromobenzoic acid 6952-59-6, 3-Bromobenzonitrile 10365-98-7, 3-Methoxyphenylboronic acid 13331-27-6, 3-Nitrophenylboronic acid 18791-99-6, 4-Bromo-2-thiophenecarbonitrile 18792-00-2, 2-Bromo-4-thiophenecarbonitrile 29578-39-0, 3-Bromo-5-fluoroanisole 33863-76-2, 1-Bromo-3-chloro-5-fluorobenzene 56182-43-5, 2-Bromo-3-thiophenecarbonitrile 60811-21-4, 1-Bromo-3-chloro-4-fluorobenzene 63503-60-6, 3-Chlorophenylboronic acid 67492-50-6, 3,5-Dichlorophenylboronic acid 112575-11-8 124289-21-0, 3-Bromo-5-methylbenzonitrile 130723-13-6, 1-Bromo-3-fluoro-5-trifluoromethylbenzene 135884-31-0 160892-07-9, 5-Bromoisophthalonitrile 179897-89-3, 5-Bromo-2-fluorobenzonitrile 179898-34-1, 3-Bromo-5-fluorobenzonitrile 207226-31-1, 1,3-Dibromo-5-trifluoromethoxybenzene 304854-51-1 304854-52-2, 5-Bromo-4-methyl-2-thiophenecarbonitrile 304854-53-3 304854-54-4 304854-55-5 304854-56-6 304854-57-7 304854-58-8 304854-59-9 304854-60-2 304854-61-3 304854-62-4, 2-Bromo-3-propyl-5-thiophenecarbonitrile 304854-63-5, 4-Bromo-2-furancarbonitrile
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of cyclothiocarbamate derivs. as **progesterone**

receptor modulators)

IT 21440-97-1P 304853-89-2P, 2-(2-Amino-5-bromophenyl)propan-2-ol
304853-90-5P 304853-91-6P 304853-92-7P 304853-93-8P 304853-94-9P
304853-95-0P 304853-96-1P 304853-97-2P 304853-98-3P
304853-99-4P 304854-00-0P 304854-01-1P 304854-02-2P 304854-03-3P
304854-04-4P 304854-05-5P 304854-06-6P 304854-07-7P
304854-08-8P 304854-09-9P 304854-10-2P 304854-11-3P 304854-12-4P
304854-13-5P 304854-14-6P 304854-15-7P 304854-16-8P 304854-17-9P
304854-18-0P 304854-19-1P 304854-20-4P 304854-21-5P 304854-22-6P
304854-23-7P 304854-24-8P 304854-25-9P 304854-26-0P 304854-27-1P
304854-28-2P 304854-29-3P 304854-30-6P 304854-31-7P 304854-32-8P
304854-33-9P 304854-34-0P 304854-35-1P 304854-36-2P 304854-37-3P
304854-38-4P 304854-39-5P 304854-40-8P 304854-41-9P 304854-42-0P
304854-43-1P 304854-44-2P 304854-45-3P 304854-46-4P 304854-47-5P
304854-48-6P 304854-49-7P 304854-50-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of cyclothiocarbamate derivs. as **progesterone receptor modulators**)

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Dong A Pharm Co Ltd; EP 0510235 A 1992 HCAPLUS
(2) Du Pont Merck Pharma; WO 9814436 A 1998 HCAPLUS
(3) Ligand Pharm Inc; WO 9619458 A 1996 HCAPLUS
(4) Ligand Pharm Inc; US 5688810 A 1997 HCAPLUS
(5) Merck & Co Inc; WO 9520389 A 1995 HCAPLUS

IT **304853-32-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of cyclothiocarbamate derivs. as **progesterone receptor modulators**)

RN 304853-32-5 HCAPLUS
CN 2H-3,1-Benzoxazine-2-thione, 6-(3-chlorophenyl)-1,4-dihydro-4,4-dimethyl- (9CI) (CA INDEX NAME)



L119 ANSWER 9 OF 9 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2000:790347 HCAPLUS
DN 133:350205
ED Entered STN: 10 Nov 2000
TI Contraceptive compositions containing antiprogestinic and progestinic dihydro-2H-3,1-benzoxazin-2-ones
IN Grubb, Gary S.; Zhi, Lin; Jones, Todd K.; Marschke, Keith B.; Tegley, Christopher M.
PA American Home Products Corporation, USA; Ligand Pharmaceuticals, Inc.
SO PCT Int. Appl., 146 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K045-06

ICS A61K031-57; A61K031-565; A61P015-18; A61K031-57; A61K031-535; A61K031-565; A61K031-565; A61K031-535; A61K031-565
CC 28-7 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 2, 63
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 2000066164	A1	20001109	WO 2000-US11643	20000501	<--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
	US 6498154	B1	20021224	US 2000-552357	20000419	<--
	CA 2372773	AA	20001109	CA 2000-2372773	20000501	<--
	EP 1173210	A1	20020123	EP 2000-928611	20000501	<--
	EP 1173210	B1	20040915			
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
	JP 2002543155	T2	20021217	JP 2000-615048	20000501	<--
	AT 275973	E	20041015	AT 2000-928611	20000501	<--
	HK 1043736	A1	20050401	HK 2002-104868	20020628	<--
PRAI	US 1999-304712	A	19990504	<--		
	US 2000-552357	A1	20000419	<--		
	US 1999-183042P	P	19990504	<--		
	US 2000-552350	A	20000419	<--		
	WO 2000-US11643	W	20000501	<--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES	
WO 2000066164	ICM	A61K045-06	
	ICS	A61K031-57; A61K031-565; A61P015-18; A61K031-57; A61K031-535; A61K031-565; A61K031-565; A61K031-535; A61K031-565	
WO 2000066164	ECLA	A61K031/565+M; A61K031/57+M; A61K045/06	<--
US 6498154	NCL	514/171.000; 514/170.000; 514/230.500; 514/266.200; 514/266.240; 514/266.300; 514/314.000	
	ECLA	A61K031/565+M; A61K031/57+M; A61K045/06	<--

OS MARPAT 133:350205
GI



I



II



III

AB The dihydrobenzoxazinones I [R1, R2 = H, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, acyl, acylamino; or R1R2 are fused to form spirocyclic or hetero-spirocyclic rings substituted by F, alkyl, alkoxy, alkylthio, F3C, HO, cyano, H2N, alkylamino; R3 = H, OH, NH2, C1-6 alkyl, C3-6 alkenyl, alkynyl, CORC; RC = H, C1-3 alkyl, aryl, C1-3 alkoxy, C1-3 aminoalkyl; R4 = H, halo, cyano, NO2, alkyl, alkynyl, alkoxy, alkoxy, amino, aminoalkyl; R5 = XYZC6H2, X = halo, cyano, alkyl, alkenyl, alkynyl, alkoxy, thioalkoxy, H2N, aminoalkyl, NO2, perfluoroalkyl, 5- or 6-membered heterocyclyl; Y, Z = H, halo, cyano, NO2, H2N, aminoalkyl, alkoxy, alkyl, thioalkoxy; or R5 = 5- or 6-membered heterocyclyl with O, S, SO, SO2 heteroatoms substituted by H, halo, cyano, NO2, H2N, alkyl, alkoxy, perfluoroacyl, perfluoroacylamino] and their pharmaceutically acceptable salts were prepared as antagonists of the progesterone receptor and were useful to induce contraception in mammals in cyclic combination therapies using an antiprogestin and progestin where the progestin is administered in the alternating presence and absence of an antiprogestin. These methods of treatment may be used for contraception or for the treatment and/or prevention of secondary amenorrhea, dysfunctional bleeding, uterine leiomyomata, **endometriosis**; polycystic ovary syndrome, carcinomas and adenocarcinomas of the endometrium, ovary, breast, colon, prostate, or minimization of side effects of cyclic menstrual bleeding. Addnl. uses of the invention include stimulation of food intake. Thus, cyclocondensation of 2-(2-amino-5-bromophenyl)-2-propanol with carbonyldiimidazole gave the dimethylbenzoxazinone II which coupled with 3-chlorophenylboronic acid in DME/H2O containing (Ph3P)4Pd and Na2CO3 to give the (chlorophenyl)benzoxazinone III.

ST menstrual bleeding side effect treatment dihydrobenzoxazinone prepn; prostate carcinoma treatment dihydrobenzoxazinone prepn; colon carcinoma treatment dihydrobenzoxazinone prepn; breast carcinoma treatment dihydrobenzoxazinone prepn; ovary carcinoma treatment dihydrobenzoxazinone prepn; endometrium carcinoma treatment dihydrobenzoxazinone prepn; polycystic ovary treatment dihydrobenzoxazinone prepn; **endometriosis** treatment dihydrobenzoxazinone prepn; uterine leiomyomata treatment dihydrobenzoxazinone prepn; amenorrhea secondary treatment dihydrobenzoxazinone prepn; progesterone receptor antagonist dihydrobenzoxazinone prepn; benzoxazinone dihydro prepn contraceptive

IT **Progesterone receptors**
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(antagonists; preparation of substituted dihydrobenzoxazinones with

progesterone receptor antagonist activity for use in contraceptive compns.)

IT **Progestogens**
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(**antiprogestins**; preparation of substituted dihydrobenzoxazinones with progesterone receptor antagonist activity for use in contraceptive compns.)

IT Contraceptives
(preparation of substituted dihydrobenzoxazinones with progesterone receptor antagonist activity for use in contraceptive compns.)

IT 51-98-9, Norethindrone acetate 68-22-4, Norethindrone 427-51-0, Cyproterone acetate 797-63-7, Levonorgestrel 6533-00-2, Norgestrel 35189-28-7, Norgestimate 53016-31-2, 17-Deacetylnorgestimate 54024-22-5, Desogestrel 54048-10-1, 3-Ketodesogestrel 58691-88-6, Nomegestrol 60282-87-3, Gestodene 65928-58-7, Dienogest 67392-87-4, Drospirenone 74513-62-5, Trimegestone 105149-04-0, Osaterone
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of substituted dihydrobenzoxazinones with progesterone receptor antagonist activity for use in contraceptive compns.)

IT 304853-29-0P 304853-30-3P 304854-07-7P 304854-08-8P 304854-49-7P 305800-19-5P 305800-20-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of substituted dihydrobenzoxazinones with progesterone receptor antagonist activity for use in contraceptive compns.)

IT 304853-28-9P 304853-31-4P 304853-93-8P 304853-94-9P 304853-98-3P
304854-01-1P 304854-06-6P 304854-09-9P 304854-12-4P 304854-13-5P
304854-14-6P 304854-15-7P 304854-16-8P 304854-17-9P 304854-20-4P
304854-21-5P 304854-22-6P 304854-23-7P 304854-24-8P 304854-25-9P
304854-26-0P 304854-27-1P 304854-28-2P 304854-29-3P 304854-30-6P
304854-31-7P 304854-32-8P 304854-33-9P 304854-34-0P 304854-35-1P
304854-36-2P 304854-37-3P 304854-38-4P 304854-39-5P 304854-41-9P
304854-42-0P 304854-43-1P 304854-44-2P 304854-46-4P 304854-47-5P
304854-48-6P 304854-50-0P 305799-74-0P 305799-76-2P 305799-78-4P
305799-80-8P 305799-81-9P 305799-83-1P 305799-85-3P 305799-86-4P
305799-87-5P 305799-88-6P 305799-89-7P 305799-93-3P 305799-95-5P
305799-97-7P 305799-98-8P 305800-00-4P 305800-02-6P 305800-03-7P
305800-04-8P 305800-05-9P 305800-08-2P 305800-10-6P 305800-11-7P
305800-12-8P 305800-14-0P 305800-15-1P 305800-16-2P 305800-18-4P
305800-21-9P 305800-22-0P 305800-23-1P 305800-24-2P 305800-25-3P
305800-26-4P 305800-27-5P 305800-34-4P 305800-35-5P 305800-37-7P
305800-40-2P 305800-45-7P 305800-46-8P 305800-47-9P 305800-48-0P
305800-50-4P 305800-51-5P 305800-52-6P 305800-53-7P 305800-56-0P
305800-57-1P 305800-59-3P 305800-61-7P 305800-62-8P 305800-63-9P
305800-64-0P 305800-65-1P 305800-66-2P 305800-67-3P 305800-68-4P
305800-72-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted dihydrobenzoxazinones with progesterone receptor antagonist activity for use in contraceptive compns.)

IT 100-58-3, Phenylmagnesium bromide 107-30-2, Chloromethyl methyl ether 108-36-1, 1,3-Dibromobenzene 110-52-1, 1,4-Dibromobutane 111-24-0, 1,5-Dibromopentane 122-51-0, Triethyl orthoformate 326-66-9 348-61-8, 1-Bromo-3,4-difluorobenzene 460-00-4, 1-Bromo-4-fluorobenzene 461-96-1, 1-Bromo-3,5-difluorobenzene 623-49-4, Ethyl cyanoformate

625-92-3, 3,5-Dibromopyridine 814-49-3, Diethyl chlorophosphate
1066-54-2, (Trimethylsilyl)acetylene 1072-85-1, 1-Bromo-2-fluorobenzene
1072-97-5, 2-Amino-5-bromopyridine 1073-06-9, 1-Bromo-3-fluorobenzene
1191-95-3, Cyclobutanone 1435-51-4, 1,3-Dibromo-5-fluorobenzene
1546-79-8, 1-(Trifluoroacetyl)imidazole 1589-82-8, Benzylmagnesium
bromide 1611-92-3, 3,5-Dibromotoluene 1679-18-1, 4-Chlorophenylboronic
acid 1730-25-2, Allylmagnesium bromide 2357-52-0, 4-Bromo-2-
fluoroanisole 3177-80-8, 2-Amino-3-methoxybenzoic acid 3900-89-8,
2-Chlorophenylboronic acid 4301-14-8, Ethynylmagnesium bromide
4333-56-6, Cyclopropyl bromide 4692-98-2, 5-Bromoisatoic anhydride
4701-17-1 4915-06-4, 5-Bromo-2-furancarbonitrile 5419-55-6,
Triisopropyl borate 5794-88-7, 2-Amino-5-bromobenzoic acid 6165-69-1,
3-Thiopheneboronic acid 6638-79-5, N,O-Dimethylhydroxylamine
hydrochloride 6952-59-6, 3-Bromobenzonitrile 7087-65-2 10365-98-7,
(3-Methoxyphenyl)boronic acid 13331-27-6, 3-Nitrophenylboronic acid
14282-76-9, 2-Bromo-3-methylthiophene 16466-97-0, 1-Propynylmagnesium
bromide 18242-39-2, 1-Bromo-3,5-dinitrobenzene 18437-66-6 18791-99-6
18792-00-2 19472-74-3, 2-Bromophenylacetonitrile 27065-51-6
29578-39-0 31938-07-5, 3-Bromophenylacetonitrile 33743-87-2
33863-76-2 35590-37-5, 3-Bromo-5-cyanopyridine 51437-00-4
53119-61-2, 2-Bromo-3-ethylthiophene 53595-65-6 56182-43-5
60811-21-4 63503-60-6, (3-Chlorophenyl)boronic acid 65854-91-3
67492-50-6, 3,5-Dichlorophenylboronic acid 69249-60-1 73852-19-4
79630-23-2 89599-01-9 105942-08-3 112575-11-8 114897-91-5
121359-48-6 130723-13-6 135884-31-0 141940-30-9 144432-85-9,
3-Chloro-4-fluorophenylboronic acid 145543-82-4 160892-07-9,
5-Bromoisophthalonitrile 161957-56-8 179897-89-3 179898-34-1
188813-02-7 207226-31-1 211315-75-2 304854-51-1 304854-53-3
304854-55-5 304854-61-3 304854-63-5 305799-73-9 305799-77-3
305799-79-5 305799-92-2 305800-01-5 305800-07-1 305800-13-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of substituted dihydrobenzoxazinones with progesterone receptor antagonist activity for use in contraceptive compns.)

IT 2160-62-5P, 5-Bromo-2-thiophenecarbonitrile 2160-63-6P 21440-97-1P
21440-99-3P 99725-12-9P 149947-15-9P 154598-53-5P 189331-47-3P
206551-41-9P 216755-56-5P 216755-57-6P 304853-36-9P 304853-89-2P
304853-90-5P 304853-91-6P 304853-92-7P 304853-96-1P 304854-03-3P
304854-04-4P 304854-05-5P 304854-10-2P 304854-11-3P
304854-18-0P 304854-19-1P 304854-40-8P 304854-45-3P 304854-52-2P
304854-54-4P 304854-58-8P 304854-60-2P 304854-62-4P 304874-29-1P
305799-75-1P 305799-82-0P **305799-84-2P** 305799-90-0P
305799-91-1P 305799-94-4P 305799-96-6P 305799-99-9P 305800-06-0P
305800-09-3P 305800-17-3P 305800-29-7P 305800-32-2P 305800-36-6P
305800-38-8P 305800-39-9P 305800-41-3P 305800-42-4P 305800-43-5P
305800-44-6P 305800-49-1P 305800-54-8P 305800-55-9P 305800-58-2P
305800-60-6P 305800-70-8P 305800-71-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of substituted dihydrobenzoxazinones with progesterone receptor antagonist activity for use in contraceptive compns.)

IT 304857-58-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of substituted dihydrobenzoxazinones with progesterone receptor antagonist activity for use in contraceptive compns.)

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Akzo Nobel Nv; WO 9749407 A 1997 HCAPLUS
(2) Balance Pharmaceuticals Inc; WO 9615794 A 1996 HCAPLUS
(3) Grubb, G; US 5521166 A 1996 HCAPLUS
(4) Schering Ag; DE 4330234 A 1995 HCAPLUS

(5) Schering Ag; DE 4344463 A 1995 HCAPLUS
(6) Schneider, M; US 5733902 A 1998 HCAPLUS
IT **304854-04-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of substituted dihydrobenzoxazinones with progesterone receptor antagonist activity for use in contraceptive compns.)
RN 304854-04-4 HCAPLUS
CN Spiro[4H-3,1-benzoxazine-4,1'-cyclohexan]-2(1H)-one, 6-bromo- (9CI) (CA INDEX NAME)



=> => d l113 all fhitstr tot

L113 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2000:475543 HCAPLUS
DN 133:105042
ED Entered STN: 14 Jul 2000
TI Preparation of 2-amino-4H-3,1-benzoxazin-4-one derivatives for the treatment of obesity
IN Hodson, Harold Francis; Downham, Robert; Mitchell, Timothy John; Carr, Beverley Jane; Dunk, Christopher Robert; Palmer, Richard Michael John
PA Alizyme Therapeutics Limited, UK
SO PCT Int. Appl., 70 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K031-536
ICS A61P003-04; C07D265-24; C07D498-04; C07D413-12; C07D498-04; C07D265-00; C07D221-00
CC 28-13 (Heterocyclic Compounds (More Than One Hetero Atom))
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000040247	A1	20000713	WO 2000-GB32	20000106 <--
	WO 2000040247	C2	20021024		
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2359819	AA	20000713	CA 2000-2359819	20000106 <--
	EP 1143977	A1	20011017	EP 2000-900082	20000106 <--
	EP 1143977	B1	20050420		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

JP 2002534388	T2	20021015	JP 2000-592004	20000106	<--
AU 765147	B2	20030911	AU 2000-18846	20000106	<--
NZ 512740	A	20031031	NZ 2000-512740	20000106	<--
AT 293447	E	20050515	AT 2000-900082	20000106	<--
ZA 2000003398	A	20020107	ZA 2000-3398	20000706	<--
RU 2245331	C2	20050127	RU 2001-123171	20010106	<--
NO 2001003381	A	20010907	NO 2001-3381	20010706	<--
US 2003027821	A1	20030206	US 2001-901887	20010706	<--
US 6624161	B2	20030923			
US 2003195206	A1	20031016	US 2002-306377	20021127	<--
PRAI GB 1999-413	A	19990108	<--		
GB 1999-17294	A	19990722	<--		
WO 2000-GB32	W	20000106	<--		
US 2001-901887	A3	20010706	<--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES	
WO 2000040247	ICM	A61K031-536	
	ICS	A61P003-04; C07D265-24; C07D498-04; C07D413-12; C07D498-04; C07D265-00; C07D221-00	
WO 2000040247	ECLA	C07C271/28; C07D265/26B	<--
US 2003027821	NCL	514/230.500; 544/093.000; 544/094.000	
	ECLA	C07C271/28; C07D265/26B	<--
US 2003195206	NCL	514/230.500	
	ECLA	C07C271/28; C07D265/26B	<--

OS MARPAT 133:105042

GI



I

AB The title compds. I [A = 6-membered aromatic or heteroarom. ring; R1 = branched or unbranched alkyl (optionally interrupted by one or more oxygen atoms), alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, arylalkyl, reduced arylalkyl, arylalkenyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, reduced aryl, reduced heteroaryl, reduced heteroarylalkyl], useful in the treatment of obesity, were prepared E.g., 2-phenylamino-4H-3,1-benzoxazin-4-one was prepared I were tested as inhibitors of pancreatic lipase.

ST aminobenzoxazinone prepn obesity treatment; benzoxazinone amino prepn obesity treatment

IT Antiobesity agents
(preparation of aminobenzoxazinones for the treatment of obesity)

IT 945-04-0P 1026-16-0P 54722-44-0P 81905-02-4P 86672-55-1P
86672-56-2P 86672-60-8P 278609-56-6P 282529-85-5P 282529-86-6P
282529-87-7P 282529-88-8P 282529-89-9P 282529-90-2P 282529-91-3P
282529-92-4P 282529-93-5P 282529-94-6P 282529-96-8P 282529-97-9P
282529-98-0P 282530-00-1P 282530-01-2P 282530-03-4P 282530-05-6P
282530-07-8P 282530-08-9P 282530-09-0P 282530-11-4P 282530-13-6P
282530-14-7P 282530-16-9P 282530-17-0P 282530-18-1P 282530-20-5P
282530-22-7P 282530-24-9P 282530-26-1P 282530-28-3P 282530-30-7P

282530-32-9P 282530-33-0P 282530-35-2P 282530-36-3P 282530-37-4P
282530-39-6P 282530-40-9P **282530-42-1P** 282530-43-2P
282530-47-6P 282530-49-8P 282530-51-2P 282530-53-4P 282530-55-6P
282530-57-8P 282530-59-0P 282530-61-4P 282530-62-5P 282530-64-7P
282530-66-9P 282530-68-1P 282530-69-2P 282530-70-5P 282530-73-8P
282530-74-9P 282530-75-0P 282530-76-1P 282530-77-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aminobenzoxazinones for the treatment of obesity)

IT 9001-62-1
RL: BPR (Biological process); BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study); PROC (Process)
(preparation of aminobenzoxazinones for the treatment of obesity)

IT 2305-36-4, 2-Amino-4-methylbenzoic acid 2909-38-8, 3-Chlorophenyl isocyanate 2941-78-8, 2-Amino-5-methylbenzoic acid 51554-93-9 59377-19-4, 4-Phenoxyphenyl isocyanate 132586-17-5 282530-78-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of aminobenzoxazinones for the treatment of obesity)

IT 282526-99-2P 282527-00-8P 282527-01-9P 282527-03-1P 282530-83-0P 282530-84-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of aminobenzoxazinones for the treatment of obesity)

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Bayer Ag; DE 2315303 A 1974 HCAPLUS
(2) GUtschow, M; BIOORGANIC & MEDICINAL CHEMISTRY 1997, V5(10), P1935 HCAPLUS
(3) Jarvest, R; BIOORGANIC & MEDICINAL CHEMISTRY LETTERS 1996, V6(20), P2463 HCAPLUS
(4) Searle & Co; WO 9637485 A 1996 HCAPLUS
(5) Syntex Inc; US 4657893 A HCAPLUS
(6) Syntex Inc; EP 0147211 A 1985 HCAPLUS
(7) Ulrich, H; US 3450700 A 1969 HCAPLUS
(8) Warner Lambert Co; US 5652237 A HCAPLUS
(9) Warner Lambert Co; WO 9607648 A 1996 HCAPLUS

IT **282530-42-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aminobenzoxazinones for the treatment of obesity)

RN 282530-42-1 HCAPLUS
CN 4H-3,1-Benzoxazin-4-one, 6-cyclopropyl-2-(phenylamino)- (9CI) (CA INDEX NAME)



L113 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 1993:213099 HCAPLUS
DN 118:213099
ED Entered STN: 29 May 1993
TI Imidazole-substituted benzoxazine and benzothiazine derivatives

IN Kim, Moohi Y.; Shin, Hyun T.; Lee, Choon W.; Kim, Joon W.; Kim, Soon H.; Choi, Youngmoon; Son, Moon H.
PA Dong-A Pharm. Co., Ltd., S. Korea
SO U.S., 12 pp.
CODEN: USXXAM
DT Patent
LA English
IC ICM C07D413-02
ICS C07D413-10; C07D417-02; C07D417-10
INCL 544050000
CC 28-15 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 5171851	A	19921215	US 1991-674183	19910325 <--
KR 164842	B1	19990115	KR 1990-3989	19900324 <--
JP 04217977	A2	19920807	JP 1991-82966	19910325 <--
PRAI KR 1990-3989	A	19900324 <--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 5171851	ICM	C07D413-02
	ICS	C07D413-10; C07D417-02; C07D417-10
	INCL	544050000
US 5171851	NCL	544/050.000; 544/092.000 <--

OS CASREACT 118:213099; MARPAT 118:213099
GI



I

AB Title compds. I (X, X1 = O, S; R-R2 = H, alkyl; R1R2 = CH:CHCH:CH) were prepared as cardiac stimulants. Thus, reduction of 2-amino-3-methyl-5-(4-methyl-1H-imidazol-1-yl)benzaldehyde gave 59% 2-amino-3-methyl-5-(4-methyl-1H-imidazol-1-yl)benzyl alc. which was converted to the N-ethoxycarbonyl derivative Cyclocondensation of the latter gave 87% I (X, X1 = O, R = Me, R1 = H, R2 = 4-Me, II). At 1.2 μg II caused 30% increase in the contractile force of an isolated dog heart and a 5% increase in sinus rate.
ST cardiotonic imidazolylbenzoxazine imidazolylbenzothiazine; benzoxazinone imidazolyl cardiotonic prepn; benzothiazinone imidazolyl cardiotonic prepn
IT Cardiotonics
(inotropics, (imidazolyl)benzoxazinones and -thiones, (imidazolyl)benzothiazinones and -thiones)
IT 81840-03-1P 145622-93-1P 145622-94-2P 145622-95-3P 145622-97-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as intermediate for (imidazolyl)benzoxazinone (inotropic))
IT 145622-96-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as intermediate for (imidazolyl)benzoxazinone or

(imidazolyl)benzothiazinone (inotropic))
IT 102791-88-8P 102791-94-6P 147030-57-7P 147030-58-8P 147030-59-9P
147030-60-2P 147030-61-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as intermediate for (imidazolyl)benzoxazinone or
(imidazolyl)benzothiazinone derivative (inotropic))
IT 145622-69-1P 145622-70-4P 145622-71-5P 145622-72-6P 145622-73-7P
145622-74-8P 145622-75-9P 145622-76-0P 145622-77-1P 145622-78-2P
145622-80-6P 145622-81-7P 145622-82-8P 145622-83-9P 145622-84-0P
145622-85-1P 145622-86-2P 145622-87-3P 145622-88-4P 145622-89-5P
145622-90-8P 145622-91-9P **145622-92-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as pos. inotropic)
IT 147017-49-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant for (imidazolyl)benzothiazinone (inotropic))
IT 140-89-6, Ethyl potassium xanthate
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant for (imidazolyl)benzothiazinone derivative (inotropic))
IT 693-98-1, 2-Methyl-1H-imidazole 6628-86-0, 5-Chloro-2-nitrobenzaldehyde
147017-50-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant for (imidazolyl)benzoxazinone (inotropic))
IT 446-33-3, 5-Fluoro-2-nitrotoluene 822-36-6, 4-Methyl-1H-imidazole
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant for (imidazolyl)benzoxazinone or (imidazolyl)benzothiazinone
derivative (inotropic))
IT 147789-30-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with potassium Et xanthate, in preparation of inotropic
cardiac stimulants)
IT **145622-92-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as pos. inotropic)
RN 145622-92-0 HCAPLUS
CN 2H-3,1-Benzoxazine-2-thione, 1,4-dihydro-8-methyl-6-(4-methyl-1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)



L113 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 1993:101972 HCAPLUS
DN 118:101972
ED Entered STN: 19 Mar 1993
TI Preparation of benzoxazinones, benzothiazinones, and related compounds as cardiotonics
IN Moohi, Yoo Kim; Hyun, Tae Shin; Choon, Woo Lee; Joon, Wan Kim; Soon, Hoe Kim; Youngmoon, Choi; Moon, Ho Son
PA Dong A Pharm. Co., Ltd., S. Korea
SO Eur. Pat. Appl., 31 pp.
CODEN: EPXXDW

DT Patent
LA English
IC ICM C07D413-04
ICS C07D417-04; C07D471-04; A61K031-535; A61K031-54
ICA C07D233-58; C07D233-61
ICI C07D471-04, C07D235-00, C07D221-00
CC 28-14 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 510235	A1	19921028	EP 1991-106822	19910426 <--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE
PRAI EP 1991-106822 19910426 <--
CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
EP 510235	ICM	C07D413-04
	ICS	C07D417-04; C07D471-04; A61K031-535; A61K031-54
	ICA	C07D233-58; C07D233-61
	ICI	C07D471-04, C07D235-00, C07D221-00

OS MARPAT 118:101972
GI



I



II

AB Title compds. (I; X, Y = O, S; R1-R3 = H, alkyl; R1R2 = atoms to form a fused aromatic heterocycle) were prepared Thus, Et 2-ethoxycarbonylamino-5-(2-methylimidazol-1-yl)benzyl carbonate (preparation starting from 5-chloro-2-nitrobenzaldehyde given) was stirred with NaOMe in MeOH at 0° to room temperature to give 75% title compound II. I increased contractility in blood-perfused dog papillary muscle preparation by 5.24-79.2% at 1-30 μg.
ST imidazolylbenzoxazinone prepn cardiotonic; benzothiazinone imidazolyl cardiotonic; benzoxazinone imidazolyl cardiotonic
IT Cardiotonics
(imidazolylbenzoxazinones and -benzothiazinones and related compds.)
IT 145622-69-1P 145622-70-4P 145622-71-5P 145622-72-6P 145622-73-7P
145622-74-8P 145622-75-9P 145622-76-0P 145622-77-1P 145622-78-2P
145622-79-3P 145622-80-6P 145622-81-7P 145622-82-8P 145622-83-9P
145622-84-0P 145622-85-1P 145622-86-2P 145622-87-3P 145622-88-4P
145622-89-5P 145622-90-8P 145622-91-9P **145622-92-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as cardiotonic)
IT 81840-03-1P 102791-89-9P 102791-95-7P 145622-93-1P 145622-94-2P
145622-95-3P 145622-96-4P 145622-97-5P 145622-98-6P 145622-99-7P
145623-00-3P 145623-01-4P 145623-02-5P
RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of, as intermediate for imidazolylbenzoxazinone cardiotonic)
IT 140-89-6, Potassium ethyl xanthate 145623-03-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, in preparation of imidazolylbenzothiazinone cardiotonic)
IT 6160-65-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, in preparation of imidazolylbenzoxazinethione cardiotonic)
IT 541-41-3, Ethyl chloroformate 693-98-1, 2-Methylimidazole 822-36-6, 4-Methylimidazole 5367-28-2, 5-Chloro-2-nitrotoluene 6628-86-0, 5-Chloro-2-nitrobenzaldehyde
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, in preparation of imidazolylbenzoxazinone cardiotonic)
IT **145622-92-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as cardiotonic)
RN 145622-92-0 HCAPLUS
CN 2H-3,1-Benzoxazine-2-thione, 1,4-dihydro-8-methyl-6-(4-methyl-1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)



L113 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 1989:95163 HCAPLUS
DN 110:95163
ED Entered STN: 17 Mar 1989
TI Studies on positive inotropic agents. VI. Synthesis of 1-aromatic ring substituted 4-(3,4-dimethoxybenzoyl)piperazine derivatives
AU Ogawa, Hidenori; Tamada, Shigeharu; Fujioka, Takafumi; Teramoto, Shuji; Kondo, Kazumi; Yamashita, Shuji; Yabuuchi, Youichi; Tominaga, Michiaki; Nakagawa, Kazuyuki
CS Tokushima Res. Inst., Otsuka Pharm. Co., Ltd., Tokushima, 771-01, Japan
SO Chemical & Pharmaceutical Bulletin (**1988**), 36(7), 2401-9
CODEN: CPBTAL; ISSN: 0009-2363
DT Journal
LA English
CC 28-17 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1
OS CASREACT 110:95163
GI



I

AB Piperazines I (R1 = H, Me; Z1 = S, O, NH, NMe; Z2 = H2, O; Z3 = S, O) were prepared, and they showed inotropic activity. A Me 5-(1-pipeazinyl)anthranilate derivative was treated with MeNCO to give I (R1 = H, Z1 = NMe, Z2 = Z3 = O).

ST piperazine heteroaryl prepn inotropic; inotropic heteroarylbenzoylpiperazine prepn

IT Cardiotonics
(inotropics, heteroaryl(dimethoxybenzoyl)piperazines)

IT 407-25-0, Trifluoroacetic anhydride
RL: RCT (Reactant); RACT (Reactant or reagent)
(acylation by, of anthranilic acid derivative)

IT 3535-37-3, 3,4-Dimethoxybenzoyl chloride
RL: RCT (Reactant); RACT (Reactant or reagent)
(acylation by, of piperazines)

IT 74-88-4, reactions
RL: RCT (Reactant); RACT (Reactant or reagent)
(alkylation by, of quinazolinedione derivative and anthranilic acid derivative)

IT 13796-06-0, 5-Chloro-2-nitrobenzaldehyde dimethyl acetal
RL: RCT (Reactant); RACT (Reactant or reagent)
(arylation by, of piperazine)

IT 51282-49-6, Methyl 5-chloro-2-nitrobenzoate
RL: RCT (Reactant); RACT (Reactant or reagent)
(arylation by, of piperazine derivative)

IT 2759-28-6, 1-Benzylpiperazine
RL: RCT (Reactant); RACT (Reactant or reagent)
(arylation of, by chlorobenzoic acid derivative)

IT 110-85-0, Piperazine, reactions
RL: RCT (Reactant); RACT (Reactant or reagent)
(arylation of, by chloronitrobenzaldehyde derivative)

IT 43204-63-3, Bis(2-bromoethyl)amine hydrobromide
RL: RCT (Reactant); RACT (Reactant or reagent)
(cycloalkylation by, of aminoindole and aminobenzothiazole derivs.)

IT 20876-36-2 56354-98-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(cycloalkylation of, by bis(bromoethyl)amine)

IT 140-89-6, Potassium ethyl xanthate
RL: RCT (Reactant); RACT (Reactant or reagent)
(cyclocondensation reaction of, with aminobenzyl alc. derivative)

IT 76-02-8, Trichloroacetyl chloride
RL: RCT (Reactant); RACT (Reactant or reagent)
(cyclocondensation reaction of, with aminobenzyl alc. derivative, in preparation
benzoxazinone derivative)

IT 75-15-0, Carbon disulfide, reactions 75-44-5, Phosgene 7791-25-5, Sulfuryl chloride
RL: RCT (Reactant); RACT (Reactant or reagent)
(cyclocondensation reaction of, with aminobenzylamine derivative)

IT 334-88-3, Diazomethane
RL: RCT (Reactant); RACT (Reactant or reagent)
(esterification by, of anthranilic acid derivative)
IT 590-28-3, Potassium isocyanate 624-83-9, Methyl isocyanate
RL: RCT (Reactant); RACT (Reactant or reagent)
(of cyclocondensation reaction of, with anthranilate ester derivative)
IT 86813-46-9P 99111-45-2P 102358-66-7P 119198-22-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and acylation of, by benzoyl chloride derivative)
IT 119198-29-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and conversion of, to anthranilate ester derivative)
IT 81840-07-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and conversion of, to benzyl alc., benzoic acid and benzylamine analogs)
IT 119198-33-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and cyclocondensation reaction of, with potassium isocyanate)
IT 119198-30-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and cyclocondensation reactions of, with alkali and alkyl isocyanates)
IT 119198-38-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and cyclocondensation reactions of, with sulfuryl chloride, phosgene and carbon disulfide)
IT 119198-24-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and cyclocondensation reactions of, with xanthate ester and trichloroacetyl chloride)
IT 119198-34-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and hydrogenolysis of)
IT 99111-46-3P 102358-67-8P 119198-23-1P 119198-25-3P
119198-26-4P 119198-27-5P 119198-28-6P 119198-31-1P
119198-32-2P 119198-35-5P 119198-36-6P 119198-39-9P 119198-40-2P
119198-41-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and inotropic activity of)
IT 119198-45-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and methylation-deacylation of)
IT 119198-37-7P 119198-42-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reduction of)
IT 119198-43-5P 119198-44-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and trifluoroacetylation of)

IT 74-89-5, Methylamine, reactions
RL: RCT (Reactant); RACT (Reactant or reagent)
(reductive amination by, of aminobenzaldehyde derivative)
IT **119198-26-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and inotropic activity of)
RN 119198-26-4 HCAPLUS
CN Piperazine, 1-(1,4-dihydro-2-thioxo-2H-3,1-benzoxazin-6-yl)-4-(3,4-dimethoxybenzoyl)- (9CI) (CA INDEX NAME)



=> => d his l120-

(FILE 'USPATFULL' ENTERED AT 07:56:32 ON 05 JUL 2005)
L120 5 S L116
L121 10 S L23
L122 8 S L24
L123 10 S L120-L122
L124 9 S L123 AND (PY<=2002 OR PRY<=2002 OR AY<=2002)
L125 10 S L123,L124

=> fil uspatful
FILE 'USPATFULL' ENTERED AT 07:57:34 ON 05 JUL 2005
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 5 Jul 2005 (20050705/PD)
FILE LAST UPDATED: 5 Jul 2005 (20050705/ED)
HIGHEST GRANTED PATENT NUMBER: US6915531
HIGHEST APPLICATION PUBLICATION NUMBER: US2005144692
CA INDEXING IS CURRENT THROUGH 5 Jul 2005 (20050705/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 5 Jul 2005 (20050705/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Apr 2005
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Apr 2005

>>> USPAT2 is now available. USPATFULL contains full text of the <<<
>>> original, i.e., the earliest published granted patents or <<<
>>> applications. USPAT2 contains full text of the latest US <<<
>>> publications, starting in 2001, for the inventions covered in <<<
>>> USPATFULL. A USPATFULL record contains not only the original <<<
>>> published document but also a list of any subsequent <<<
>>> publications. The publication number, patent kind code, and <<<
>>> publication date for all the US publications for an invention <<<
>>> are displayed in the PI (Patent Information) field of USPATFULL <<<
>>> records and may be searched in standard search fields, e.g., /PN, <<<

```
>>>  /PK, etc.                                                          <<<

>>>  USPATFULL and USPAT2 can be accessed and searched together        <<<
>>>  through the new cluster USPATALL.  Type FILE USPATALL to          <<<
>>>  enter this cluster.                                               <<<
>>>                                                                    <<<
>>>  Use USPATALL when searching terms such as patent assignees,       <<<
>>>  classifications, or claims, that may potentially change from      <<<
>>>  the earliest to the latest publication.                           <<<

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> d l125 bib abs hitrn fhitstr tot

L125 ANSWER 1 OF 10  USPATFULL on STN
AN      2005:62604  USPATFULL
TI      Partially absorbable fiber-reinforced composites for controlled drug
        delivery
IN      Shalaby, Shalaby W, Anderson, SC, UNITED STATES
PI      US 2005053639      A1   20050310
AI      US 2004-935808     A1   20040908 (10)
RLI     Continuation-in-part of Ser. No. US 2004-860677, filed on 3 Jun 2004,
        PENDING
PRAI    US 2003-482898P     20030626 (60)
DT      Utility
FS      APPLICATION
LREP    LEIGH P. GREGORY, ATTORNEY AT LAW, PO BOX 168, CLEMSON, SC, 29633-0168
CLMN    Number of Claims: 30
ECL     Exemplary Claim: 1
DRWN    No Drawings
LN.CNT 774
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB      This invention describes a partially absorbable, fiber-reinforced
        composite in the form of a ring, or a suture-like thread, with modified
        terminals for use as a controlled delivery system of at least one
        bioactive agent, wherein said composite comprising an absorbable fiber
        construct capable of providing time-dependent mechanical properties of a
        biostable elastomeric matrix containing an absorbable microparticulate
        ion-exchanger to modulate the release of the bioactive agent(s) for a
        desired period(s) of time at a specific biological site; this can be a
        vaginal canal, peritoneal cavity, scrotum, prostate gland, an ear loop
        or subcutaneous tissue. Such drug delivery systems can be used for the
        local administration of at least one bioactive agent, including those
        used as contraceptive, antimicrobial, anti-inflammatory and/or antiviral
        agents as well as for cancer treatment.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT   304853-42-7, Tanaproget
        (partially absorbable fiber-reinforced composites for controlled drug
        delivery)
IT  304853-42-7, Tanaproget
        (partially absorbable fiber-reinforced composites for controlled drug
        delivery)
RN   304853-42-7  USPATFULL
CN   1H-Pyrrole-2-carbonitrile, 5-(1,4-dihydro-4,4-dimethyl-2-thioxo-2H-3,1-
       benzoxazin-6-yl)-1-methyl- (9CI)  (CA INDEX NAME)
```



L125 ANSWER 2 OF 10 USPATFULL on STN
AN 2004:19494 USPATFULL
TI Cyclothiocarbamate derivatives as progesterone receptor modulators and methods of treating skin disorders
IN Fensome, Andrew, Wayne, PA, UNITED STATES
Harrison, Diane Deborah, Villanova, PA, UNITED STATES
Winneker, Richard Craig, Penllyn, PA, UNITED STATES
Zhang, Puwen, Audubon, PA, UNITED STATES
Kern, Jeffrey Curtis, Gilbertsville, PA, UNITED STATES
Terefenko, Eugene Anthony, Quakertown, PA, UNITED STATES
PA Wyeth, Madison, NJ (U.S. corporation)
PI US 2004014798 A1 20040122
AI US 2003-601968 A1 20030623 (10)
PRAI US 2002-391885P 20020625 (60) <--
DT Utility
FS APPLICATION
LREP HOWSON AND HOWSON, CATHY A. KODROFF, ONE SPRING HOUSE CORPORATE CENTER, BOX 457, SPRING HOUSE, PA, 19477
CLMN Number of Claims: 27
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2498
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides methods of treating skin disorders includes delivering to a mammal a composition containing a compound of formula I, or tautomers thereof, in a regimen, wherein formula I is: ##STR1##

and wherein R.sup.1-R.sup.5 and Q.sup.1 are defined as described herein. Specifically, methods for treating acne, hirsutism, and conditioning the skin are described. Also provided are novel PR modulators of formula II.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **638989-33-0P 638989-38-5P 638989-41-0P**
638989-44-3P 638989-46-5P 638989-48-7P
(cyclothiocarbamate derivs. as progesterone receptor modulators and use thereof for treatment of skin disorders)
IT **304853-32-5 304853-35-8 304853-37-0**
304853-38-1 304853-39-2 304853-40-5
304853-41-6 304853-42-7 304853-43-8
304853-44-9 304853-45-0 304853-46-1
304853-47-2 304853-48-3 304853-49-4
304853-50-7 304853-51-8 304853-52-9
304853-53-0 304853-54-1 304853-55-2
304853-56-3 304853-57-4 304853-58-5
304853-59-6 304853-60-9 304853-61-0
304853-62-1 304853-63-2 304853-64-3
304853-66-5 304853-67-6 304853-68-7
304853-69-8 304853-70-1 304853-71-2

304853-72-3 304853-73-4 304853-74-5
304853-75-6 304853-76-7 304853-77-8
304853-78-9 304853-79-0 304853-80-3
304853-81-4 304853-82-5 304853-83-6
304853-84-7 304853-85-8 304853-86-9
304853-87-0 304853-88-1 304853-95-0
(cyclothiocarbamate derivs. as progesterone receptor modulators and use thereof for treatment of skin disorders)

IT **638989-33-0P**
(cyclothiocarbamate derivs. as progesterone receptor modulators and use thereof for treatment of skin disorders)

RN 638989-33-0 USPATFULL

CN 1H-Pyrrole-2-carbonitrile, 5-(1,2-dihydro-2-thioxospiro[4H-3,1-benzoxazine-4,1'-cyclobutan]-6-yl)-1-methyl- (9CI) (CA INDEX NAME)



L125 ANSWER 3 OF 10 USPATFULL on STN

AN 2004:7820 USPATFULL

TI Methods of treating hormone-related conditions using cyclothiocarbamate derivatives

IN Fensome, Andrew, Wayne, PA, UNITED STATES
Grubb, Gary S., Newtown Square, PA, UNITED STATES
Harrison, Diane Deborah, Villanova, PA, UNITED STATES
Winneker, Richard Craig, Penllyn, PA, UNITED STATES
Zhang, Puwen, Audubon, PA, UNITED STATES
Kern, Jeffrey Curtis, Gilbertsville, PA, UNITED STATES
Terefenko, Eugene Anthony, Quakertown, PA, UNITED STATES

PA Wyeth, Madison, NJ (U.S. corporation)

PI US 2004006060 A1 20040108

AI US 2003-601481 A1 20030623 (10)

PRAI US 2002-391871P 20020625 (60) <--

DT Utility

FS APPLICATION

LREP HOWSON AND HOWSON, CATHY A. KODROFF, ONE SPRING HOUSE CORPORATE CENTER, BOX 457, SPRING HOUSE, PA, 19477

CLMN Number of Claims: 28

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 2452

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides methods of inducing contraception which includes delivering to a female a composition containing a compound of formula I or formula II, or tautomers thereof, in a regimen which involves delivering one or more of a selective estrogen receptor modulator, wherein formula I is: ##STR1##

and wherein R.sup.1-R.sup.5 and Q.sup.1 are defined as described herein. Methods of providing hormone replacement therapy and for treating carcinomas, dysfunctional bleeding, uterine leiomyomata, endometriosis, and polycystic ovary syndrome is provided which includes delivering a

compound of formula I and a selective estrogen receptor modulator are also described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **304853-32-5P**, 6-(3-Chlorophenyl)-4,4-dimethyl-1,4-dihydrobenzo[d][1,3]oxazin-2-thione **304853-33-6P**, 4-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-benzo[d][1,3]oxazin-6-yl)thiophene-2-carbonitrile **304853-35-8P**, 3-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-benzo[d][1,3]oxazin-6-yl)-5-fluorobenzonitrile **304853-37-0P**, 3-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-benzo[d][1,3]oxazin-6-yl)benzonitrile **304853-38-1P**, 6-(3-Fluorophenyl)-4-methyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione **304853-39-2P**, 5-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-4-methylthiophene-2-carbonitrile **304853-40-5P**, 5-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1H-pyrrole-2-carbonitrile **304853-41-6P**, [6-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)pyridin-2-yl]acetonitrile **304853-42-7P**, 5-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1-methyl-1H-pyrrole-2-carbonitrile **304853-43-8P**, 5-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1H-pyrrole-2-carbothioamide **304853-44-9P**, 5-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-benzo[d][1,3]oxazin-6-yl)thiophene-3-carbonitrile **304853-45-0P**, 5-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1-ethyl-1H-pyrrole-2-carbonitrile **304853-46-1P**, 4-[1,2-Dihydro-2-thioxospiro[4H-3,1-benzoxazin-4,1-cyclohexan]-6-yl]-2-thiophenecarbonitrile **304853-47-2P**, 5-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-2-fluorobenzonitrile **304853-48-3P**, 6-(5-Bromopyridin-3-yl)-4,4-dimethyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione **304853-49-4P**, 6-(3-Chloro-5-fluorophenyl)-4,4-dimethyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione **304853-50-7P**, 6-(3-Bromo-5-methylphenyl)-4,4-dimethyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione **304853-51-8P**, 6-(3-Bromo-5-trifluoromethoxyphenyl)-4,4-dimethyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione **304853-52-9P**, 3-[1,2-Dihydro-2-thioxospiro[4H-3,1-benzoxazine-4,1-cyclohexan]-6-yl]-5-fluorobenzonitrile **304853-53-0P**, 3-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-5-methylbenzonitrile **304853-54-1P**, 6-(3,5-Dichlorophenyl)-4,4-dimethyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione **304853-56-3P**, 5-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-2-furonitrile **304853-57-4P**, 4,4-Diethyl-6-(3-nitrophenyl)-1,4-dihydro-2H-3,1-benzoxazine-2-thione **304853-58-5P**, 6-(3-Chlorophenyl)-4-methyl-4-phenyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione **304853-59-6P**, 4-Allyl-6-(3-chlorophenyl)-4-methyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione **304853-60-9P**, 3-Chloro-5-(4,4-dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)benzonitrile **304853-61-0P**, 6-(3,5-Difluorophenyl)-4,4-dimethyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione **304853-62-1P**, 6-(3-Fluoro-5-methoxyphenyl)-4,4-dimethyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione **304853-63-2P**, 3-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-5-methoxybenzonitrile **304853-64-3P**, 6-(3-Fluorophenyl)-4,4-dimethyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione **304853-65-4P**, 6-[3-Fluoro-5-(trifluoromethyl)phenyl]-4,4-dimethyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione **304853-66-5P**, 6-(2-Fluorophenyl)-4,4-dimethyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione **304853-67-6P**, 6-(3,4-Difluorophenyl)-4,4-dimethyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione **304853-68-7P**, 6-(4-Fluorophenyl)-4,4-dimethyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione **304853-69-8P**, 3-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-4-fluorobenzonitrile **304853-70-1P**, 6-(2,3-Difluorophenyl)-4,4-

dimethyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione **304853-71-2P**, 3-(8-Bromo-4,4-dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-5-fluorobenzonitrile **304853-72-3P**, 4,4-Dimethyl-6-(3-nitrophenyl)-1,4-dihydro-2H-3,1-benzoxazine-2-thione **304853-73-4P**, 6-(3-Chlorophenyl)-4,4-diethyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione **304853-74-5P**, 6-(3-Methoxyphenyl)-4,4-dimethyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione **304853-75-6P**, 6-(2-Chlorophenyl)-4,4-dimethyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione **304853-76-7P**, 4-Benzyl-6-(3-chlorophenyl)-4-methyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione **304853-77-8P**, 6-(3-Bromo-5-fluorophenyl)-4,4-dimethyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione **304853-78-9P**, 5-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)thiophene-2-carbonitrile **304853-79-0P**, 3-Fluoro-5-(8-fluoro-4,4-dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)benzonitrile **304853-80-3P**, 3-[1,2-Dihydro-2-thioxospiro[4H-3,1-benzoxazine-4,1'-cyclohexan]-6-yl]benzonitrile **304853-81-4P**, 5-[1,2-Dihydro-2-thioxospiro[4H-3,1-benzoxazine-4,1'-cyclohexan]-6-yl]-4-methyl-2-thiophenecarbonitrile **304853-82-5P**, 5-[1,2-Dihydro-2-thioxospiro[4H-3,1-benzoxazine-4,1'-cyclohexan]-6-yl]-2-thiophenecarbonitrile **304853-83-6P**, 6-(3-Chloro-4-fluorophenyl)-4,4-dimethyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione **304853-84-7P**, 5-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-4-propylthiophene-2-carbonitrile **304853-85-8P**, 4-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-2-furonitrile **304853-86-9P**, 4-Butyl-5-(4,4-dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)thiophene-2-carbonitrile **304853-87-0P**, 6-(3-Bromophenyl)-4,4-dimethyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione **304853-88-1P**, 2-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)thiophene-3-carbonitrile **304853-95-0P**, 2-Cyano-5-(4,4-dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1H-pyrrole-1-carboxylic acid tert-Butyl ester **638989-33-0P**, 1-Methyl-5-[2-thioxo-1,2-dihydrospiro[3,1-benzoxazine-4,1'-cyclobutan]-6-yl]-1H-pyrrole-2-carbonitrile **638989-38-5P**, 5-(4,4-Diethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1-methyl-1H-pyrrole-2-carbonitrile **638989-41-0P**, 5-(4-Ethyl-4-methyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1-methyl-1H-pyrrole-2-carbonitrile **638989-44-3P**, 1-Methyl-5-[2-thioxo-1,2-dihydrospiro[3,1-benzoxazine-4,1'-cyclohexan]-6-yl]-1H-pyrrole-2-carbonitrile **638989-46-5P**, 1-Methyl-5-[2-thioxo-1,2-dihydrospiro[3,1-benzoxazine-4,1'-cyclopentan]-6-yl]-1H-pyrrole-2-carbonitrile **638989-48-7P**, 1-Methyl-5-[2-thioxo-4,4-bis(trifluoromethyl)-1,4-dihydro-2H-3,1-benzoxazin-6-yl]-1H-pyrrole-2-carbonitrile **639085-00-0P**, 5-(4,4-Dimethyl-1,2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)isophthalonitrile
(drug candidate; use of cyclothiocarbamate derivs. as selective androgen antagonists in contraception, hormone replacement therapy and in treatment of other hormone-related conditions)

IT **304853-32-5P**, 6-(3-Chlorophenyl)-4,4-dimethyl-1,4-dihydrobenzo[d][1,3]oxazin-2-thione
(drug candidate; use of cyclothiocarbamate derivs. as selective androgen antagonists in contraception, hormone replacement therapy and in treatment of other hormone-related conditions)

RN 304853-32-5 USPATFULL

CN 2H-3,1-Benzoxazine-2-thione, 6-(3-chlorophenyl)-1,4-dihydro-4,4-dimethyl- (9CI) (CA INDEX NAME)



L125 ANSWER 4 OF 10 USPATFULL on STN
AN 2003:277179 USPATFULL
TI 2-Oxy-benzoxazinone derivatives for the treatment of obesity
IN Hodson, Harold Francis, Beckenham, UNITED KINGDOM
Downham, Robert, Cambridge, UNITED KINGDOM
Mitchell, Timothy john, Cambridge, UNITED KINGDOM
Carr, Beverley Jane, Royston, UNITED KINGDOM
Dunk, Christopher Robert, Ely, UNITED KINGDOM
Palmer, Richard Michael John, Hayes, UNITED KINGDOM
PI US 2003195206 A1 20031016
AI US 2002-306377 A1 20021127 (10) <--
RLI Division of Ser. No. US 2001-901887, filed on 6 Jul 2001, PENDING
Continuation of Ser. No. WO 2000-GB32, filed on 6 Jan 2000, UNKNOWN
PRAI GB 1999-413 19990108 <--
GB 1999-17294 19990722 <--
DT Utility
FS APPLICATION
LREP Choate, Hall & Stewart, Exchange Place, 53 State Street, Boston, MA, 02109
CLMN Number of Claims: 53
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1846
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The use of a compound comprising formula (I): ##STR1##

or a salt, ester, amide or prodrug therof in the inhibition of an enzyme whose preferred mode of action is to catalyse the hydrolysis of an ester functionality, e.g. in the control and inhibition of unwanted enzymes in products and processes. The compounds are also useful in medicine e.g. in the treatment of obesity and related conditions. The invention also relates to novel compounds within formula (I), to processes for preparing them and pharmaceutical compositions containing them.

In formula (I) A is a 6-membered aromatic or heteroaromatic ring; and R.sup.1 is a branched or unbranched alkyl (optionally interrupted by one or more oxygen atoms), alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, arylalkyl, reduced arylalkyl, arylalkenyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, reduced aryl, reduced heteroaryl, reduced heteroarylalkyl or a substituted derivative of any of the foregoing groups.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **282530-42-1P**
(preparation of aminobenzoxazinones for the treatment of obesity)
IT **282530-42-1P**
(preparation of aminobenzoxazinones for the treatment of obesity)
RN 282530-42-1 USPATFULL
CN 4H-3,1-Benzoxazin-4-one, 6-cyclopropyl-2-(phenylamino)- (9CI) (CA INDEX NAME)



L125 ANSWER 5 OF 10 USPATFULL on STN
AN 2003:188712 USPATFULL
TI Bicyclic androgen and progesterone receptor modulator compounds and methods
IN Zhi, Lin, San Diego, CA, UNITED STATES
Tegley, Christopher, San Diego, CA, UNITED STATES
Pio, Barbara, San Diego, CA, UNITED STATES
Van Oerveren, Cornelis Arjan, San Diego, CA, UNITED STATES
Motamedi, Mehrnouch, San Diego, CA, UNITED STATES
Martinborough, Esther, San Diego, CA, UNITED STATES
West, Sarah, San Diego, CA, UNITED STATES
Higuchi, Robert, Solana Beach, CA, UNITED STATES
Hamann, Lawrence G., Cherry Hill, NJ, UNITED STATES
Farmer, Luc, Foxborough, MA, UNITED STATES
PI US 2003130505 A1 20030710
AI US 2002-299909 A1 20021118 (10) <--
RLI Division of Ser. No. US 2000-649466, filed on 24 Aug 2000, PENDING
PRAI US 1999-150987P 19990827 (60) <--
DT Utility
FS APPLICATION
LREP Richard H. Pagliery, Brobeck, Phleger & Harrison LLP, 12390 El Camino Real, San Diego, CA, 92130-2081
CLMN Number of Claims: 41
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 11834
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to compounds, pharmaceutical compositions, and methods for modulating processes mediated by AR and PR. More particularly, the invention relates to nonsteroidal compounds and compositions that are high affinity, high specificity agonists, partial agonists (i.e., partial activators and/or tissue-specific activators) and antagonists for AR and PR. Also provided are methods of making such compounds and pharmaceutical compositions, as well as critical intermediates used in their synthesis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **328954-75-2P 328954-81-0P 328954-82-1P**
(preparation of quinolinones and related bicyclic compds. as androgen and progesterone receptor modulators)
IT **328954-75-2P**
(preparation of quinolinones and related bicyclic compds. as androgen and progesterone receptor modulators)
RN 328954-75-2 USPATFULL
CN 2H-3,1-Benzoxazine-2-thione, 6-(1-cyclohexen-1-yl)-1,4-dihydro-4,4-dimethyl- (9CI) (CA INDEX NAME)



L125 ANSWER 6 OF 10 USPATFULL on STN
AN 2003:137084 USPATFULL
TI Bicyclic androgen and progesterone receptor modulator compounds and methods
IN Zhi, Lin, San Diego, CA, United States
Tegley, Christopher, San Diego, CA, United States
Pio, Barbara, San Diego, CA, United States
Van Oeveren, Cornelis Arjan, San Diego, CA, United States
Motamedi, Mehrnouch, San Diego, CA, United States
Martinborough, Esther, San Diego, CA, United States
West, Sarah, San Diego, CA, United States
PA Ligand Pharmaceuticals Incorporated, San Diego, CA, United States (U.S. corporation)
PI US 6566372 B1 20030520
AI US 2000-649466 20000824 (9) <--
PRAI US 1999-150987P 19990827 (60) <--
DT Utility
FS GRANTED
EXNAM Primary Examiner: Dentz, Bernard
LREP Paul, Hastings, Janofsky & Walker LLP
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 10630
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to compounds, pharmaceutical compositions, and methods for modulating processes mediated by AR and PR. More particularly, the invention relates to nonsteroidal compounds and compositions that are high affinity, high specificity agonists, partial agonists (i.e., partial activators and/or tissue-specific activators) and antagonists for AR and PR. Also provided are methods of making such compounds and pharmaceutical compositions, as well as critical intermediates used in their synthesis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **328954-75-2P 328954-81-0P 328954-82-1P**
(preparation of quinolinones and related bicyclic compds. as androgen and progesterone receptor modulators)
IT **328954-75-2P**
(preparation of quinolinones and related bicyclic compds. as androgen and progesterone receptor modulators)
RN 328954-75-2 USPATFULL
CN 2H-3,1-Benzoxazine-2-thione, 6-(1-cyclohexen-1-yl)-1,4-dihydro-4,4-dimethyl- (9CI) (CA INDEX NAME)



L125 ANSWER 7 OF 10 USPATFULL on STN
AN 2003:134622 USPATFULL
TI Cyclothiocarbamate derivatives as progesterone receptor modulators
IN Zhang, Puwen, Audubon, PA, UNITED STATES
Fensome, Andrew, Wayne, PA, UNITED STATES
Terefenko, Eugene A., Quakertown, PA, UNITED STATES
Zhi, Lin, San Diego, CA, UNITED STATES
Jones, Todd K., Solana Beach, CA, UNITED STATES
Edwards, James P., San Diego, CA, UNITED STATES
Tegley, Christopher M., Thousand Oaks, CA, UNITED STATES
Wrobel, Jay E., Lawrenceville, NJ, UNITED STATES
Collins, Mark A., Norristown, PA, UNITED STATES
PI US 2003092711 A1 20030515
AI US 2002-140034 A1 20020506 (10) <--
RLI Continuation of Ser. No. US 2000-552354, filed on 19 Apr 2000, GRANTED, Pat. No. US 6436929
PRAI US 1999-183013P 19990504 (60) <--
DT Utility
FS APPLICATION
LREP HOWSON AND HOWSON, ONE SPRING HOUSE CORPORATION CENTER, BOX 457, 321 NORRISTOWN ROAD, SPRING HOUSE, PA, 19477
CLMN Number of Claims: 93
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4051
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods of using compounds which are progesterone receptor agonists for contraception and the treatment of progesterone-related maladies alone or in combination with an estrogen receptor agonist or progesterone receptor antagonist are provided. These compounds have the structure: ##STR1##

wherein R.sub.1 and R.sub.2 are selected from the group of H, optionally substituted C.sub.1 to C.sub.6 alkyl, alkenyl, alkynyl, or alkynyl groups C.sub.3 to C.sub.8 cycloalkyl, aryl, substituted aryl, or heterocyclic groups, or COR.sup.A or NR.sup.BCOR.sup.A; or R.sup.1 and R.sup.2 are fused to form an optionally substituted ring structure as defined herein; R.sup.A and R.sup.B are as defined herein; R.sup.3 is H, OH, NH.sub.2, COR.sup.C, or optionally substituted C.sub.1 to C.sub.6 alkyl, C.sub.3 to C.sub.6 alkenyl, or alkynyl groups; R.sup.C is as defined herein; Q.sup.1 is S, NR.sup.7, or CR.sup.8R.sup.9; R.sup.5 is an optionally trisubstituted benzene ring or an optionally substituted five or six membered heterocyclic ring.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **304853-32-5P 304853-33-6P 304853-35-8P**
304853-37-0P 304853-38-1P 304853-39-2P
304853-40-5P 304853-41-6P 304853-42-7P
304853-43-8P 304853-44-9P 304853-45-0P
304853-46-1P 304853-47-2P 304853-48-3P

304853-49-4P 304853-50-7P 304853-51-8P
304853-52-9P 304853-53-0P 304853-54-1P
304853-55-2P 304853-56-3P 304853-57-4P
304853-58-5P 304853-59-6P 304853-60-9P
304853-61-0P 304853-62-1P 304853-63-2P
304853-64-3P 304853-65-4P 304853-66-5P
304853-67-6P 304853-68-7P 304853-69-8P
304853-70-1P 304853-71-2P 304853-72-3P
304853-73-4P 304853-74-5P 304853-75-6P
304853-76-7P 304853-77-8P 304853-78-9P
304853-79-0P 304853-80-3P 304853-81-4P
304853-82-5P 304853-83-6P 304853-84-7P
304853-85-8P 304853-86-9P 304853-87-0P
304853-88-1P
(preparation of cyclothiocarbamate derivs. as progesterone receptor modulators)

IT **304853-95-0P**
(preparation of cyclothiocarbamate derivs. as progesterone receptor modulators)

IT **304853-32-5P**
(preparation of cyclothiocarbamate derivs. as progesterone receptor modulators)

RN 304853-32-5 USPATFULL

CN 2H-3,1-Benzoxazine-2-thione, 6-(3-chlorophenyl)-1,4-dihydro-4,4-dimethyl- (9CI) (CA INDEX NAME)



L125 ANSWER 8 OF 10 USPATFULL on STN

AN 2003:38174 USPATFULL

TI 2-Oxy-benzoxazinone derivatives for the treatment of obesity

IN Hodson, Harold Francis, Beckenham, UNITED KINGDOM
Downham, Robert, Cambridge, UNITED KINGDOM
Mitchell, Timothy John, Cambridge, UNITED KINGDOM
Carr, Beverley Jane, Royston, UNITED KINGDOM
Dunk, Christopher Robert, Ely, UNITED KINGDOM
Palmer, Richard Michael John, Kent, UNITED KINGDOM

PI US 2003027821 A1 20030206
US 6624161 B2 20030923

AI US 2001-901887 A1 20010706 (9) <--

RLI Continuation of Ser. No. WO 2000-GB32, filed on 6 Jan 2000, UNKNOWN

PRAI GB 1999-413 19990108 <--
GB 1999-17294 19990722 <--

DT Utility

FS APPLICATION

LREP Choate, Hall & Stewart, Exchange Place, 53 State Street, Boston, MA, 02109

CLMN Number of Claims: 53

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1822

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The use of a compound comprising formula (I): ##STR1##

(I)

or a salt, ester, amide or prodrug therof in the inhibition of an enzyme whose preferred mode of action is to catalyse the hydrolysis of an ester functionality, e.g. in the control and inhibition of unwanted enzymes in products and processes. The compounds are also useful in medicine e.g. in the treatment of obesity and related conditions. The invention also relates to novel compounds within formula (I), to processes for preparing them and pharmaceutical compositions containing them.

In formula (I) A is a 6-membered aromatic or heteroaromatic ring; and R.sup.1 is a branched or unbranched alkyl (optionally interrupted by one or more oxygen atoms), alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, arylalkyl, reduced arylalkyl, arylalkenyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, reduced aryl, reduced heteroaryl, reduced heteroarylalkyl or a substituted derivative of any of the foregoing groups.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **282530-42-1P**
(preparation of aminobenzoxazinones for the treatment of obesity)
IT **282530-42-1P**
(preparation of aminobenzoxazinones for the treatment of obesity)
RN 282530-42-1 USPATFULL
CN 4H-3,1-Benzoxazin-4-one, 6-cyclopropyl-2-(phenylamino)- (9CI) (CA INDEX NAME)



L125 ANSWER 9 OF 10 USPATFULL on STN
AN 2002:209520 USPATFULL
TI Cyclothiocarbamate derivatives as progesterone receptor modulators
IN Zhang, Puwen, Audubon, PA, United States
Fensome, Andrew, Wayne, PA, United States
Terefenko, Eugene A., Quakertown, PA, United States
Zhi, Lin, San Diego, CA, United States
Jones, Todd K., Solana Beach, CA, United States
Edwards, James P., San Diego, CA, United States
Tegley, Christopher M., Thousand Oaks, CA, United States
Wrobel, Jay E., Lawrenceville, NJ, United States
Collins, Mark A., Norristown, PA, United States
PA Wyeth, Madison, NJ, United States (U.S. corporation)
Ligand Pharmaceuticals, Inc., San Diego, CA, United States (U.S. corporation)
PI US 6436929 B1 20020820 <--
AI US 2000-552354 20000419 (9) <--
PRAI US 1999-183013P 19990504 (60) <--
DT Utility
FS GRANTED
EXNAM Primary Examiner: Raymond, Richard L.; Assistant Examiner: Truong,

Tamthom N.
LREP Howson and Howson
CLMN Number of Claims: 111
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 3617
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides compounds which are agonists of the progesterone receptor and have the structures: ##STR1##

wherein R.sub.1 and R.sub.2 are independent substituents selected from the group of H, optionally substituted C.sub.1 to C.sub.6 alkyl, alkenyl, alkynyl, or alkynyl groups C.sub.3 to C.sub.8 cycloalkyl, aryl, substituted aryl, or heterocyclic groups, or COR.sup.A or NR.sup.BCOR.sup.A; or R.sup.1 and R.sup.2 are fused to form an optionally substituted 3 to 8 membered Spiro cyclic alkyl or alkenyl ring or a Spiro cyclic ring containing one to three heteroatoms selected from O, S and N; R.sup.A is selected from H, amino, or optionally substituted C.sub.1 to C.sub.3 alkyl, aryl, C.sub.1 to C.sub.3 alkoxy, or C.sub.1 to C.sub.3 aminoalkyl groups; R.sup.B is H, C.sub.1 to C.sub.3 alkyl, or substituted C.sub.1 to C.sub.3 alkyl; R.sup.3 is H, OH, NH.sub.2, COR.sup.C, or optionally substituted C.sub.1 to C.sub.6 alkyl, C.sub.3 to C.sub.6 alkenyl, or alkynyl groups; R.sup.C is selected from H or optionally substituted C.sub.1 to C.sub.3 alkyl, aryl, C.sub.1 to C.sub.3 alkoxy, or C.sub.1 to C.sub.3 aminoalkyl groups; Q.sup.1 is S, NR.sup.7, or CR.sup.8R.sup.9; R.sup.5 is an optionally trisubstituted benzene ring or an optionally substituted five or six membered heterocyclic ring with 1, 2, or 3 ring heteroatoms selected from the group of O, S, SO, SO.sub.2 or NR.sup.6; or a pharmaceutically acceptable salt thereof, as well as methods of using these compounds for contraception and the treatment of progesterone-related maladies.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **304853-32-5P 304853-33-6P 304853-35-8P**
304853-37-0P 304853-38-1P 304853-39-2P
304853-40-5P 304853-41-6P 304853-42-7P
304853-43-8P 304853-44-9P 304853-45-0P
304853-46-1P 304853-47-2P 304853-48-3P
304853-49-4P 304853-50-7P 304853-51-8P
304853-52-9P 304853-53-0P 304853-54-1P
304853-55-2P 304853-56-3P 304853-57-4P
304853-58-5P 304853-59-6P 304853-60-9P
304853-61-0P 304853-62-1P 304853-63-2P
304853-64-3P 304853-65-4P 304853-66-5P
304853-67-6P 304853-68-7P 304853-69-8P
304853-70-1P 304853-71-2P 304853-72-3P
304853-73-4P 304853-74-5P 304853-75-6P
304853-76-7P 304853-77-8P 304853-78-9P
304853-79-0P 304853-80-3P 304853-81-4P
304853-82-5P 304853-83-6P 304853-84-7P
304853-85-8P 304853-86-9P 304853-87-0P
304853-88-1P
(preparation of cyclothiocarbamate derivs. as progesterone receptor modulators)
IT **304853-95-0P**
(preparation of cyclothiocarbamate derivs. as progesterone receptor modulators)
IT **304853-32-5P**
(preparation of cyclothiocarbamate derivs. as progesterone receptor

modulators)
RN 304853-32-5 USPATFULL
CN 2H-3,1-Benzoxazine-2-thione, 6-(3-chlorophenyl)-1,4-dihydro-4,4-dimethyl- (9CI) (CA INDEX NAME)



L125 ANSWER 10 OF 10 USPATFULL on STN
AN 92:103164 USPATFULL
TI Imidazole substituted benzoxazine or benzothiazine derivatives
IN Kim, Moohi Y., Seoul, Korea, Republic of
Shin, Hyun T., Seoul, Korea, Republic of
Lee, Choon W., Seoul, Korea, Republic of
Kim, Joon W., Kyungki, Korea, Republic of
Kim, Soon H., Kyungki, Korea, Republic of
Choi, Youngmoon, Seoul, Korea, Republic of
Son, Moon H., Kyungki, Korea, Republic of
PA Dong-A Pharm. Co., Ltd., Seoul, Korea, Republic of (non-U.S. corporation)
PI US 5171851 19921215 <--
AI US 1991-674183 19910325 (7) <--
PRAI KR 1990-3989 19900324 <--
DT Utility
FS Granted
EXNAM Primary Examiner: Shah, Mukund J.; Assistant Examiner: Dalton, Philip I.
LREP Birch, Stewart, Kolasch & Birch
CLMN Number of Claims: 26
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 813
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A benzoxazine or benzothiazine derivative of the formula (A), ##STR1## wherein R.sub.1, R.sub.2 and R.sub.3 are the same or different and represent a hydrogen atom or a C.sub.1-4 alkyl group; or R.sub.1 and R.sub.2 can be joined together along with the imidazole ring to form a benzimidazole; X and Y are the same or different and represent an oxygen or sulfur atom; or a pharmaceutically acceptable salt thereof, exhibits an excellent inotropic effect and can be used as a cardiac stimulant.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **145622-92-0P**
(preparation of, as pos. inotropic)
IT **145622-92-0P**
(preparation of, as pos. inotropic)
RN 145622-92-0 USPATFULL
CN 2H-3,1-Benzoxazine-2-thione, 1,4-dihydro-8-methyl-6-(4-methyl-1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)



```
=> fil reg
FILE 'REGISTRY' ENTERED AT 07:57:47 ON 05 JUL 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:     4 JUL 2005  HIGHEST RN 853727-85-2
DICTIONARY FILE UPDATES:    4 JUL 2005  HIGHEST RN 853727-85-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

**********************************************************************
*                                                                    *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,    *
* effective March 20, 2005.  A new display format, IDERL, is now     *
* available and contains the CA role and document type information.  *
*                                                                    *
**********************************************************************

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

 => s l23 not l115
L127        76 L23 NOT L115

=> d ide can tot

L127 ANSWER 1 OF 76  REGISTRY  COPYRIGHT 2005 ACS on STN
RN   639085-00-0  REGISTRY
ED   Entered STN:  19 Jan 2004
CN   1,3-Benzenedicarbonitrile, 5-(1,4-dihydro-1-mercapto-4,4-dimethyl-2-thioxo-
     2H-3,1-benzoxazin-6-yl)- (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   5-(4,4-Dimethyl-1,2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-
     yl)isophthalonitrile
```

FS 3D CONCORD
MF C18 H13 N3 O S2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:71530

L127 ANSWER 2 OF 76 REGISTRY COPYRIGHT 2005 ACS on STN
RN 638989-48-7 REGISTRY
ED Entered STN: 19 Jan 2004
CN 1H-Pyrrole-2-carbonitrile, 5-[1,4-dihydro-2-thioxo-4,4-bis(trifluoromethyl)-2H-3,1-benzoxazin-6-yl]-1-methyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 1-Methyl-5-[2-thioxo-4,4-bis(trifluoromethyl)-1,4-dihydro-2H-3,1-benzoxazin-6-yl]-1H-pyrrole-2-carbonitrile
FS 3D CONCORD
MF C16 H9 F6 N3 O S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:71530

REFERENCE 2: 140:53469

L127 ANSWER 3 OF 76 REGISTRY COPYRIGHT 2005 ACS on STN
RN 638989-46-5 REGISTRY

ED Entered STN: 19 Jan 2004
CN 1H-Pyrrole-2-carbonitrile, 5-(1,2-dihydro-2-thioxospiro[4H-3,1-benzoxazine-4,1'-cyclopentan]-6-yl)-1-methyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 1-Methyl-5-[2-thioxo-1,2-dihydrospiro[3,1-benzoxazine-4,1'-cyclopentan]-6-yl]-1H-pyrrole-2-carbonitrile
FS 3D CONCORD
MF C18 H17 N3 O S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:71530

REFERENCE 2: 140:53469

L127 ANSWER 4 OF 76 REGISTRY COPYRIGHT 2005 ACS on STN
RN 638989-44-3 REGISTRY
ED Entered STN: 19 Jan 2004
CN 1H-Pyrrole-2-carbonitrile, 5-(1,2-dihydro-2-thioxospiro[4H-3,1-benzoxazine-4,1'-cyclohexan]-6-yl)-1-methyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 1-Methyl-5-[2-thioxo-1,2-dihydrospiro[3,1-benzoxazine-4,1'-cyclohexan]-6-yl]-1H-pyrrole-2-carbonitrile
FS 3D CONCORD
MF C19 H19 N3 O S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:71530

REFERENCE 2: 140:53469

L127 ANSWER 5 OF 76 REGISTRY COPYRIGHT 2005 ACS on STN
RN 638989-41-0 REGISTRY
ED Entered STN: 19 Jan 2004
CN 1H-Pyrrole-2-carbonitrile, 5-(4-ethyl-1,4-dihydro-4-methyl-2-thioxo-2H-3,1-benzoxazin-6-yl)-1-methyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 5-(4-Ethyl-4-methyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1-methyl-1H-pyrrole-2-carbonitrile
FS 3D CONCORD
MF C17 H17 N3 O S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:71530

REFERENCE 2: 140:53469

L127 ANSWER 6 OF 76 REGISTRY COPYRIGHT 2005 ACS on STN
RN 638989-38-5 REGISTRY
ED Entered STN: 19 Jan 2004
CN 1H-Pyrrole-2-carbonitrile, 5-(4,4-diethyl-1,4-dihydro-2-thioxo-2H-3,1-benzoxazin-6-yl)-1-methyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 5-(4,4-Diethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1-methyl-1H-pyrrole-2-carbonitrile
FS 3D CONCORD
MF C18 H19 N3 O S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:71530

REFERENCE 2: 140:53469

L127 ANSWER 7 OF 76 REGISTRY COPYRIGHT 2005 ACS on STN
RN 638989-33-0 REGISTRY
ED Entered STN: 19 Jan 2004
CN 1H-Pyrrole-2-carbonitrile, 5-(1,2-dihydro-2-thioxospiro[4H-3,1-benzoxazine-4,1'-cyclobutan]-6-yl)-1-methyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 1-Methyl-5-[2-thioxo-1,2-dihydrospiro[3,1-benzoxazine-4,1'-cyclobutan]-6-yl]-1H-pyrrole-2-carbonitrile
FS 3D CONCORD
MF C17 H15 N3 O S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:71530

REFERENCE 2: 140:53469

L127 ANSWER 8 OF 76 REGISTRY COPYRIGHT 2005 ACS on STN
RN 560992-05-4 REGISTRY
ED Entered STN: 05 Aug 2003
CN Benzonitrile, 4-(8-bromo-1,4-dihydro-4,4-dimethyl-2-thioxo-2H-3,1-benzoxazin-6-yl)-2-fluoro- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C17 H12 Br F N2 O S
SR CA
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 139:111065

L127 ANSWER 9 OF 76 REGISTRY COPYRIGHT 2005 ACS on STN
RN 560992-04-3 REGISTRY
ED Entered STN: 05 Aug 2003
CN 2H-3,1-Benzoxazine-2-thione, 8-bromo-6-(4-chloro-3-fluorophenyl)-1,4-dihydro-4,4-dimethyl- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C16 H12 Br Cl F N O S
SR CA
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 139:111065

L127 ANSWER 10 OF 76 REGISTRY COPYRIGHT 2005 ACS on STN
RN 560992-03-2 REGISTRY
ED Entered STN: 05 Aug 2003
CN Benzonitrile, 3-(1-ethyl-1,4-dihydro-4,4-dimethyl-2-thioxo-2H-3,1-benzoxazin-6-yl)-5-fluoro- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C19 H17 F N2 O S
SR CA
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 139:111065

L127 ANSWER 11 OF 76 REGISTRY COPYRIGHT 2005 ACS on STN
RN 560992-02-1 REGISTRY
ED Entered STN: 05 Aug 2003
CN 2H-3,1-Benzoxazine-2-thione, 6-(3-bromo-5-fluorophenyl)-1,4-dihydro-1,4,4-trimethyl- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C17 H15 Br F N O S
SR CA
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 139:111065

L127 ANSWER 12 OF 76 REGISTRY COPYRIGHT 2005 ACS on STN
RN 560992-01-0 REGISTRY
ED Entered STN: 05 Aug 2003
CN 2H-3,1-Benzoxazine-2-thione, 6-(3-bromophenyl)-1,4-dihydro-1,4,4-trimethyl- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C17 H16 Br N O S
SR CA
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 139:111065

L127 ANSWER 13 OF 76 REGISTRY COPYRIGHT 2005 ACS on STN
RN 560992-00-9 REGISTRY
ED Entered STN: 05 Aug 2003
CN 2H-3,1-Benzoxazine-2-thione, 6-(3-chlorophenyl)-1,4-dihydro-4,4-bis(phenylmethyl)- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C28 H22 Cl N O S
SR CA
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 139:111065

L127 ANSWER 14 OF 76 REGISTRY COPYRIGHT 2005 ACS on STN
RN 560991-99-3 REGISTRY
ED Entered STN: 05 Aug 2003
CN Benzonitrile, 3-(1,4-dihydro-4,4-dimethyl-2-thioxo-2H-3,1-benzoxazin-6-yl)-5-(trifluoromethoxy)- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C18 H13 F3 N2 O2 S
SR CA
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 139:111065

L127 ANSWER 15 OF 76 REGISTRY COPYRIGHT 2005 ACS on STN
RN 560991-98-2 REGISTRY
ED Entered STN: 05 Aug 2003
CN Benzonitrile, 3-bromo-5-(1,4-dihydro-4,4-dimethyl-2-thioxo-2H-3,1-benzoxazin-6-yl)- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C17 H13 Br N2 O S
SR CA
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 139:111065

L127 ANSWER 16 OF 76 REGISTRY COPYRIGHT 2005 ACS on STN
RN 328954-82-1 REGISTRY
ED Entered STN: 26 Mar 2001
CN 2H-3,1-Benzoxazine-2-thione, 1,4-dihydro-6-(3-hydroxy-1-cyclohexen-1-yl)-4,4-dimethyl- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C16 H19 N O2 S
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:207727

L127 ANSWER 17 OF 76 REGISTRY COPYRIGHT 2005 ACS on STN
RN 328954-81-0 REGISTRY
ED Entered STN: 26 Mar 2001
CN 2-Cyclohexen-1-one, 3-(1,4-dihydro-4,4-dimethyl-2-thioxo-2H-3,1-benzoxazin-6-yl)- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C16 H17 N O2 S
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:207727

L127 ANSWER 18 OF 76 REGISTRY COPYRIGHT 2005 ACS on STN
RN 328954-75-2 REGISTRY
ED Entered STN: 26 Mar 2001
CN 2H-3,1-Benzoxazine-2-thione, 6-(1-cyclohexen-1-yl)-1,4-dihydro-4,4-dimethyl- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C16 H19 N O S
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:207727

L127 ANSWER 19 OF 76 REGISTRY COPYRIGHT 2005 ACS on STN
RN 304853-95-0 REGISTRY
ED Entered STN: 29 Nov 2000
CN 1H-Pyrrole-1-carboxylic acid, 2-cyano-5-(1,4-dihydro-4,4-dimethyl-2-thioxo-2H-3,1-benzoxazin-6-yl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 2-Cyano-5-(4,4-dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1H-pyrrole-1-carboxylic acid tert-Butyl ester
FS 3D CONCORD
MF C20 H21 N3 O3 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:71530

REFERENCE 2: 140:53469

REFERENCE 3: 133:350228

L127 ANSWER 20 OF 76 REGISTRY COPYRIGHT 2005 ACS on STN
RN 304853-88-1 REGISTRY
ED Entered STN: 29 Nov 2000
CN 3-Thiophenecarbonitrile, 2-(1,4-dihydro-4,4-dimethyl-2-thioxo-2H-3,1-benzoxazin-6-yl)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 2-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)thiophene-3-

carbonitrile
FS 3D CONCORD
MF C15 H12 N2 O S2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:71530

REFERENCE 2: 140:53469

REFERENCE 3: 133:350228

L127 ANSWER 21 OF 76 REGISTRY COPYRIGHT 2005 ACS on STN
RN 304853-87-0 REGISTRY
ED Entered STN: 29 Nov 2000
CN 2H-3,1-Benzoxazine-2-thione, 6-(3-bromophenyl)-1,4-dihydro-4,4-dimethyl-(9CI) (CA INDEX NAME)
OTHER NAMES:
CN 6-(3-Bromophenyl)-4,4-dimethyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione
FS 3D CONCORD
MF C16 H14 Br N O S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:71530

REFERENCE 2: 140:53469

REFERENCE 3: 139:111065

REFERENCE 4: 133:350228

L127 ANSWER 22 OF 76 REGISTRY COPYRIGHT 2005 ACS on STN
RN 304853-86-9 REGISTRY
ED Entered STN: 29 Nov 2000
CN 2-Thiophenecarbonitrile, 4-butyl-5-(1,4-dihydro-4,4-dimethyl-2-thioxo-2H-3,1-benzoxazin-6-yl)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 4-Butyl-5-(4,4-dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)thiophene-2-carbonitrile
FS 3D CONCORD
MF C19 H20 N2 O S2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:71530

REFERENCE 2: 140:53469

REFERENCE 3: 133:350228

L127 ANSWER 23 OF 76 REGISTRY COPYRIGHT 2005 ACS on STN
RN 304853-85-8 REGISTRY
ED Entered STN: 29 Nov 2000
CN 2-Furancarbonitrile, 4-(1,4-dihydro-4,4-dimethyl-2-thioxo-2H-3,1-benzoxazin-6-yl)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 4-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-2-furonitrile
FS 3D CONCORD
MF C15 H12 N2 O2 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:71530

REFERENCE 2: 140:53469

REFERENCE 3: 139:111065

REFERENCE 4: 133:350228

L127 ANSWER 24 OF 76 REGISTRY COPYRIGHT 2005 ACS on STN
RN 304853-84-7 REGISTRY
ED Entered STN: 29 Nov 2000
CN 2-Thiophenecarbonitrile, 5-(1,4-dihydro-4,4-dimethyl-2-thioxo-2H-3,1-benzoxazin-6-yl)-4-propyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 5-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-4-propylthiophene-2-carbonitrile
FS 3D CONCORD
MF C18 H18 N2 O S2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:71530

REFERENCE 2: 140:53469

REFERENCE 3: 133:350228

L127 ANSWER 25 OF 76 REGISTRY COPYRIGHT 2005 ACS on STN
RN 304853-83-6 REGISTRY
ED Entered STN: 29 Nov 2000
CN 2H-3,1-Benzoxazine-2-thione, 6-(3-chloro-4-fluorophenyl)-1,4-dihydro-4,4-dimethyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 6-(3-Chloro-4-fluorophenyl)-4,4-dimethyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione
FS 3D CONCORD
MF C16 H13 Cl F N O S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:71530

REFERENCE 2: 140:53469

REFERENCE 3: 139:111065

REFERENCE 4: 133:350228

L127 ANSWER 26 OF 76 REGISTRY COPYRIGHT 2005 ACS on STN
RN 304853-82-5 REGISTRY
ED Entered STN: 29 Nov 2000
CN 2-Thiophenecarbonitrile, 5-(1,2-dihydro-2-thioxospiro[4H-3,1-benzoxazine-4,1'-cyclohexan]-6-yl)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 5-[1,2-Dihydro-2-thioxospiro[4H-3,1-benzoxazine-4,1'-cyclohexan]-6-yl]-2-thiophenecarbonitrile
FS 3D CONCORD
MF C18 H16 N2 O S2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:71530

REFERENCE 2: 140:53469

REFERENCE 3: 133:350228

L127 ANSWER 27 OF 76 REGISTRY COPYRIGHT 2005 ACS on STN
RN 304853-81-4 REGISTRY
ED Entered STN: 29 Nov 2000
CN 2-Thiophenecarbonitrile, 5-(1,2-dihydro-2-thioxospiro[4H-3,1-benzoxazine-4,1'-cyclohexan]-6-yl)-4-methyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 5-[1,2-Dihydro-2-thioxospiro[4H-3,1-benzoxazine-4,1'-cyclohexan]-6-yl]-4-methyl-2-thiophenecarbonitrile
FS 3D CONCORD
MF C19 H18 N2 O S2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:71530

REFERENCE 2: 140:53469

REFERENCE 3: 133:350228

L127 ANSWER 28 OF 76 REGISTRY COPYRIGHT 2005 ACS on STN
RN 304853-80-3 REGISTRY
ED Entered STN: 29 Nov 2000
CN Benzonitrile, 3-(1,2-dihydro-2-thioxospiro[4H-3,1-benzoxazine-4,1'-cyclohexan]-6-yl)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 3-[1,2-Dihydro-2-thioxospiro[4H-3,1-benzoxazine-4,1'-cyclohexan]-6-yl]benzonitrile
FS 3D CONCORD
MF C20 H18 N2 O S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:71530

REFERENCE 2: 140:53469

REFERENCE 3: 139:111065

REFERENCE 4: 133:350228

L127 ANSWER 29 OF 76 REGISTRY COPYRIGHT 2005 ACS on STN
RN 304853-79-0 REGISTRY
ED Entered STN: 29 Nov 2000
CN Benzonitrile, 3-fluoro-5-(8-fluoro-1,4-dihydro-4,4-dimethyl-2-thioxo-2H-3,1-benzoxazin-6-yl)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 3-Fluoro-5-(8-fluoro-4,4-dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)benzonitrile
FS 3D CONCORD
MF C17 H12 F2 N2 O S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:71530

REFERENCE 2: 140:53469

REFERENCE 3: 139:111065

REFERENCE 4: 133:350228

L127 ANSWER 30 OF 76 REGISTRY COPYRIGHT 2005 ACS on STN
RN 304853-78-9 REGISTRY
ED Entered STN: 29 Nov 2000
CN 2-Thiophenecarbonitrile, 5-(1,4-dihydro-4,4-dimethyl-2-thioxo-2H-3,1-benzoxazin-6-yl)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 5-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)thiophene-2-carbonitrile

FS 3D CONCORD
MF C15 H12 N2 O S2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:71530

REFERENCE 2: 140:53469

REFERENCE 3: 139:111065

REFERENCE 4: 133:350228

L127 ANSWER 31 OF 76 REGISTRY COPYRIGHT 2005 ACS on STN
RN 304853-77-8 REGISTRY
ED Entered STN: 29 Nov 2000
CN 2H-3,1-Benzoxazine-2-thione, 6-(3-bromo-5-fluorophenyl)-1,4-dihydro-4,4-dimethyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 6-(3-Bromo-5-fluorophenyl)-4,4-dimethyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione
FS 3D CONCORD
MF C16 H13 Br F N O S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:71530

REFERENCE 2: 140:53469

REFERENCE 3: 139:111065

REFERENCE 4: 133:350228

L127 ANSWER 32 OF 76 REGISTRY COPYRIGHT 2005 ACS on STN
RN 304853-76-7 REGISTRY
ED Entered STN: 29 Nov 2000
CN 2H-3,1-Benzoxazine-2-thione, 6-(3-chlorophenyl)-1,4-dihydro-4-methyl-4-(phenylmethyl)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 4-Benzyl-6-(3-chlorophenyl)-4-methyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione
FS 3D CONCORD
MF C22 H18 Cl N O S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:71530

REFERENCE 2: 140:53469

REFERENCE 3: 139:111065

REFERENCE 4: 133:350228

L127 ANSWER 33 OF 76 REGISTRY COPYRIGHT 2005 ACS on STN
RN 304853-75-6 REGISTRY
ED Entered STN: 29 Nov 2000
CN 2H-3,1-Benzoxazine-2-thione, 6-(2-chlorophenyl)-1,4-dihydro-4,4-dimethyl-(9CI) (CA INDEX NAME)
OTHER NAMES:
CN 6-(2-Chlorophenyl)-4,4-dimethyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione
FS 3D CONCORD
MF C16 H14 Cl N O S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:71530

REFERENCE 2: 140:53469

REFERENCE 3: 139:111065

REFERENCE 4: 133:350228

L127 ANSWER 34 OF 76 REGISTRY COPYRIGHT 2005 ACS on STN
RN 304853-74-5 REGISTRY
ED Entered STN: 29 Nov 2000
CN 2H-3,1-Benzoxazine-2-thione, 1,4-dihydro-6-(3-methoxyphenyl)-4,4-dimethyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 6-(3-Methoxyphenyl)-4,4-dimethyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione
FS 3D CONCORD
MF C17 H17 N O2 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:71530

REFERENCE 2: 140:53469

REFERENCE 3: 139:111065

REFERENCE 4: 133:350228

L127 ANSWER 35 OF 76 REGISTRY COPYRIGHT 2005 ACS on STN

RN 304853-73-4 REGISTRY
ED Entered STN: 29 Nov 2000
CN 2H-3,1-Benzoxazine-2-thione, 6-(3-chlorophenyl)-4,4-diethyl-1,4-dihydro-(9CI) (CA INDEX NAME)
OTHER NAMES:
CN 6-(3-Chlorophenyl)-4,4-diethyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione
FS 3D CONCORD
MF C18 H18 Cl N O S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:71530

REFERENCE 2: 140:53469

REFERENCE 3: 139:111065

REFERENCE 4: 133:350228

L127 ANSWER 36 OF 76 REGISTRY COPYRIGHT 2005 ACS on STN
RN 304853-72-3 REGISTRY
ED Entered STN: 29 Nov 2000
CN 2H-3,1-Benzoxazine-2-thione, 1,4-dihydro-4,4-dimethyl-6-(3-nitrophenyl)-(9CI) (CA INDEX NAME)
OTHER NAMES:
CN 4,4-Dimethyl-6-(3-nitrophenyl)-1,4-dihydro-2H-3,1-benzoxazine-2-thione
FS 3D CONCORD
MF C16 H14 N2 O3 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:71530

REFERENCE 2: 140:53469

REFERENCE 3: 139:111065

REFERENCE 4: 133:350228

L127 ANSWER 37 OF 76 REGISTRY COPYRIGHT 2005 ACS on STN
RN 304853-71-2 REGISTRY
ED Entered STN: 29 Nov 2000
CN Benzonitrile, 3-(8-bromo-1,4-dihydro-4,4-dimethyl-2-thioxo-2H-3,1-benzoxazin-6-yl)-5-fluoro- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 3-(8-Bromo-4,4-dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-5-fluorobenzonitrile
FS 3D CONCORD
MF C17 H12 Br F N2 O S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:71530

REFERENCE 2: 140:53469

REFERENCE 3: 139:111065

REFERENCE 4: 133:350228

L127 ANSWER 38 OF 76 REGISTRY COPYRIGHT 2005 ACS on STN
RN 304853-70-1 REGISTRY
ED Entered STN: 29 Nov 2000
CN 2H-3,1-Benzoxazine-2-thione, 6-(2,3-difluorophenyl)-1,4-dihydro-4,4-dimethyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 6-(2,3-Difluorophenyl)-4,4-dimethyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione
FS 3D CONCORD
MF C16 H13 F2 N O S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:71530

REFERENCE 2: 140:53469

REFERENCE 3: 139:111065

REFERENCE 4: 133:350228

L127 ANSWER 39 OF 76 REGISTRY COPYRIGHT 2005 ACS on STN
RN 304853-69-8 REGISTRY
ED Entered STN: 29 Nov 2000
CN Benzonitrile, 3-(1,4-dihydro-4,4-dimethyl-2-thioxo-2H-3,1-benzoxazin-6-yl)-4-fluoro- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 3-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-4-fluorobenzonitrile
FS 3D CONCORD
MF C17 H13 F N2 O S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:71530

REFERENCE 2: 140:53469

REFERENCE 3: 133:350228

L127 ANSWER 40 OF 76 REGISTRY COPYRIGHT 2005 ACS on STN
RN 304853-68-7 REGISTRY

ED Entered STN: 29 Nov 2000
CN 2H-3,1-Benzoxazine-2-thione, 6-(4-fluorophenyl)-1,4-dihydro-4,4-dimethyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 6-(4-Fluorophenyl)-4,4-dimethyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione
FS 3D CONCORD
MF C16 H14 F N O S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:71530

REFERENCE 2: 140:53469

REFERENCE 3: 133:350228

L127 ANSWER 41 OF 76 REGISTRY COPYRIGHT 2005 ACS on STN
RN 304853-67-6 REGISTRY
ED Entered STN: 29 Nov 2000
CN 2H-3,1-Benzoxazine-2-thione, 6-(3,4-difluorophenyl)-1,4-dihydro-4,4-dimethyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 6-(3,4-Difluorophenyl)-4,4-dimethyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione
FS 3D CONCORD
MF C16 H13 F2 N O S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:71530

REFERENCE 2: 140:53469

REFERENCE 3: 139:111065

REFERENCE 4: 133:350228

L127 ANSWER 42 OF 76 REGISTRY COPYRIGHT 2005 ACS on STN
RN 304853-66-5 REGISTRY
ED Entered STN: 29 Nov 2000
CN 2H-3,1-Benzoxazine-2-thione, 6-(2-fluorophenyl)-1,4-dihydro-4,4-dimethyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 6-(2-Fluorophenyl)-4,4-dimethyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione
FS 3D CONCORD
MF C16 H14 F N O S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:71530

REFERENCE 2: 140:53469

REFERENCE 3: 139:111065

REFERENCE 4: 133:350228

L127 ANSWER 43 OF 76 REGISTRY COPYRIGHT 2005 ACS on STN
RN 304853-65-4 REGISTRY
ED Entered STN: 29 Nov 2000
CN 2H-3,1-Benzoxazine-2-thione, 6-[3-fluoro-5-(trifluoromethyl)phenyl]-1,4-dihydro-4,4-dimethyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 6-[3-Fluoro-5-(trifluoromethyl)phenyl]-4,4-dimethyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione
FS 3D CONCORD
MF C17 H13 F4 N O S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:71530

REFERENCE 2: 139:111065

REFERENCE 3: 133:350228

L127 ANSWER 44 OF 76 REGISTRY COPYRIGHT 2005 ACS on STN
RN 304853-64-3 REGISTRY
ED Entered STN: 29 Nov 2000
CN 2H-3,1-Benzoxazine-2-thione, 6-(3-fluorophenyl)-1,4-dihydro-4,4-dimethyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 6-(3-Fluorophenyl)-4,4-dimethyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione
FS 3D CONCORD
MF C16 H14 F N O S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:71530

REFERENCE 2: 140:53469

REFERENCE 3: 139:111065

REFERENCE 4: 133:350228

L127 ANSWER 45 OF 76 REGISTRY COPYRIGHT 2005 ACS on STN
RN 304853-63-2 REGISTRY
ED Entered STN: 29 Nov 2000

CN Benzonitrile, 3-(1,4-dihydro-4,4-dimethyl-2-thioxo-2H-3,1-benzoxazin-6-yl)-5-methoxy- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 3-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-5-methoxybenzonitrile
FS 3D CONCORD
MF C18 H16 N2 O2 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:71530

REFERENCE 2: 140:53469

REFERENCE 3: 139:111065

REFERENCE 4: 133:350228

L127 ANSWER 46 OF 76 REGISTRY COPYRIGHT 2005 ACS on STN
RN 304853-62-1 REGISTRY
ED Entered STN: 29 Nov 2000
CN 2H-3,1-Benzoxazine-2-thione, 6-(3-fluoro-5-methoxyphenyl)-1,4-dihydro-4,4-dimethyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 6-(3-Fluoro-5-methoxyphenyl)-4,4-dimethyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione
FS 3D CONCORD
MF C17 H16 F N O2 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:71530

REFERENCE 2: 140:53469

REFERENCE 3: 139:111065

REFERENCE 4: 133:350228

L127 ANSWER 47 OF 76 REGISTRY COPYRIGHT 2005 ACS on STN
RN 304853-61-0 REGISTRY
ED Entered STN: 29 Nov 2000
CN 2H-3,1-Benzoxazine-2-thione, 6-(3,5-difluorophenyl)-1,4-dihydro-4,4-dimethyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 6-(3,5-Difluorophenyl)-4,4-dimethyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione
FS 3D CONCORD
MF C16 H13 F2 N O S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:71530

REFERENCE 2: 140:53469

REFERENCE 3: 139:111065

REFERENCE 4: 133:350228

L127 ANSWER 48 OF 76 REGISTRY COPYRIGHT 2005 ACS on STN
RN 304853-60-9 REGISTRY
ED Entered STN: 29 Nov 2000
CN Benzonitrile, 3-chloro-5-(1,4-dihydro-4,4-dimethyl-2-thioxo-2H-3,1-benzoxazin-6-yl)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 3-Chloro-5-(4,4-dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)benzonitrile
FS 3D CONCORD
MF C17 H13 Cl N2 O S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:71530

REFERENCE 2: 140:53469

REFERENCE 3: 139:111065

REFERENCE 4: 133:350228

L127 ANSWER 49 OF 76 REGISTRY COPYRIGHT 2005 ACS on STN
RN 304853-59-6 REGISTRY
ED Entered STN: 29 Nov 2000
CN 2H-3,1-Benzoxazine-2-thione, 6-(3-chlorophenyl)-1,4-dihydro-4-methyl-4-(2-propenyl)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 4-Allyl-6-(3-chlorophenyl)-4-methyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione
FS 3D CONCORD
MF C18 H16 Cl N O S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:71530

REFERENCE 2: 140:53469

REFERENCE 3: 139:111065

REFERENCE 4: 133:350228

L127 ANSWER 50 OF 76 REGISTRY COPYRIGHT 2005 ACS on STN
RN 304853-58-5 REGISTRY
ED Entered STN: 29 Nov 2000
CN 2H-3,1-Benzoxazine-2-thione, 6-(3-chlorophenyl)-1,4-dihydro-4-methyl-4-phenyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 6-(3-Chlorophenyl)-4-methyl-4-phenyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione
FS 3D CONCORD
MF C21 H16 Cl N O S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:71530

REFERENCE 2: 140:53469

REFERENCE 3: 139:111065

REFERENCE 4: 133:350228

L127 ANSWER 51 OF 76 REGISTRY COPYRIGHT 2005 ACS on STN
RN 304853-57-4 REGISTRY
ED Entered STN: 29 Nov 2000
CN 2H-3,1-Benzoxazine-2-thione, 4,4-diethyl-1,4-dihydro-6-(3-nitrophenyl)-(9CI) (CA INDEX NAME)
OTHER NAMES:
CN 4,4-Diethyl-6-(3-nitrophenyl)-1,4-dihydro-2H-3,1-benzoxazine-2-thione
FS 3D CONCORD
MF C18 H18 N2 O3 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:71530

REFERENCE 2: 140:53469

REFERENCE 3: 139:111065

REFERENCE 4: 133:350228

L127 ANSWER 52 OF 76 REGISTRY COPYRIGHT 2005 ACS on STN
RN 304853-56-3 REGISTRY
ED Entered STN: 29 Nov 2000
CN 2-Furancarbonitrile, 5-(1,4-dihydro-4,4-dimethyl-2-thioxo-2H-3,1-benzoxazin-6-yl)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 5-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-2-furonitrile
FS 3D CONCORD
MF C15 H12 N2 O2 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:71530

REFERENCE 2: 140:53469

REFERENCE 3: 139:111065

REFERENCE 4: 133:350228

L127 ANSWER 53 OF 76 REGISTRY COPYRIGHT 2005 ACS on STN
RN 304853-55-2 REGISTRY
ED Entered STN: 29 Nov 2000
CN 1,3-Benzenedicarbonitrile, 5-(1,4-dihydro-4,4-dimethyl-2-thioxo-2H-3,1-benzoxazin-6-yl)- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C18 H13 N3 O S
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:53469

REFERENCE 2: 139:111065

REFERENCE 3: 133:350228

L127 ANSWER 54 OF 76 REGISTRY COPYRIGHT 2005 ACS on STN
RN 304853-54-1 REGISTRY
ED Entered STN: 29 Nov 2000
CN 2H-3,1-Benzoxazine-2-thione, 6-(3,5-dichlorophenyl)-1,4-dihydro-4,4-dimethyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 6-(3,5-Dichlorophenyl)-4,4-dimethyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione
FS 3D CONCORD
MF C16 H13 Cl2 N O S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:71530

REFERENCE 2: 140:53469

REFERENCE 3: 139:111065

REFERENCE 4: 133:350228

L127 ANSWER 55 OF 76 REGISTRY COPYRIGHT 2005 ACS on STN
RN 304853-53-0 REGISTRY

ED Entered STN: 29 Nov 2000
CN Benzonitrile, 3-(1,4-dihydro-4,4-dimethyl-2-thioxo-2H-3,1-benzoxazin-6-yl)-5-methyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 3-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-5-methylbenzonitrile
FS 3D CONCORD
MF C18 H16 N2 O S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:71530

REFERENCE 2: 140:53469

REFERENCE 3: 139:111065

REFERENCE 4: 133:350228

L127 ANSWER 56 OF 76 REGISTRY COPYRIGHT 2005 ACS on STN
RN 304853-52-9 REGISTRY
ED Entered STN: 29 Nov 2000
CN Benzonitrile, 3-(1,2-dihydro-2-thioxospiro[4H-3,1-benzoxazine-4,1'-cyclohexan]-6-yl)-5-fluoro- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 3-[1,2-Dihydro-2-thioxospiro[4H-3,1-benzoxazine-4,1'-cyclohexan]-6-yl]-5-fluorobenzonitrile
FS 3D CONCORD
MF C20 H17 F N2 O S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:71530

REFERENCE 2: 140:53469

REFERENCE 3: 133:350228

L127 ANSWER 57 OF 76 REGISTRY COPYRIGHT 2005 ACS on STN
RN 304853-51-8 REGISTRY
ED Entered STN: 29 Nov 2000
CN 2H-3,1-Benzoxazine-2-thione, 6-[3-bromo-5-(trifluoromethoxy)phenyl]-1,4-dihydro-4,4-dimethyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 6-(3-Bromo-5-trifluoromethoxyphenyl)-4,4-dimethyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione
FS 3D CONCORD
MF C17 H13 Br F3 N O2 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:71530

REFERENCE 2: 140:53469

REFERENCE 3: 139:111065

REFERENCE 4: 133:350228

L127 ANSWER 58 OF 76 REGISTRY COPYRIGHT 2005 ACS on STN
RN 304853-50-7 REGISTRY
ED Entered STN: 29 Nov 2000
CN 2H-3,1-Benzoxazine-2-thione, 6-(3-bromo-5-methylphenyl)-1,4-dihydro-4,4-dimethyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 6-(3-Bromo-5-methylphenyl)-4,4-dimethyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione
FS 3D CONCORD
MF C17 H16 Br N O S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:71530

REFERENCE 2: 140:53469

REFERENCE 3: 139:111065

REFERENCE 4: 133:350228

L127 ANSWER 59 OF 76 REGISTRY COPYRIGHT 2005 ACS on STN
RN 304853-49-4 REGISTRY
ED Entered STN: 29 Nov 2000
CN 2H-3,1-Benzoxazine-2-thione, 6-(3-chloro-5-fluorophenyl)-1,4-dihydro-4,4-dimethyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 6-(3-Chloro-5-fluorophenyl)-4,4-dimethyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione
FS 3D CONCORD
MF C16 H13 Cl F N O S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:71530

REFERENCE 2: 140:53469

REFERENCE 3: 139:111065

REFERENCE 4: 133:350228

L127 ANSWER 60 OF 76 REGISTRY COPYRIGHT 2005 ACS on STN
RN 304853-48-3 REGISTRY
ED Entered STN: 29 Nov 2000
CN 2H-3,1-Benzoxazine-2-thione, 6-(5-bromo-3-pyridinyl)-1,4-dihydro-4,4-dimethyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 6-(5-Bromopyridin-3-yl)-4,4-dimethyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione
FS 3D CONCORD
MF C15 H13 Br N2 O S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:71530

REFERENCE 2: 140:53469

REFERENCE 3: 139:111065

REFERENCE 4: 133:350228

L127 ANSWER 61 OF 76 REGISTRY COPYRIGHT 2005 ACS on STN
RN 304853-47-2 REGISTRY
ED Entered STN: 29 Nov 2000
CN Benzonitrile, 5-(1,4-dihydro-4,4-dimethyl-2-thioxo-2H-3,1-benzoxazin-6-yl)-2-fluoro- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 5-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-2-fluorobenzonitrile
FS 3D CONCORD
MF C17 H13 F N2 O S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:71530

REFERENCE 2: 140:53469

REFERENCE 3: 133:350228

L127 ANSWER 62 OF 76 REGISTRY COPYRIGHT 2005 ACS on STN
RN 304853-46-1 REGISTRY
ED Entered STN: 29 Nov 2000
CN 2-Thiophenecarbonitrile, 4-(1,2-dihydro-2-thioxospiro[4H-3,1-benzoxazine-4,1'-cyclohexan]-6-yl)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 4-[1,2-Dihydro-2-thioxospiro[4H-3,1-benzoxazin-4,1'-cyclohexan]-6-yl]-2-thiophenecarbonitrile
FS 3D CONCORD
MF C18 H16 N2 O S2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:71530

REFERENCE 2: 140:53469

REFERENCE 3: 133:350228

L127 ANSWER 63 OF 76 REGISTRY COPYRIGHT 2005 ACS on STN
RN 304853-45-0 REGISTRY

ED Entered STN: 29 Nov 2000
CN 1H-Pyrrole-2-carbonitrile, 5-(1,4-dihydro-4,4-dimethyl-2-thioxo-2H-3,1-benzoxazin-6-yl)-1-ethyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 5-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1-ethyl-1H-pyrrole-2-carbonitrile
FS 3D CONCORD
MF C17 H17 N3 O S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:71530

REFERENCE 2: 140:53469

REFERENCE 3: 133:350228

L127 ANSWER 64 OF 76 REGISTRY COPYRIGHT 2005 ACS on STN
RN 304853-44-9 REGISTRY
ED Entered STN: 29 Nov 2000
CN 3-Thiophenecarbonitrile, 5-(1,4-dihydro-4,4-dimethyl-2-thioxo-2H-3,1-benzoxazin-6-yl)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 5-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-benzo[d][1,3]oxazin-6-yl)thiophene-3-carbonitrile
FS 3D CONCORD
MF C15 H12 N2 O S2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)

3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:71530

REFERENCE 2: 140:53469

REFERENCE 3: 133:350228

L127 ANSWER 65 OF 76 REGISTRY COPYRIGHT 2005 ACS on STN
RN 304853-43-8 REGISTRY
ED Entered STN: 29 Nov 2000
CN 1H-Pyrrole-2-carbothioamide, 5-(1,4-dihydro-4,4-dimethyl-2-thioxo-2H-3,1-benzoxazin-6-yl)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 5-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1H-pyrrole-2-carbothioamide
FS 3D CONCORD
MF C15 H15 N3 O S2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:71530

REFERENCE 2: 140:53469

REFERENCE 3: 133:350228

L127 ANSWER 66 OF 76 REGISTRY COPYRIGHT 2005 ACS on STN
RN 304853-41-6 REGISTRY
ED Entered STN: 29 Nov 2000
CN 2-Pyridineacetonitrile, 6-(1,4-dihydro-4,4-dimethyl-2-thioxo-2H-3,1-benzoxazin-6-yl)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN [6-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)pyridin-2-yl]acetonitrile
FS 3D CONCORD
MF C17 H15 N3 O S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:71530

REFERENCE 2: 140:53469

REFERENCE 3: 133:350228

L127 ANSWER 67 OF 76 REGISTRY COPYRIGHT 2005 ACS on STN
RN 304853-40-5 REGISTRY
ED Entered STN: 29 Nov 2000
CN 1H-Pyrrole-2-carbonitrile, 5-(1,4-dihydro-4,4-dimethyl-2-thioxo-2H-3,1-benzoxazin-6-yl)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 5-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1H-pyrrole-2-carbonitrile
FS 3D CONCORD
MF C15 H13 N3 O S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:71530

REFERENCE 2: 140:53469

REFERENCE 3: 133:350228

L127 ANSWER 68 OF 76 REGISTRY COPYRIGHT 2005 ACS on STN
RN 304853-39-2 REGISTRY
ED Entered STN: 29 Nov 2000
CN 2-Thiophenecarbonitrile, 5-(1,4-dihydro-4,4-dimethyl-2-thioxo-2H-3,1-

benzoxazin-6-yl)-4-methyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 5-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-4-methylthiophene-2-carbonitrile
FS 3D CONCORD
MF C16 H14 N2 O S2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:71530

REFERENCE 2: 140:53469

REFERENCE 3: 133:350228

L127 ANSWER 69 OF 76 REGISTRY COPYRIGHT 2005 ACS on STN
RN 304853-38-1 REGISTRY
ED Entered STN: 29 Nov 2000
CN 2H-3,1-Benzoxazine-2-thione, 6-(3-fluorophenyl)-1,4-dihydro-4-methyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 6-(3-Fluorophenyl)-4-methyl-1,4-dihydro-2H-3,1-benzoxazine-2-thione
FS 3D CONCORD
MF C15 H12 F N O S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:71530

REFERENCE 2: 140:53469

REFERENCE 3: 139:111065

REFERENCE 4: 133:350228

L127 ANSWER 70 OF 76 REGISTRY COPYRIGHT 2005 ACS on STN
RN 304853-37-0 REGISTRY
ED Entered STN: 29 Nov 2000
CN Benzonitrile, 3-(1,4-dihydro-4,4-dimethyl-2-thioxo-2H-3,1-benzoxazin-6-yl)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 3-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-benzo[d][1,3]oxazin-6-yl)benzonitrile
FS 3D CONCORD
MF C17 H14 N2 O S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:71530

REFERENCE 2: 140:53469

REFERENCE 3: 139:111065

REFERENCE 4: 133:350228

L127 ANSWER 71 OF 76 REGISTRY COPYRIGHT 2005 ACS on STN
RN 304853-35-8 REGISTRY
ED Entered STN: 29 Nov 2000
CN Benzonitrile, 3-(1,4-dihydro-4,4-dimethyl-2-thioxo-2H-3,1-benzoxazin-6-yl)-5-fluoro- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 3-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-benzo[d][1,3]oxazin-6-yl)-5-fluorobenzonitrile
FS 3D CONCORD
MF C17 H13 F N2 O S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:71530

REFERENCE 2: 140:53469

REFERENCE 3: 139:111065

REFERENCE 4: 133:350228

L127 ANSWER 72 OF 76 REGISTRY COPYRIGHT 2005 ACS on STN
RN 304853-33-6 REGISTRY
ED Entered STN: 29 Nov 2000
CN 2-Thiophenecarbonitrile, 4-(1,4-dihydro-4,4-dimethyl-2-thioxo-2H-3,1-benzoxazin-6-yl)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 4-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-benzo[d][1,3]oxazin-6-yl)thiophene-2-carbonitrile
FS 3D CONCORD
MF C15 H12 N2 O S2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:71530

REFERENCE 2: 139:111065

REFERENCE 3: 133:350228

L127 ANSWER 73 OF 76 REGISTRY COPYRIGHT 2005 ACS on STN
RN 304853-32-5 REGISTRY

ED Entered STN: 29 Nov 2000
CN 2H-3,1-Benzoxazine-2-thione, 6-(3-chlorophenyl)-1,4-dihydro-4,4-dimethyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 6-(3-Chlorophenyl)-4,4-dimethyl-1,4-dihydrobenzo[d][1,3]oxazin-2-thione
FS 3D CONCORD
MF C16 H14 Cl N O S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:71530

REFERENCE 2: 140:53469

REFERENCE 3: 139:111065

REFERENCE 4: 133:350228

L127 ANSWER 74 OF 76 REGISTRY COPYRIGHT 2005 ACS on STN
RN 282530-42-1 REGISTRY
ED Entered STN: 02 Aug 2000
CN 4H-3,1-Benzoxazin-4-one, 6-cyclopropyl-2-(phenylamino)- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C17 H14 N2 O2
SR CA
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 133:105042

L127 ANSWER 75 OF 76 REGISTRY COPYRIGHT 2005 ACS on STN
RN 145622-92-0 REGISTRY
ED Entered STN: 29 Jan 1993
CN 2H-3,1-Benzoxazine-2-thione, 1,4-dihydro-8-methyl-6-(4-methyl-1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C13 H13 N3 O S
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 118:213099

REFERENCE 2: 118:101972

L127 ANSWER 76 OF 76 REGISTRY COPYRIGHT 2005 ACS on STN
RN 119198-26-4 REGISTRY
ED Entered STN: 24 Feb 1989
CN Piperazine, 1-(1,4-dihydro-2-thioxo-2H-3,1-benzoxazin-6-yl)-4-(3,4-dimethoxybenzoyl)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 2H-3,1-Benzoxazine, piperazine deriv.
FS 3D CONCORD
MF C21 H23 N3 O4 S
SR CA
LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 110:95163

=> d ide can tot l22

L22 ANSWER 1 OF 14 REGISTRY COPYRIGHT 2005 ACS on STN
RN **638989-51-2** REGISTRY
ED Entered STN: 19 Jan 2004
CN 1H-Pyrrole-2-carbonitrile, 5-[1,4-dihydro-2-oxo-4,4-bis(trifluoromethyl)-2H-3,1-benzoxazin-6-yl]-1-methyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 1-Methyl-5-[2-oxo-4,4-bis(trifluoromethyl)-1,4-dihydro-2H-3,1-benzoxazin-6-yl]-1H-pyrrole-2-carbonitrile
FS 3D CONCORD
MF C16 H9 F6 N3 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:71530

REFERENCE 2: 140:53469

L22 ANSWER 2 OF 14 REGISTRY COPYRIGHT 2005 ACS on STN
RN **638989-50-1** REGISTRY
ED Entered STN: 19 Jan 2004
CN 2H-3,1-Benzoxazin-2-one, 6-bromo-1,4-dihydro-4,4-bis(trifluoromethyl)-(9CI) (CA INDEX NAME)
OTHER NAMES:
CN 6-Bromo-4,4-bis(trifluoromethyl)-1,4-dihydro-2H-3,1-benzoxazin-2-one
FS 3D CONCORD
MF C10 H4 Br F6 N O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:71530

REFERENCE 2: 140:53469

L22 ANSWER 3 OF 14 REGISTRY COPYRIGHT 2005 ACS on STN
RN **638989-49-8** REGISTRY
ED Entered STN: 19 Jan 2004
CN 2H-3,1-Benzoxazin-2-one, 1,4-dihydro-4,4-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 4,4-Bis(trifluoromethyl)-1,4-dihydro-2H-3,1-benzoxazin-2-one
FS 3D CONCORD
MF C10 H5 F6 N O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:71530

REFERENCE 2: 140:53469

L22 ANSWER 4 OF 14 REGISTRY COPYRIGHT 2005 ACS on STN
RN **638989-47-6** REGISTRY
ED Entered STN: 19 Jan 2004
CN 1H-Pyrrole-2-carbonitrile, 5-(1,2-dihydro-2-oxospiro[4H-3,1-benzoxazine-4,1'-cyclopentan]-6-yl)-1-methyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 1-Methyl-5-[2-oxo-1,2-dihydrospiro[3,1-benzoxazine-4,1'-cyclopentan]-6-yl]-1H-pyrrole-2-carbonitrile

FS 3D CONCORD
MF C18 H17 N3 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:71530

REFERENCE 2: 140:53469

L22 ANSWER 5 OF 14 REGISTRY COPYRIGHT 2005 ACS on STN
RN **638989-45-4** REGISTRY
ED Entered STN: 19 Jan 2004
CN 1H-Pyrrole-2-carbonitrile, 5-(1,2-dihydro-2-oxospiro[4H-3,1-benzoxazine-4,1'-cyclohexan]-6-yl)-1-methyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 1-Methyl-5-[2-oxo-1,2-dihydrospiro[3,1-benzoxazine-4,1'-cyclohexan]-6-yl]-1H-pyrrole-2-carbonitrile
FS 3D CONCORD
MF C19 H19 N3 O2
SR CA
LC STN Files: CA, CAPLUS, PROUSDDR, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:71530

REFERENCE 2: 140:53469

L22 ANSWER 6 OF 14 REGISTRY COPYRIGHT 2005 ACS on STN

RN **638989-43-2** REGISTRY
ED Entered STN: 19 Jan 2004
CN 1H-Pyrrole-2-carbonitrile, 5-(4-ethyl-1,4-dihydro-4-methyl-2-oxo-2H-3,1-benzoxazin-6-yl)-1-methyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 5-(4-Ethyl-4-methyl-2-oxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1-methyl-1H-pyrrole-2-carbonitrile
FS 3D CONCORD
MF C17 H17 N3 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:71530

REFERENCE 2: 140:53469

L22 ANSWER 7 OF 14 REGISTRY COPYRIGHT 2005 ACS on STN
RN **638989-42-1** REGISTRY
ED Entered STN: 19 Jan 2004
CN 2H-3,1-Benzoxazin-2-one, 6-bromo-4-ethyl-1,4-dihydro-4-methyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 6-Bromo-4-ethyl-4-methyl-1,4-dihydro-2H-3,1-benzoxazin-2-one
FS 3D CONCORD
MF C11 H12 Br N O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:71530

REFERENCE 2: 140:53469

L22 ANSWER 8 OF 14 REGISTRY COPYRIGHT 2005 ACS on STN
RN **638989-40-9** REGISTRY
ED Entered STN: 19 Jan 2004
CN 2H-3,1-Benzoxazin-2-one, 6-bromo-4,4-diethyl-1,4-dihydro- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 6-Bromo-4,4-diethyl-1,4-dihydrobenzo[d][1,3]oxazin-2-one
FS 3D CONCORD
MF C12 H14 Br N O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:71530

REFERENCE 2: 140:53469

L22 ANSWER 9 OF 14 REGISTRY COPYRIGHT 2005 ACS on STN
RN **638989-39-6** REGISTRY
ED Entered STN: 19 Jan 2004
CN 1H-Pyrrole-2-carbonitrile, 5-(4,4-diethyl-1,4-dihydro-2-oxo-2H-3,1-benzoxazin-6-yl)-1-methyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 5-(4,4-Diethyl-2-oxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1-methyl-1H-pyrrole-2-carbonitrile
FS 3D CONCORD
MF C18 H19 N3 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:71530

REFERENCE 2: 140:53469

L22 ANSWER 10 OF 14 REGISTRY COPYRIGHT 2005 ACS on STN
RN **638989-37-4** REGISTRY
ED Entered STN: 19 Jan 2004
CN 1H-Pyrrole-2-carbonitrile, 5-(1,2-dihydro-2-oxospiro[4H-3,1-benzoxazine-4,1'-cyclobutan]-6-yl)-1-methyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 1-Methyl-5-[2-oxo-1,2-dihydrospiro[3,1-benzoxazine-4,1'-cyclobutan]-6-yl]-1H-pyrrole-2-carbonitrile
FS 3D CONCORD
MF C17 H15 N3 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:71530

REFERENCE 2: 140:53469

L22 ANSWER 11 OF 14 REGISTRY COPYRIGHT 2005 ACS on STN
RN **638989-36-3** REGISTRY
ED Entered STN: 19 Jan 2004
CN Spiro[4H-3,1-benzoxazine-4,1'-cyclobutan]-2(1H)-one, 6-bromo- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 6-Bromospiro[3,1-benzoxazine-4,1'-cyclobutan]-2(1H)-one
FS 3D CONCORD
MF C11 H10 Br N O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:71530

REFERENCE 2: 140:53469

L22 ANSWER 12 OF 14 REGISTRY COPYRIGHT 2005 ACS on STN
RN **638989-35-2** REGISTRY
ED Entered STN: 19 Jan 2004
CN Spiro[4H-3,1-benzoxazine-4,1'-cyclobutan]-2(1H)-one (9CI) (CA INDEX NAME)
OTHER NAMES:
CN Spiro[3,1-benzoxazine-4,1'-cyclobutan]-2(1H)-one
FS 3D CONCORD
MF C11 H11 N O2
SR CA
LC STN Files: CA, CAPLUS, CHEMCATS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:71530

REFERENCE 2: 140:53469

L22 ANSWER 13 OF 14 REGISTRY COPYRIGHT 2005 ACS on STN
RN **305799-84-2** REGISTRY
ED Entered STN: 01 Dec 2000
CN Spiro[4H-3,1-benzoxazine-4,1'-cyclopentan]-2(1H)-one, 6-bromo- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 6-Bromospiro[4H-3,1-benzoxazine-4,1'-cyclopentan]-2(1H)-one
FS 3D CONCORD
MF C12 H12 Br N O2

SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

5 REFERENCES IN FILE CA (1907 TO DATE)
5 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:71530

REFERENCE 2: 140:53469

REFERENCE 3: 137:201317

REFERENCE 4: 133:350229

REFERENCE 5: 133:350205

L22 ANSWER 14 OF 14 REGISTRY COPYRIGHT 2005 ACS on STN
RN **304854-04-4** REGISTRY
ED Entered STN: 29 Nov 2000
CN Spiro[4H-3,1-benzoxazine-4,1'-cyclohexan]-2(1H)-one, 6-bromo- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 6-Bromospiro[4H-3,1-benzoxazine-4,1'-cyclohexan]-2(1H)-one
FS 3D CONCORD
MF C13 H14 Br N O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

6 REFERENCES IN FILE CA (1907 TO DATE)
6 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:71530

```
REFERENCE   2:  140:53469

REFERENCE   3:  137:201317

REFERENCE   4:  133:350229

REFERENCE   5:  133:350228

REFERENCE   6:  133:350205


=> d his

     (FILE 'HOME' ENTERED AT 07:18:36 ON 05 JUL 2005)
               SET COST OFF

     FILE 'REGISTRY' ENTERED AT 07:18:43 ON 05 JUL 2005
L1             STR
L2           5 S L1

     FILE 'HCAPLUS' ENTERED AT 07:20:57 ON 05 JUL 2005
L3             1 S US20040014798/PN OR (US2003-601968# OR WO2003-US19860 OR US20
               E FONSOME A/AU
               E FENSOME A/AU
L4            37 S E3,E6,E7
               E HARRISON D/AU
L5           123 S E3,E8,E114-E116,E118
               E WINNEKER R/AU
L6            59 S E4-E7
               E ZHANG P/AU
L7           307 S E3,E17
               E ZHANG PU/AU
L8           136 S E3,E24,E25
               E ZHANG P/AU
L9           694 S E3-E20
               E KERN J/AU
L10          203 S E3,E5,E29-E31,E34
               E TEREFENKO E/AU
L11           24 S E4-E7
               E WYETH/PA,CS
               E WYET/PA,CS
L12         4429 S E4-E7 OR WYETH?/PA,CS
               SEL RN L3

     FILE 'REGISTRY' ENTERED AT 07:24:43 ON 05 JUL 2005
L13           84 S E1-E84
               STR L1
L14
L15           50 S L14
L16         1063 S L14 FUL
               SAV L16 KWON601/A
L17           60 S L13 AND L16
L18           24 S L13 NOT L17
L19           10 S L18 AND NR>=3 NOT C5-C6-C6-C6/ES
L20           14 S L18 NOT L19
L21            4 S L20 AND NCOC3-C6/ES
L22           14 S L19,L21
L23           77 S L1 FUL SUB=L16
               SAV L23 KWON601A/A
L24           17 S L23 NOT L17
```

```
     FILE 'HCAOLD' ENTERED AT 07:28:34 ON 05 JUL 2005
L25           0 S L23
L26           0 S L22

     FILE 'HCAPLUS' ENTERED AT 07:28:44 ON 05 JUL 2005
L27          10 S L23
L28           6 S L22
L29          13 S L27,L28
L30           6 S L29 AND L3-L12
                E HIRSUTISM/CT
                E E3+ALL
L31         968 S E4
L32        1517 S E4,E5/BI
                E HYPERTRICH
L33         134 S E4-E7
                E HIRSUT
L34           1 S L29 AND L31-L33
L35           1 S L29 AND HIRSUT?
                E ACNE/CT
L36        3716 S E3-E8
                E E3+ALL
L37        3741 S E6+NT
L38        6082 S E6,E7/BI
L39         243 S PIMPL?
L40        6272 S ACNE?
                E ACNE/CT
                E E6+ALL
L41         301 S E2
L42           1 S L29 AND L36-L41
                E ECZEMA/CT
L43        2222 S E3,E4
                E E3+ALL
L44        2222 S E9
L45        3655 S E9,E10/BI
L46           1 S L29 AND ECZEM?
L47           1 S L3,L34,L35,L42,L46
                E SKIN/CT
                E E3+ALL
L48      105580 S E6+OLD,NT
L49      124391 S E6+PFT,RT
                E E37+ALL
L50      139455 S E5+OLD,NT,PFT,RT
                E E181+ALL
L51      155162 S E3+OLD,NT,PFT,RT
L52      142584 S E13+OLD,NT,PFT,RT
L53       16036 S E16+OLD,NT,PFT,RT
L54           2 S L29 AND L48-L53
                E HAIR/CT
L55       52596 S E3+OLD,NT,PFT,RT
L56       52664 S E43+OLD,NT,PFT,RT
L57       20289 S E86+OLD,NT,PFT,RT
                E SKIN CONDITION/CT
                E E4+ALL
L58        1145 S E2
L59           1 S L29 AND L55-L58
L60           2 S L47,L54,L59
L61           4 S L29 AND PROGESTERONE(L)RECEPTOR(L)?MODULAT?
                E PROGESTERONE RECEPTOR/CT
L62        3809 S E8-E14
                E E8+ALL
```

```
L63        4894 S E11+OLD,NT
L64        9236 S E11+PFT,RT
L65           7 S L29 AND L62-L64
                E ENDOMETRIOSIS/CT
                E E3+ALL
L66        1849 S E2
L67        2470 S E1/BI
                E BENIGN PROSTATIC HYPERTROPHY/CT
                E E3+ALL
L68        1469 S E3
L69         655 S E1/BI
                E BENIGN PROSTATIC HYPERTROPHY/CT
L70        2319 S E2/BI
                E ENDOMETRIUM/CT
                E E3+ALL
L71        9801 S E2
L72         647 S E6,E7
L73        1424 S E9,E10
L74         854 S E12,E13
L75         370 S E15,E16
L76         386 S E18,E19
L77         243 S E21,E22
L78        3398 S E24
                E OVARY/CT
L79       57237 S E3+OLD,NT
L80       18487 S E54+OLD,NT
L81       14597 S E67+OLD,NT
                E BREAST/CT
                E E3+ALL
                E E2+ALL
L82       63582 S E3+OLD,NT
L83       50658 S E9+OLD,NT
                E MAMMARY GLAND/CT
L84       65709 S E3+OLD,NT OR E47+OLD,NT
L85       47677 S E53+OLD,NT
                E COLON/CT
                E E3+ALL
L86       31294 S E1,E2
                E COLON, DISEASE/CT
                E E2+ALL
L87       18615 S E2
                E PROSTATE/CT
L88          26 S E3+OLD,NT
L89       32483 S E18+OLD,NT
L90       32840 S E53+OLD,NT,PFT,RT OR E57+OLD,NT,PFT,RT
                E PITUITARY/CT
                E E3+ALL
                E E2+ALL
L91       41881 S E3+OLD,NT OR E15+OLD,NT
                E MENINGIOMA/CT
                E E3+ALL
L92         668 S E2,E3
                E UTERIN MYOMETRIAL FIBROID/CT
                E UTERINE MYOMETRIAL FIBROID/CT
                E MYOMETRIAL FIBROID/CT
                E E5+ALL
L93        3124 S E2
                E UTERINE FIBROID/CT
                E FIBROID/CT
                E E4+ALL
```

```
L94          722 S E2
L95            3 S L29 AND L66-L94
L96            9 S L60,L65,L95
                 E UTERUS, NEOPLASM/CT
L97        12762 S E3+OLD,NT
                 E PROSTATE, NEOPLASM/CT
                 E PROSTATIC NEOPLASM/CT
                 E E4+ALL
L98        19786 S E2+OLD,NT
                 E PITUITARY NEOPLASM/CT
                 E E3+ALL
L99         3354 S E2+OLD,NT
                 E BREAST, NEOPLASM/CT
                 E BREAST NEOPLASM/CT
                 E E3+ALL
L100       47677 S E2+OLD,NT
                 E OVARY, NEOPLASM/CT
L101       14597 S E3+OLD,NT
                 E COLON, NEOPLASM/CT
                 E COLON NEOPLASM/CT
                 E E4+ALL
L102       18615 S E2
L103           2 S L29 AND L97-L102
L104           9 S L96,L103
                 E CARCINOMA/CT
L105      108005 S E3+OLD,NT
L106           1 S L29 AND L105
                 E ANTIPROGEST/CT
                 E E4+ALL
L107         344 S E1,E2
L108           5 S L29 AND L107
L109           9 S L104,L106,L108
L110           9 S L30,L109
L111          11 S L29 AND (PD<=20020625 OR PRD<=20020625 OR AD<=20020625)
L112           7 S L110 AND L111
L113           4 S L111 NOT L112

     FILE 'REGISTRY' ENTERED AT 07:51:16 ON 05 JUL 2005
L114          11 S L23 AND NC4/ES
L115           1 S L114 AND C16H15N3OS

     FILE 'HCAPLUS' ENTERED AT 07:53:31 ON 05 JUL 2005
L116           5 S L115 OR TANAPROGET OR NSP989 OR NSP 989
L117           3 S L116 AND (PD<=20020625 OR PRD<=20020625 OR AD<=20020625)
L118           9 S L116,L117,L112
L119           9 S L118 AND L3-L12,L27-L113

     FILE 'REGISTRY' ENTERED AT 07:55:02 ON 05 JUL 2005

     FILE 'HCAPLUS' ENTERED AT 07:55:28 ON 05 JUL 2005

     FILE 'USPATFULL' ENTERED AT 07:56:32 ON 05 JUL 2005
L120           5 S L116
L121          10 S L23
L122           8 S L24
L123          10 S L120-L122
L124           9 S L123 AND (PY<=2002 OR PRY<=2002 OR AY<=2002)
L125          10 S L123,L124

     FILE 'USPATFULL' ENTERED AT 07:57:34 ON 05 JUL 2005
```

```
     FILE 'REGISTRY' ENTERED AT 07:57:47 ON 05 JUL 2005
L126          76 S L123 NOT L115
L127          76 S L23 NOT L115

=>
```